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Abstract 
The AMPK-related kinase NUAK1 has been implicated in the regulation of a 
spectrum of biological processes such as cell proliferation, metabolism, cell 
adhesion and migration. As deregulation of such processes plays an important 
role in cancer, NUAK1 targeting has been suggested as a promising therapeutic 
strategy. In addition, higher NUAK1 expression has been correlated with more 
advanced tumour stages and poor prognosis in multiple cancer types, indicating 
that its targeting could be clinically relevant. However, manipulation of NUAK1 
for therapeutic purposes is still restricted by our limited knowledge of its 
regulation and function.  
Therefore, the work presented in this thesis aimed to further explore the NUAK1 
signalling network, with particular focus on a more comprehensive 
understanding of the previously described synthetic lethal interaction between 
NUAK1 and MYC. 
 
The tumour suppressor LKB1 is considered as the master upstream regulator of 
the AMPK-related kinases, including NUAK1. Our analysis performed in HeLa 
cells, which are characterized by LKB1 deficiency and high levels of MYC, 
revealed that NUAK1 activity was maintained by an alternative pathway 
involving Ca2+-dependent activation of PKC. Ca2+/PKC-dependent activation of 
NUAK1 supported the engagement of the Raptor-mTORC1 metabolic checkpoint 
to protect cells from MYC-driven cell death. Indeed, we have revealed that MYC 
selects for this pathway via amplification of Ca2+ signalling, which involves 
increased activation of PKC.  
 
MYC upregulation in Non-small cell lung cancer (NSCLC) is frequently observed 
due to oncogenic activation of upstream signalling pathways that promote MYC 
stability, e.g. by RAS activation. Therefore, in light of the synthetic lethal 
interaction between NUAK1 and MYC but also aware of the emblematic tumour 
suppressor role of LKB1 in lung tumorigenesis, we sought to investigated the role 
of NUAK1 in a pre-clinical model of NSCLC driven by mutant KRas. Interestingly, 
NUAK1 did not replicate the tumour suppressive function of LKB1, while Nuak1 
deletion decreased tumour angiogenesis and delayed tumour progression, which 
was reflected by an increased overall survival. 
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Finally, as we investigated the molecular mechanisms of progression of KRas 
mutant-driven NSCLC, we uncovered the upregulation of the ERBB network in 
association with the tumorigenic process. Inhibition of ERBB receptors 
cooperated with MEK inhibition in enhancing overall survival, proposing a novel 
therapeutic relevance for multi-ERBB inhibitors. 
 
Taken together our data have provided a more comprehensive understanding of 
NUAK1 signalling network and have proposed new targets that could be exploited 
for therapeutic purposes in lung cancer and potentially in many other tumour 
types. 
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Chapter 1 – Introduction 
The Novel (Nua) kinase family 1 (NUAK1, also known as ARK5), is a 
serine/threonine kinase identified as the fifth AMPK-related kinase (ARK) (Suzuki 
et al., 2003a). The biological function of NUAK1 has not been extensively studied 
but multiple experimental evidence has suggested a role for NUAK1 in a broad 
variety of processes ranging from metabolism to cell adhesion, migration and 
neuronal axon branching. Although the information obtained so far places NUAK1 
as a potential target in cancer therapy, additional studies are required to fully 
explore and understand its roles. On the other hand, a large number of 
investigations have been carried out on the function and activity of AMPK, which 
provided the molecular basis for the understanding of the roles of other AMPK-
related kinases, such as NUAK1. Therefore, in this chapter an overview of AMPK 
and the AMPK-related kinases is given before discussing in more detail the 
function and regulation of NUAK1. Lung cancer is also discussed, as the 
mechanisms of progression and the involvement of NUAK1 in lung tumorigenesis 
have been investigated as part of this thesis. 
 
 
1.1 AMPK, the master energy sensor 
1.1.1 Structure and expression of AMPK 
The AMP-activated protein kinase (AMPK) is a threonine/serine kinase with a 
fundamental role in the maintenance of energy homeostasis. The key function 
exerted by AMPK is to act as a sensor of cellular energetic levels and to 
rebalance them when energetic stress occurs. It is conserved across most 
eukaryotes, with one of the exception represented by the intracellular parasite 
Encephalitozoon cuniculi, and exists as a heterotrimeric complex composed by 
an  catalytic subunit and two regulatory subunits,  and . The existence of 
multiple isoforms for each subunit further increases the level of complexity of 
AMPK. Specifically, the genes PRKAA1 and PRKAA2 encode for two isoforms of 
the catalytic subunit, 1 and 2, respectively; two and three isoforms for the  
and  regulatory subunits are encoded by PRKAB1, PRKAB2 and PRKAG1, PRKAG2 
and PRKAG3, respectively.  
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Several studies have been carried out in the recent years to characterize the 
structure of AMPK. Starting from the identification of the crystal structure of 
isolated domains and fragments of the heterotrimeric complex (Chen et al., 
2009; Townley and Shapiro, 2007), more recent studies have obtained data on 
full-length complexes (Li et al., 2015b; Xiao et al., 2013), contributing with 
precious information to the function of the kinase. The  subunit is formed by an 
N-terminal kinase domain (KD), which possesses catalytic activity and that 
contains a conserved threonine in the activation loop (Thr172) that can be 
phosphorylated resulting in full activation of the kinase. The kinase domain is 
then followed by an auto-inhibitory domain (AID) and by the α regulatory 
subunit-interacting motifs (RIMs), which has been shown to be important for 
allosteric activation (Chen et al., 2009). Located at the C-terminus of the  
subunit, the subunit-interacting domain mediates the interaction with the  
regulatory subunit (Fig. 1.1). 
The  subunits are characterized by a glycogen-binding domain (GBD) that allows 
binding of the complex to glycogen and β-cyclodextrin (Polekhina et al., 2005) 
and by a C-terminal domain (CTD) for interaction with -CTD. Finally, the 
structure of three  subunits slightly differ from each other because the 2 and 
3 subunits contain an N-terminal extension that is missing in 1. The  isoforms, 
which form complexes with the β subunits through β-strands interactions (Xiao 
et al., 2007), comprise four tandem repeats of a cystathionine β synthase motifs 
(CBS1-4). A pair of CBS motifs forms the Bateman domain, which can bind two 
adenine nucleotides (Fig. 1.1). In particular, AMP is permanently bound to site-4 
and appears not exchangeable as soaking of ATP into AMPK crystals did not 
displace AMP from site 4 (Xiao et al., 2007). Site-2 remains constantly 
unoccupied whereas site-1 and site-3 are the two exchangeable sites in which 
ATP, ADP and AMP bind in a competitive manner. Binding of adenine nucleotides 
at site-1 is at least 30-fold stronger than at the site-3 (Xiao et al., 2011). 
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Figure 1. 1 – Domain structure of AMPK subunits. 
Schematic representation of the domain organization of the catalytic (1, 2) and 
regulatory (1, 2, 1, 2, 3) subunits of AMPK. AID, autoinhibitory domain; RIMs, 
regulatory subunit-interacting motifs; CTD, C-terminal domain; GBD, glycogen binding 
domain; NTD, N-terminal domain; CBS, cystathionine β synthase motifs. Adapted from 
(Salt and Hardie, 2017). 
 
 
Different combinations of the multiple isoforms can give rise to twelve 
distinctive holo-AMPK complexes and their expression levels differ across tissue 
types. Specifically, AMPK1, AMPK1, AMPK1 and AMPK2  are widely expressed 
whereas expression of AMPK2 and AMPK2 is dominant in the skeletal and 
cardiac muscle, but lower levels can be found in many other tissue; expression 
of AMPK3 appears to be limited to skeletal and cardiac muscle. 
 
A further level of complexity is given by the dynamic localization of AMPK in 
various cell compartments. It has been previously described that AMPK can 
shuttle between the cytoplasm and the nucleus (Kodiha et al., 2007), but 
Miyamoto and colleagues, by using a FRET-based biosensor for detection of AMPK 
activity, were additionally able to show a differential modulation of AMPK 
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activation and subcellular localization in response to stimuli like 2-Deoxyglucose 
or glucose starvation (Miyamoto et al., 2015).  
 
 
1.1.2 Nucleotide-dependent activation of AMPK 
As the key regulator of the cellular energetic status, AMPK can sense changes in 
ATP, ADP and AMP levels. During energetic stress, induced i.e. by nutrient or 
oxygen deprivation, an increased use of ATP, which represents the “energy 
currency molecule” of the cell, would lead to energetic imbalance characterized 
by increased ADP:ATP and AMP:ATP ratios. Binding of adenine nucleotide to the 
 subunit of AMPK, commonly referred to as canonical activation, can regulate 
the activity of the AMPK complex by three mechanisms. Firstly, binding of AMP, 
but not ADP, can induce allosteric activation of various folds depending on the 
type of the  isoform comprised in the complex (Cheung et al., 2000). Secondly, 
binding of AMP or ADP can promote phosphorylation at Thr172 by upstream 
kinases, such as LKB1 or CaMKK, which represents the most important event for 
full activation. However, the mechanism still remains controversial, with some 
experimental evidence supporting a role of CaMKK in phosphorylation of AMPK 
in response to ADP and AMP (Oakhill et al., 2011), whereas other studies have 
highlighted that AMP can induce phosphorylation through LKB1 and not CaMKK 
(Gowans et al., 2013). In addition, myristoylation of the  subunit was reported 
to be necessary for phosphorylation at Thr172 in response to AMP binding, as loss 
of the post-translational modification resulted in a reduction of the 
phosphorylation levels (Oakhill et al., 2010). Finally, binding of either AMP or 
ADP can induce a conformational change that protects the Thr172 site in the  
catalytic subunit from dephosphorylation by phosphatases (Gowans et al., 2013; 
Xiao et al., 2011), with a more potent effect exerted by binding of AMP in 
comparison to ADP (Ross et al., 2016). Binding of ATP instead of ADP or AMP can 
inhibit all the three mechanisms of activation. 
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1.1.3 Pharmacological activation of AMPK 
As a consequence of energetic stress, changes in adenine nucleotide ratios can 
finely tune the activation of AMPK. However, many other xenobiotics and natural 
compounds have been found to induce AMPK activity. Natural products such as 
Resveratrol (polyphenol compound found in grapes), or other plant extracts such 
as Berberine and Curcumine can activate AMPK and were utilised since ancient 
times as part of herbal remedies (Kim et al., 2009; Lee et al., 2006; Park et al., 
2007). In addition, synthetic compounds such as Metformin, extensively used for 
the treatment of type II diabetes, and phenformin have also been described for 
their ability to induce AMPK. Although some of those compounds, like 
Resveratrol, phenformin and Berberine are mitochondrial poisons that interfere 
with ATP generation (Owen et al., 2000; Turner et al., 2008; Zheng and Ramirez, 
2000), thereby activating AMPK by increasing the ADP or AMP levels, other drugs 
have revealed novel and AMP/ADP-independent mechanisms of activation. For 
example, Salicylate, which is the active metabolite of aspirin and a natural 
molecule found in many flowering plants, has been shown to directly induce 
AMPK activation. Similarly to AMP Salicylate is inducing allosteric activation and 
inhibits dephosphorylation of Thr172, but without affecting the AMP and ADP 
levels and interacting with a different site compared to the adenine nucleotides 
(Hawley et al., 2012). Furthermore, a synthetic compound member of the 
thienopyridone family and named A-769962 was identified during a screening of 
over 700,000 compounds for its ability to directly activate AMPK (Cool et al., 
2006). Particularly, A-769662 was found to activate AMPK with a similar 
mechanism to Salicylate, without affecting the levels and the binding of AMP to 
the  subunit of AMPK (Goransson et al., 2007; Sanders et al., 2007). 
Interestingly, both the synthetic and natural activators were found to require a 
wild-type AMPK1 subunit for their function. Mutation of the Ser108 residue to 
Alanine in the 1 subunit was shown to abolish the activation by both agents, 
suggesting an overlap of their site of action (Hawley et al., 2012). 
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1.1.4 Upstream kinases of AMPK 
The Thr172 was identified as the major site for phosphorylation in AMPK (Hawley 
et al., 1996), which results in more than 100-fold activation (Suter et al., 2006). 
In the long search for the upstream kinase of AMPK, the yeast enzymes Tos3p, 
Pak1p and Elm1p were initially identified as being required for the in vivo 
function but also in vitro phosphorylation of Snf1, the yeast homologue of AMPK 
(Hong et al., 2003). In addition, Tos3p was found in the same study to 
phosphorylate AMPK in vitro. The similarity of Tos3p, Pak1p and Elm1p to the 
mammalian Liver Kinase B1 (LKB1) led to the important identification of the 
latter as the major upstream kinase for AMPK (Hong et al., 2003; Woods et al., 
2003). Following studies have revealed that the activity of LKB1 was enhanced 
when in complex with two other proteins, STRAD and MO25 (Boudeau et al., 
2003), and that the same complex could activate AMPK (Hawley et al., 2003).  
The yeast activators of Snf1 displayed a similarity to the mammalian family of 
Ca2+/Calmodulin-dependent kinases CAMKK, suggesting that alternative upstream 
kinases to LKB1 could take part in AMPK activation. Indeed, despite the initial 
underestimation of CaMKK as a potential alternative upstream kinase for AMPK, 
further studies have compellingly established the role of CaMKK in the activation 
of AMPK through phosphorylation at Thr172. Particularly, Carling’s group 
demonstrated that AMPK can be activated in cells lacking LKB1, such as HeLa 
cells, corroborating the theory of the existence of additional upstream kinases. 
Moreover, treatment of HeLa cells with STO-609, a pharmacological inhibitor of 
CaMKK, strikingly reduced the basal levels of AMPK activity as well as its 
response to multiple activators. Further experiments in the same study proved 
that agents that cause an increase in intracellular Ca2+ levels, such as Ionomycin, 
could induce activation of AMPK and established that the CaMKK isoform, 
rather than the  isoform, is the main regulator of AMPK in cells lacking LKB1 
(Woods et al., 2005). Corroborating the findings of Woods and colleagues, 
additional studies published in the same year also highlighted the 
Calcium/CaMKK dependent activation of AMPK (Hawley et al., 2005; Hurley et 
al., 2005). Overall, the studies provided compelling evidence on CaMKK being 
an alternative upstream kinase for AMPK and revealed a novel and Calcium-
dependent mechanism of regulation. 
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A third kinase has been suggested to play a role in the activation of AMPK. Some 
reports have suggested that the Transforming growth factor--activated kinase 
(TAK1) can phosphorylate and activate AMPK (Momcilovic et al., 2006; Xie et al., 
2006). In addition, further investigations have suggested a reciprocal regulation 
between TAK1 and AMPK, as AMPK1 was shown to induce TAK1 with a role in 
inflammatory processes (Kim et al., 2012b). However, the physiological 
implications of AMPK activation by TAK1 are not clear yet. 
 
 
1.1.5 Metabolic implications of AMPK activity 
As the pivotal regulator of energy homeostasis, a fundamental function of AMPK 
in restoring the energetic levels is to activate intracellular catabolic pathways 
intent to produce energy while inhibiting energy consuming processes (Fig. 1.2). 
Over time, several downstream targets of AMPK have been identified, ranging 
from enzymes and kinases to transcription factors. AMPK, through the 
modulation of many targets, can regulate major cellular metabolic processes, 
such as protein synthesis, glucose and lipid metabolism, mitochondrial 
biogenesis and autophagy to orchestrate the energy production and consumption 
of cells, specifically under stress conditions.  
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Figure 1. 2 – Signal pathways regulated by AMPK. 
AMPK can regulate several downstream targets to inhibit anabolic pathways in favour of 
catabolic processes. Phosphorylation of TBC1D1 (TBC1 domain family member 1) 
promotes membrane translocation of the glucose transporter GLUT4 and glucose 
uptake; phosphorylation and inhibition of Glycogen synthase (GS) inhibits glycogen 
synthesis; Phosphorylation and inhibition of ACC1 and ACC2 (Acetyl CoA carboxylase) 
impairs fatty acids biosynthesis and promotes fatty oxidation, respectively; 
Phosphorylation of ULK1 (Unc-51 Like Autophagy Activating Kinase 1) contributes to 
autophagy induction; inhibition of protein synthesis is achieved by AMPK-mediated 
inhibition of Raptor and induction of Tuberin (TSC2, Tuberous Sclerosis 2). Only some of 
the targets and pathways are represented in this image generated using items from 
Servier Medical Art. 
 
 
1.1.5.1 Regulation of protein synthesis 
AMPK has been established as an important negative regulator of the 
mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) (Fig. 1.3). mTOR 
acts as a coordinator of signals from nutrients and growth factors to regulate cell 
growth and proliferation. mTOR is the catalytic subunit of two distinct 
complexes that differ in their components but also for their substrates and 
regulation: mTORC1 and mTORC2. mTORC1 is a multi-protein complex formed by 
mTOR, Raptor (regulatory protein associated with mTOR), mLST8 (mammalian 
lethal with Sec13 protein 8, also known as GßL) and two inhibitory subunits, 
namely PRAS40 and DEPTOR. mTORC1 regulates multiple processes, such as 
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protein synthesis, lipid and glucose metabolism and autophagy. mTORC1 is 
activated by Rheb on the surface of the lysosomes but active mTOR has also 
been detected in other cellular compartments, such as nucleus and cytoplasm 
(Betz and Hall, 2013; Manifava et al., 2016). 
Regarding the regulation of protein synthesis, two important effectors are 
located downstream of mTORC1: p70S6 Kinase 1 (S6K1) and eIF4E Binding 
Protein (4E-BP1) (Fig. 1.3). Phosphorylation and consequent activation of S6K 
promotes mRNA translation. 4E-BP1 negatively regulates 5’-cap-dependent 
mRNA translation by binding the eukaryotic translation initiation factor 4E 
(eIF4E). Hyperphosphorylation of 4E-BP1 by mTORC1 induces the release of the 
eIF4E factor and stimulation of 5’-cap-dependent mRNA translation. 
Interestingly, AMPK was shown to target multiple components of the mTORC1 
pathway. In particular, AMPK activation by nutrient starvation resulted in the 
induction of TSC2, a negative regulator of mTORC1, through phosphorylation of 
Thr1227 and Ser1345 (Inoki et al., 2003). Active TSC2 can then inhibit Rheb, 
which is a GTPase of the RAS superfamily. Rheb has been proposed to control 
mTOR catalytic activity through multiple mechanisms: 1) Interaction with the 
mTOR kinase domain resulting in an increase in mTOR kinase activity (Long et 
al., 2005); 2) Rheb-GTP binds to the mTOR inhibitor FKBP (FK506-binding 
protein) 38, displacing it from mTOR (Bai et al., 2007); 3) Rheb-GTP interacts  
with phospholipase D1 (PLD1), causing the generation of phosphatidic acid, which 
positively regulates mTOR (Sun et al., 2008).  
Additionally, AMPK has been involved in the regulation of mTORC1 through 
Raptor. Raptor, as previously mentioned, is part of mTORC1 complex and it was 
shown to be necessary for mTOR signalling in vivo as well as in vitro (Hara et al., 
2002; Kim et al., 2002). Specifically, Shaw and colleagues identified Raptor as a 
direct target of AMPK and revealed that phosphorylation of Raptor at Ser722 and 
Ser792 caused its binding to the 14-3-3 protein and reduction of mTOR activity. 
Moreover, in cells stimulated with the AMPK activators phenformin and AICAR, 
inhibition of mTORC1 was not efficient when a mutant form of Raptor, in which 
Ser722 and Ser792 were replaced with Alanine, was expressed, suggesting that 
AMPK phosphorylation of Raptor is required for inhibition of mTORC1 (Gwinn et 
al., 2008). 
Further checkpoints activated by AMPK for the regulation of translation have 
been described over time. For example, AMPK can directly activate eEF2K 
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(Eukaryotic elongation factor-2 kinase) to block translation elongation (Leprivier 
et al., 2013). Overall, the modulation of multiple components of the TOR 
pathway makes AMPK a key regulator of translation during energetic stress. 
 
 
 
 
Figure 1. 3 – The mTORC1 signalling pathway. 
The mTORC1 complex is formed by a catalytic subunit (mTOR) and regulatory 
components (Raptor, PRAS40, DEPTOR, GL). Active mTOR transmits the signal to the 
downstream effectors 4E-BP1 and S6K1 to modulate mRNA translation. AMPK can inhibit 
protein synthesis by phosphorylation and inhibition of Raptor; alternatively, 
phosphorylation and induction of TSC2 results in inhibition of Rheb, which is a positive 
regulator of mTORC1 activity. Image made using items from Servier Medical Art. 
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1.1.5.2 Regulation of glucose and lipid metabolism 
Glucose and lipids are an important source of energy for cells and AMPK can 
modulate pathways involved in their metabolism to maintain energetic 
homeostasis. AMPK can stimulate glucose uptake in the skeletal muscle by 
transcriptional regulation of the glucose transporter GLUT4 through 
phosphorylation and inactivation of the transcriptional repressor Histone 
Deacetylase 5 (HDAC5) (McGee et al., 2008) and by promoting GLUT4 
translocation to the plasma membrane through phosphorylation and inhibition of 
TBC1D1 (Chavez et al., 2008; Chen et al., 2008). Furthermore, AMPK-mediated 
phosphorylation and inhibition of Thioredoxin-interacting protein (TXNIP), a 
negative regulator of GLUT1, was shown to contribute to enhanced glucose 
uptake (Wu et al., 2013). 
To increase energy production, AMPK has been described to promote the 
oxidation of glucose via stimulation of the glycolytic enzyme 6-phosphofructo-2-
kinase (PFK-2) in cardiac cells and activated monocytes (Marsin et al., 2000; 
Marsin et al., 2002). In addition, glucose storage has been reported to be 
modulated by AMPK in the liver and muscle through the inactivation of glycogen 
synthase (GS) (Bultot et al., 2012; Jorgensen et al., 2004). 
 
Lipids are an alternative source of energy when glucose levels are low. Among 
the various substrates of the lipid metabolism modulated by AMPK, inhibition of 
Acetyl-CoA Carboxylase (ACC) represents a key event in the regulation of lipid 
biosynthesis and oxidation (Ha et al., 1994; Munday et al., 1988). ACC is 
expressed in two isoforms, ACC1 and ACC2, which differ in their cellular 
localization and tissue distribution. In eukaryotes, ACC1 is expressed in all 
tissues but it is particularly enriched in lipogenic tissues such as liver, mammary 
glands and adipose tissue; ACC2 is the predominant isoform in oxidative tissues 
such as skeletal and cardiac muscle. ACC1 regulates lipid biosynthesis by 
generation of malonyl-CoA in the cytoplasm. Conversely, the malonyl-CoA 
generated by ACC2 acts as inhibitor of the carnitine/palmitoyl-transferase 1 
(CPT1), a mitochondrial enzyme involved in the movement of Acyl-CoA from the 
cytoplasm to the mitochondria for -oxidation. Therefore, by inhibiting the two 
isoforms of ACC, AMPK can on one hand downregulate lipid biosynthesis and on 
the other hand it can stimulate lipid oxidation for energy production. 
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1.1.5.3 Regulation of mitochondria biogenesis and autophagy 
Mitochondria are organelles with the important role of producing energy to 
support life. Indeed, as the key regulator of energy homeostasis, it is not 
surprising for AMPK to have been involved in the regulation of mitochondria 
biogenesis in response to energetic stress.  
AMPK1/2 deleted mice showed reduced activity and expression of 
mitochondrial enzymes such as citrate synthase and cytochrome c oxidase, as 
well as reduction in mitochondrial DNA copy number and alteration of 
mitochondria morphology (O'Neill et al., 2011). Moreover, AMPK was described 
to phosphorylate the proliferator-activated receptor γ coactivator 1α (PGC-1α), 
which is considered the master regulator of mitochondria biogenesis, causing the 
binding of PGC-1α to its own promoter to increase its expression levels (Jager et 
al., 2007). More recently, Shaw’s group revealed that following mitochondrial 
stress AMPK is activated to promote mitochondrial fission by phosphorylation of 
the mitochondrial fission factor (MFF), which is the receptor for the fission 
promoter dynamin-related protein 1 (DRP1) (Toyama et al., 2016). Mitochondrial 
fission is important for the generation of new mitochondria but also for their 
clearance when damaged and induction of this process by AMPK was suggested to 
prime cells for subsequent mitophagy. The term mitophagy refers to the 
mechanism of autophagy related to mitochondria, and represents an additional 
mechanism through which damaged mitochondria are removed.  
In addition to a role in the degradation of dysfunctional proteins and organelles, 
mitophagy and more broadly autophagy are important cellular processes that 
allow the recycle of macromolecules in response to energetic needs. In 
agreement with its role as energy sensor, it was noted that AMPK activation 
under nutrient starvation could induce autophagy by phosphorylation of the 
autophagy-initiating kinase ULK1 (Egan et al., 2011; Kim et al., 2011).  
Overall, by regulating both mitochondria biogenesis and clearance, as well as 
modulating autophagy in response to nutrient limitation, AMPK has established 
itself has a crucial coordinator of the cellular energetic engine. 
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1.1.6 Role of AMPK in the regulation of proliferation  
Cell proliferation is a high energy-demanding process that not only requires new 
nucleotides for DNA and RNA synthesis, but also building blocks necessary to 
produce two daughter cells. Indeed, back in 1974 it was noticed that cells 
cultured in a shortage of amino acids, glucose and phosphate ions were entering 
in a quiescent status that was reverted by the addition of the limiting nutrient 
(Holley and Kiernan, 1974). In agreement with its role in maintaining the 
energetic balance, activation of AMPK was described to inhibit proliferation 
under glucose deprivation. In particular, AMPK was found to activate p53 
through phosphorylation at Ser15, which induced cell cycle arrest at the G1 
phase (Jones et al., 2005). Although the finding of AMPK-mediated induction of 
p53 was confirmed by other studies (Imamura et al., 2001), Ser15 does not 
appear to conform to the consensus motif of AMPK and evidence of a direct 
interaction between p53 and AMPK has not been provided, suggesting the 
possibility of an indirect effect. However, other investigations have revealed a 
potential role of AMPK in mitosis. In particular, during a study aimed to identify 
novel substrates of AMPK2, Banko and colleagues revealed 28 new targets, 
many of them involved in mitosis and cytokinesis. AMPK was found to contribute 
to proper completion of mitosis and cytokinesis through phosphorylation of 
protein phosphatase 1 regulatory subunit 12C (PPP1R12C) (Banko et al., 2011). 
The function of AMPK in promoting mitosis might not be in line with its role of 
cell cycle inhibitor. However, the authors claimed that the regulation of mitosis 
could not be related to the energy regulating role of AMPK, as the mechanism 
was not affected by glucose deprivation. 
 
 
1.1.7 Role of AMPK in cancer 
The established function of AMPK in the regulation of metabolism has led to an 
increased interest in its role in metabolic diseases and to exploit AMPK as a 
potential therapeutic target. For example, the increase in glucose uptake and 
utilization as a result of AMPK activation is beneficial in metabolic conditions 
such as type II diabetes that is characterized by elevate blood sugar levels, 
insulin resistance and reduced insulin production. Indeed, the well-known AMPK 
Chapter 1  32 
activator Metformin has been successfully employed in clinic for the treatment 
of type II diabetes. Interestingly, a pilot case-study conducted on patients 
affected by type II diabetes that received treatment with Metformin revealed a 
decrease in the incidence of cancer (Evans et al., 2005). Similarly, aspirin, which 
is metabolized to Salicylate, a direct activator of AMPK, was shown to improve 
insulin sensitivity in diabetic patients and reduce the risk of cancer (Cuzick et 
al., 2009; Hundal et al., 2002). The metabolic and cancer preventive effects 
observed might be the overall result of additional effects on other tissues and 
beyond AMPK activation. Indeed, metformin has been reported to reduce insulin 
levels in non-diabetic patients affected by breast cancer (Goodwin et al., 2008), 
and patients affected by type II diabetes and hyperinsulinaemic have a higher 
risk of cancer development, thus suggesting that the reduction of insulin levels 
might contribute to the cancer preventive effect. Nevertheless, the role of AMPK 
in cancer remains of great interest. The features of uncontrolled proliferation 
and high metabolic demands of cancerous cells, often in a scenario of low 
availability of nutrients and oxygen, imply the intervention of AMPK to support 
energy homeostasis. However, there is still controversy on the role of AMPK as a 
friend or foe in cancer. Some studies have pointed towards a tumour suppressor 
role of AMPK. For example, it was reported that loss of AMPK1 cooperated with 
E-Myc in the acceleration of lymphomagenesis and caused a significant 
reduction in overall survival (Faubert et al., 2013). To note that the study made 
use of a full body knockout of AMPK1, giving rise to the possibility that deletion 
of AMPK in other compartments, such as stromal cells, could contribute to the 
observed phenotype.  
Several suggestions of a tumour suppressor role for AMPK come from studies 
related to LKB1 loss. In fact, given that the tumour suppressor LKB1 is the 
master upstream kinase for AMPK, it has been assumed that the effect observed 
upon LKB1 loss are mediated by the consequent loss of AMPK function. For 
example, BRAF mutation in melanoma cells was described to cause LKB1 
inactivation and consequent loss of function of AMPK, claiming a role of the 
LKB1/AMPK axis in mediating the oncogenic role of BRAF (Zheng et al., 2009). 
However, AMPK is not the only kinase downstream of LKB1 since, as elucidated 
in the next paragraph, several other AMPK-related kinases have been identified 
and they can mediate some of the functions of LKB1. In addition, genetic 
alterations of the AMPK subunits are not common events in cancer. Contrariwise, 
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we have highlighted a selective amplification of specific AMPK subunits in human 
cancer, which would suggest a tumour promoter role (Monteverde et al., 2015). 
Indeed, on one hand AMPK activity can counteract the growth of cancer cells by 
inhibiting proliferation and mTORC1 activity, but on the other hand the same 
functions can also help cancer cells to survive in stressful conditions and 
environments. In support of a tumour promoting role, increased AMPK activity 
was observed in the early phases of glioma development and was maintained 
throughout later stages (Jang et al., 2011). Moreover, an additional study 
revealed how the ability of AMPK to maintain NADPH levels by inhibition of ACC1 
and ACC2 contributed to the survival of tumour cells (Jeon et al., 2012).  
An intriguing aspect that has emerged in the recent years is to exploit the 
sensitivity to metabolic stress in case of impairments in the LKB1/AMPK axis. In 
particular, Shaw’s group revealed an increased sensitivity to the metabolic drug 
phenformin of LKB1-deficient non-small cell lung cancer (Shackelford et al., 
2013). In addition, a recent study demonstrated how the maintenance of 
Leukaemia-Initiating cells requires the activity of AMPK, as deletion of 
AMPK1/2 from the hematopoietic cells enhanced the survival of mice affected 
by Acute Myeloid Leukaemia and sensitized tumour cells to metabolic stress 
induced by dietary restriction (Saito et al., 2015).  
Further investigations are required to elucidate not only the context-dependent 
role of AMPK but also how different complexes might act as tumour promoters 
and suppressors before we can confidently manipulate AMPK for therapeutic 
purposes. 
 
 
1.2 AMPK related kinases 
AMPK was first named in 1988 by Hardie’s group (Munday et al., 1988), although 
previous reports had described an ATP-dependent kinase that could regulate 
Acetyl coenzyme A carboxylase by phosphorylation (Carlson and Kim, 1974). The 
function of AMPK has been extensively studied over time and, based on sequence 
similarity, several other kinases related to AMPK, called AMPK related kinases 
(ARKs), have emerged (Manning et al., 2002) (Fig. 1.4). Twelve other members 
have been included in the AMPK family: BRSK1 (SAD-B), BRSK2 (SAD-A), NUAK1 
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(ARK5), NUAK2 (SNARK), SIK1 (SIK), SIK2 (QIK), SIK3 (QSK), MARK1, MARK2, 
MARK3 (PAR1A or C-TAK1), MARK4 and MELK. 
 
 
Figure 1. 4 – Dendrogram of the AMPK related kinases. 
Dendrogram obtained by the analysis of the full-length amino acid sequence of the 12 
AMPK related kinases (ARKs) and AMPK using a freely available online tool from 
www.phylogeny.fr.  
 
 
These ARKs exert multiple biological functions, some of them shared with AMPK. 
In particular, the Microtubule affinity-regulating kinases (MARKs) and the Brain-
specific kinases (BRSK) are important regulator of cell polarity. The three 
isoforms of the salt-inducible kinases (SIK) exerts a variety of functions. 
Specifically, SIK1, first identified from the adrenal glands of rats that were fed 
on a high-salt diet (Wang et al., 1999), has been involved in cell cycle 
regulation, gluconeogenesis and lipogenesis regulation, muscle growth and 
differentiation; SIK2 is highly expressed in the adipose tissue but it has also been 
implicated in neuronal survival (Sasaki et al., 2011); SIK3 is thought to be 
important for cell proliferation as its downregulation resulted in chromosome 
abnormalities. The Maternal embryonic leucine zipper kinase (MELK) has been 
involved in the regulation of cell cycle and pre-mRNA splicing. NUAK2 activation 
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was described to play a role in the induction of cell-cell detachment (Suzuki et 
al., 2003b) and in the protection of tumour cells from CD95-mediated apoptosis 
(Legembre et al., 2004). In addition, NUAK2 was also described to promote cell 
migration (Namiki et al., 2011) and to share some functions and substrates with 
NUAK1, its closest AMPK related kinase, as further elucidated in the following 
paragraphs. 
 
 
1.2.1 Activation modalities of ARKs 
ARKs are characterized by a similar structure of the catalytic domain. However, 
the regulation of ARKs appears to be different from AMPK. Indeed, they do not 
contain regulatory subunits (Al-Hakim et al., 2005) and do not seem to be 
modulated by adenine nucleotides binding, although NUAK1 was reported to be 
activated by AMP and, similarly to NUAK2, by AICAR (an analogue of AMP) (Fisher 
et al., 2005; Lefebvre et al., 2001; Suzuki et al., 2003a). However, the evidence 
provided by the studies is not biochemically compelling as the response of the 
kinases to stimulation with AICAR or AMP was evaluated either exclusively by a 
cross-reacting antibody or employing a kinase assay that cannot completely 
preclude that the observed effect is mediated by other ARKs. In addition, an 
alternative study provided opposite evidence, as stimulation of MEFs with AICAR 
did not affect NUAK2 kinase activity (Lizcano et al., 2004a), questioning that 
other ARKs might be activated by AMP. 
Additionally, initial evidence suggested that AMPK was the only member to be 
responsive to increased intracellular Ca2+ levels. By using the AMARA peptide (a 
minimal phosphorylation substrate for the members of the AMPK family) multiple 
ARKs were tested for their ability to be activated in response to treatment with 
the calcium ionophore A23187. The assay revealed that none of the ARKs tested 
(SIK1/2/3, NUAK2, MARK1/2/3/4) was responsive to A23187, claiming that AMPK 
was the only member modulated by Ca2+ levels (Fogarty et al., 2010). However, 
the AMARA peptide may not be the optimal substrate for all the ARKs as it has 
been shown that they can phosphorylate peptide substrates at dissimilar rates, 
suggesting a different substrate specificity (Lizcano et al., 2004a). Additionally, 
and a more recent study has disputed the theory of AMPK being the only member 
to be responsive to Ca2+, as SIK2 was shown to be activated by an increase in 
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intracellular Ca2+ levels (Miranda et al., 2016). Therefore, further investigations 
and the development of more specific assays to test ARKs activity might reveal 
additional and surprising mechanisms of regulation. 
 
 
1.2.2 Regulation of ARKs by upstream kinases 
The finding that the Threonine 172 in the activation loop of AMPK1/2 was 
conserved across the other ARKs (Fig. 1.5) led to the hypothesis that the family 
members could share the upstream kinases. In this regard, Lizcano and 
colleagues identified the LKB1/MO25/STRAD complex to be a common upstream 
kinase of the AMPK family members, responsible for phosphorylation of the 
conserved threonine residue in the T-loop leading to over 50-fold increase in 
activity of the ARKs. The only exception was MELK, which was shown to 
autophophorylate the T-loop without the requirement of LKB1 (Lizcano et al., 
2004a). 
 
 
 
Figure 1. 5 – ARKs sequence homology of the kinase domain. 
Alignment of the T-loop amino acid sequence of the AMPK related kinases. Highlighted 
in red are the conserved amino acids across the kinases; the star denotes the conserved 
threonine in the activation loop. 
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CaMKK has been recognised as an alternative upstream kinase for AMPK and 
modulates its response to increased intracellular Ca2+ levels (Hurley et al., 2005; 
Woods et al., 2005). However, CaMKK has been disclaimed from being an 
upstream kinase for other ARKs. In particular, whereas expression of CaMKK 
was shown to enhance AMPK activation, the other ARKs tested did not respond 
similarly (Fogarty et al., 2010). In addition, in the same study BRSK1 activity 
appeared to be modulated by increased expression of CaMKK, which was also 
reported to interact with BRSK1 (Fujimoto et al., 2008), although Fogarty and 
colleagues suggested it to be a poor substrate for CaMKK. 
TAK1, the third suggested alternative kinase for AMPK, is not known to modulate 
any other ARKs. However, alternative upstream kinases have been shown to 
modulate some ARKs. For example, using a proteomic approach, the atypical 
protein kinase PKC was found to interact with MARK4 (Brajenovic et al., 2004). 
A later study identified an additional atypical PKC, PKC, to phosphorylate 
MARK2 at Thr595 and negatively affect its association to the plasma membrane 
as well as activity (Hurov et al., 2004). In addition, GSK3 was documented to 
inhibit MARK2 activity through phosphorylation at Ser212 (Timm et al., 2008). 
The three isoforms of SIK have been shown to be modulated by cAMP/Protein 
kinase A (PKA). In particular, phosphorylation at Ser577 by PKA was described to 
be required for nuclear translocation of SIK1 (Takemori et al., 2002), whereas 
phosphorylation of SIK2 on multiple serine and threonine residues by PKA was 
reported to affect cellular localization (Henriksson et al., 2012; Henriksson et 
al., 2015) and inhibit SIK3 activity in adipocytes (Berggreen et al., 2012). 
Additionally, AKT2 was shown to induce SIK2 activity by phosphorylation at 
Ser358 (Dentin et al., 2007). Finally, as already mentioned, SIK2 was found to be 
activated in response to increased Ca2+ signalling, although the responsible 
kinase was not identified in the study (Miranda et al., 2016). 
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1.3 NUAK1 
1.3.1 Structure and expression profile of NUAK1 
NUAK1 was identified during the analysis of its close member SNARK (NUAK2) 
performed by Suzuki and colleagues. By using an antibody developed against the 
SNARK peptide, they observed a cross-reacting protein by Western blot, which 
further analysis based on sequence homology revealed to be an additional 
member of the AMPK family (Suzuki et al., 2003a). 
The human NUAK1 gene is located on chromosome 12 and encodes a protein of 
661 amino acids, with a molecular weight of 78 kDa, whereas the mouse 
orthologous gene, Omphk1, is located on chromosome 10 and encodes for a 658 
amino acids protein. Expression of NUAK1 is conserved across species: from 
mammals to Zebrafish and Drosophila, with two homologous (NUAK1 and NUAK2) 
in vertebrates and only one in Drosophila melanogaster and Caenorhabditis 
elegans. Currently, there is no crystal structure available for NUAK1, but protein 
sequence analysis indicates a 55, 47 and 45.8% identity to NUAK2, AMPK1 and 
AMPK2, respectively, with a conserved threonine residue at position 211 in the 
activation loop (Fig. 1.5).  
 
The tissue distribution of mouse NUAK1 was analysed at mRNA levels and 
revealed high expression in oxidative tissues such as the cerebellum, heart and 
soleus muscle. In addition, analysis of protein levels confirmed high expression 
in the skeletal muscles (Inazuka et al., 2012). 
 
 
1.3.2 Upstream kinases regulating NUAK1 
LKB1 has been described as the master kinase for the members of the AMPK 
family. However, alternative upstream regulators have been identified for AMPK 
and other ARKs, as elucidated in the previous paragraphs. Regarding NUAK1, its 
activation was reported to be predominantly regulated by LKB1, as its deletion 
in mouse embryonic fibroblasts abolished NUAK1 basal activity (Zagorska et al., 
2010). However, a residual basal activity of NUAK1 was detected in HeLa cells, 
which are functionally null for LKB1. Furthermore, NUAK1 levels and activity 
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could still be increased by treatment with EDTA, described in the same study to 
induce NUAK1 activation, although to a lesser extent in comparisons to HeLa 
cells stably expressing LKB1 (Zagorska et al., 2010). Therefore, there are 
experimental suggestions for the presence of alternative kinases upstream of 
NUAK1. Indeed, the analysis of NUAK1 sequence revealed the presence of a 
putative site for AKT phosphorylation and in vitro analysis indicated that AKT 
could phosphorylate NUAK1 at Ser600. Activation of NUAK1 by AKT was described 
to promote ATM induction, which resulted in the phosphorylation of its target 
p53 to support cell survival under glucose starvation (Suzuki et al., 2003a). 
However, additional analysis reported that the S600A mutation of NUAK1 did not 
affect the kinase activity (Humbert et al., 2010), suggesting that the AKT 
signalling may not play a direct role in NUAK1 activity or that this mechanism of 
regulation might not be conserved in various contexts.  
The nuclear dbf2-related kinase 2 (NDR2) has been suggested in an isolated 
study as an additional alternative kinase for NUAK1. NDR1 and NDR2 were 
identified with a BLAST search for proteins with homology to the catalytic 
domain of LKB1 and CAMKK. Moreover, NDR2 was found to phosphorylate NUAK1 
at Thr211 in response to IGF-1 stimulation. Interestingly, in the study the 
deletion of LKB1 did not affect IGF-1-mediated phosphorylation of NUAK1 at 
Thr211, implicating that LKB1 does not mediate NUAK1 activation under these 
specific conditions (Suzuki et al., 2006). Although additional kinases other than 
LKB1 have been suggested to modulate NUAK1 activity, more work will be 
required to confirm those findings and clarify their functional relevance. 
 
 
1.3.3 Lesson on NUAK1’s physiological role from in vivo studies  
The physiological role of NUAK1 has been highlighted by some in vivo studies 
carried out in mouse models. In particular, during the search of genes involved 
in brain development, the mouse homologous of NUAK1, Omphalocele kinase 
(Omphk1), was found to be enriched in the brain and a mutant form of the gene 
was shown to induce defects in the abdominal wall closure during 
embryogenesis, even though it did not cause brain morphological abnormalities 
(Hirano et al., 2006). A following study reported that a mouse double knockout 
mutant for NUAK1 and NUAK2 displayed facial clefting, spina biﬁda and 
Chapter 1  40 
exencephaly, which is a malformation of the cranium that results in the external 
protrusion of brain tissue (Ohmura et al., 2012). Additionally, together with 
LKB1, NUAK1 was found to be involved in neuronal axon branching and growth by 
regulating the mitochondrial immobilization at the presynaptic site (Courchet et 
al., 2013). 
To obtain more insights on the function of NUAK1 in adult tissues, Esumi’s group 
developed the first conditional knockout mouse model for Nuak1. Furthermore, 
in light of the tissue expression analysis of NUAK1, they specifically focused on 
its role in the skeletal muscle by controlling the deletion of the gene using a 
muscle Creatin kinase (Mck)-Cre (MNUAK1KO) (Inazuka et al., 2012). Whereas 
constitutive deletion of Nuak1 is embryonically lethal, the conditional knockout 
mice did not display any abnormality. In addition, the analysis of the muscle 
fibres composition and size revealed no significant difference between 
MNUAK1KO and wild type animals. However, when the authors investigated the 
effect of Nuak1 deletion on glucose metabolism it was revealed that MNUAK1KO 
mice were characterized by lower body weight, fasting blood glucose and free 
fatty acids levels in comparison to wild type animals when fed on a high-fat diet. 
A further analysis of the mechanism of the observed regulation of glucose 
metabolism revealed that, in response to acute administration of glucose, Nuak1 
deletion resulted in enhanced membrane translocation of the glucose 
transporter GLUT4, through the increased phosphorylation of TBC1D4 at Thr649, 
which is known to regulate insulin-dependent trafficking of GLUT4. 
Phosphoproteomic analysis of isolated soleus muscle from MNUAK1KO and wild 
type mice exposed a decrease of the inhibitory phosphorylation of multiple 
proteins involved in glucose metabolism, such as the Insulin receptor substrate 1 
(IRS1), Glycogen synthase and Protein kinase , indicative of a higher insulin 
sensitivity and glycogen synthesis. Overall, data obtained from the muscle-
specific knockout of Nuak1 revealed a role of this AMPK-related kinase in the 
negative regulation of insulin signalling in soleus muscle (Inazuka et al., 2012). 
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1.3.4 Additional biological roles of NUAK1 
Investigations carried out in cancer cell lines contributed to the improvement of 
our knowledge of NUAK1 function and provided key indications on its potential 
use as target for cancer therapy. As a matter of fact, NUAK1 has been involved 
in a plethora of biological processes that can be exploited by cancer cells to 
support their survival and help them to disseminate to distant sites. 
 
 
1.3.4.1 Migration and Invasion 
Multiple independent studies have established over time a crucial role of NUAK1 
in cell migration and invasion to such an extent that initial reports were using 
those processes as a readout for NUAK1 activity.  
An initial study that highlighted NUAK1’s involvement in cell migration was 
carried out in a human pancreatic cancer cell line (PANC-1). Overexpression of 
NUAK1 in PANC-1 cells significantly increased their invasive capacity, which was 
further enhanced by IGF-1 stimulation and attenuated by AKT inhibition, 
suggesting an IGF/AKT regulatory mode. The mechanism through which NUAK1 
contributed to cell invasion was suggested to involve increased activity of 
metalloproteinase 2 and 9 (MMP-2 and MMP-9), as a higher activity of those two 
enzymes was detected in NUAK1 overexpressing PANC-1 cells. In addition, the 
increased invasion upon NUAK1 overexpression was also confirmed in vivo. 
Subcutaneous tumours derived from transplantation of PANC-1 cells stably 
overexpressing NUAK1 displayed an extensive degree of invasion of the muscle 
layer and metastasis at multiple organs were also detected at earlier stages in 
comparison to PANC-1 cells expressing endogenous levels of NUAK1 (Suzuki et 
al., 2004). Additional investigations have further establishing the pivotal role of 
NUAK1 in cell migration and invasion in multiple cancer settings (Chang et al., 
2012; Lu et al., 2013; Shi et al., 2014). 
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1.3.4.2 Cell adhesion 
A proteomic study carried out on immunoprecipitated NUAK1 identified 
interactors belonging to the myosin phosphatase complex, which is responsible 
for dephosphorylation of proteins such as Myosin light chain 2 (MLC2) and Polo-
like kinase-1 (PLK1) (Zagorska et al., 2010). The myosin phosphatase complex is 
formed by a catalytic subunit represented by the Protein Phosphatase 1 (PP1), 
and two regulatory subunits termed Myosin phosphatase target subunit (MYPT), 
which is expressed in three isoforms, and M20, of unknown function. NUAK1 was 
reported to interact with the complex formed by PP1 and MYPT1 and 
phosphorylate the latter at three different sites, Ser445, Ser472, Ser910 to 
promote binding of 14-3-3 protein to MYPT1, resulting in the inhibition of the 
myosin phosphatase complex (Zagorska et al., 2010). The described function of 
NUAK1 was shown to depend on the upstream kinase LKB1, since phosphorylation 
of MYPT1 was reduced in cells with LKB1 deletion. Moreover, inhibition of the 
myosin phosphatase complex following activation of the LKB1/NUAK1 axis was 
shown to result in higher phosphorylation levels of MLC2, which promotes cell 
detachment (Fig. 1.6). In addition, the study also identified the presence of a 
Gly-Ile-Leu-Lys (GILK) motif in NUAK1 sequence that mediates the interaction 
with the MYPT1-PP1 complex. Interestingly, NUAK2 was also shown to contain 
the GILK motif and to interact with the MYPT1-PP1 complex, sharing with 
NUAK1 the same phosphorylation sites on MYPT1, confirming previous reports 
that indicated MYPT1 phosphorylation by NUAK2 (Yamamoto et al., 2008; 
Zagorska et al., 2010). NUAK1 and NUAK2 are the only AMPK related kinases 
containing a GILK motif and evidence provided by Zagorska’s study also 
indicated that they are the only kinases of the family able to interact with 
MYPT1-PP1. 
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Figure 1. 6 – Mechanism of regulation of cell adhesion by NUAK1. 
Following phosphorylation and activation by LKB1, NUAK1 forms a complex with the 
Protein Phosphatase 1  (PP1) and with its regulatory subunit Myosin phosphatase 
target subunit (MYPT1). NUAK1 then phosphorylates MYPT1 at Ser445, Ser472, Ser910 to 
promote binding of 14-3-3 protein to MYPT1 and inhibition of the phosphatase activity 
of PP1. The overall outcome represented in the diagram is the increased 
phosphorylation of the myosin light chain 2 (MLC2) which promotes Myosin II activation 
and cell detachment. Image adapted from (Zagorska et al., 2010) using items from 
Servier Medical Art. 
 
 
1.3.4.3 Cell proliferation and senescence 
Experimental evidence has suggested that NUAK1 takes part in the regulation of 
cell proliferation, although with contradictive findings on its role as promoter or 
inhibitor of cell cycle progression. Specifically, NUAK1 was found to interact and 
phosphorylate p53 at Ser15 and Ser392, causing induction of p21 and cell cycle 
arrest at the G1/S checkpoint (Hou et al., 2011). In contrast, a function as 
positive regulator of cell cycle was suggested by Alessi’s group. In their study 
inhibition of NUAK1 activity using the selective inhibitor HTH-01-015 reduced the 
percentage of cells in the S-phase of the cell cycle and restricted the 
progression to the mitotic phase. A more detailed analysis of the mechanism 
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revealed an interplay between NUAK1 and Polo like kinase 1 (PLK1). The 
inhibition of the phosphatase activity of the PP1MYPT1 complex upon NUAK1 
induction was suggested to increase PLK1 phosphorylation and activity to 
promote G2/M transition. In addition, active PLK1 was shown to phosphorylate 
NUAK1 at Ser476 and Ser480, inducing the interaction of SCFTrCP E3 ubiquitin 
ligase complex with NUAK1 for its ubiquitylation and degradation. Thus, 
reciprocal modulation of PLK1 and NUAK1 levels during the different phases of 
cell cycle was suggested to orchestrate cell cycle progression (Banerjee et al., 
2014b). Further studies have supported a positive role of NUAK1 in cell cycle 
regulation as its downregulation resulted in cell cycle arrest (Perumal et al., 
2016) and its overexpression was described to enhance proliferation (Huang et 
al., 2014). 
NUAK1 has also been involved regulation of ploidy and senescence (Humbert et 
al., 2010). During a screening to identify genes involved in senescence, 
downregulation of NUAK1 was found to increase the replicative potential of 
senescent cells. Additional analysis revealed that NUAK1-induced senescence 
was related to its role in the regulation of cell ploidy. In particular, NUAK1 was 
reported to induce aneuploidy via the negative regulation of the protein levels 
of the Large Tumour Suppressor kinase 1 (LATS1) (Humbert et al., 2010), known 
to promote cytokinesis (Yang et al., 2004). 
 
 
1.3.4.4 Metabolic homeostasis 
In addition to a biological role in adhesion, invasion and cell proliferation, 
NUAK1 was reported to regulate metabolic homeostasis and promote the survival 
of MYC-overexpressing cells. In particular, NUAK1 was identified in a synthetic 
lethality screening carried out to search for genes for which the loss of function 
was lethal only in the presence of MYC overexpression (Liu et al., 2012). In 
addition to the intriguing discovery that NUAK1 depletion led to cell death of 
MYC-overexpressing cells, the study confirmed some of the previous findings, 
such as a cell cycle arrest in the S-phase upon NUAK1 depletion, but most 
importantly it revealed new functions in the regulation of metabolic 
homeostasis. Indeed, NUAK1 was found to contribute to the maintenance of ATP 
levels by two major mechanisms: inhibition of the mTOR pathway and promotion 
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of the expression of components of the mitochondrial respiratory chain. 
Activation of MYC resulted in an increased induction of AMPK and in a decrease 
of mTORC1 activity. However, NUAK1 depletion ablated the increase in AMPK 
activity, resulting in an overall enhancement of protein synthesis, probably due 
to the inability of AMPK to restrain mTORC1. Treatment with Rapamycin, an 
mTORC1 inhibitor, could protect cells form death by relieving the metabolic 
stress induced by NUAK1 depletion, supporting NUAK1 contribution to cell 
survival through restraining mTORC1 activity. Furthermore, NUAK1 was shown to 
sustain metabolic homeostasis through the maintenance of the mitochondrial 
respiratory chain, as NUAK1 depletion caused a significant decrease in the 
expression of multiple subunits of the electron transport chain. Finally, analysis 
of a tumour model obtained by the transplantation of hepatoma cells expressing 
MYC revealed that downregulation of NUAK1 reduced the incidence of tumour 
formation but also increased survival of mice in comparison to the NUAK1 wild 
type counterpart (Liu et al., 2012). Therefore, overall the study suggested 
important implications of NUAK1 in metabolism and proposed targeting of NUAK1 
as therapeutic approach in cancer.  
 
 
1.3.5 Clinical relevance for NUAK1 
Some of the investigations on NUAK1 function have been carried out in tumour 
cell lines, elucidating not only its roles but also a relevance for tumour biology 
and cancer therapy. Although NUAK1 gene alterations do not frequently occur in 
the four most common human cancers, with the exception of neuroendocrine 
prostate cancer (Fig. 1.7), studies done in human samples have strengthen the 
idea of a tumour promoter role.  
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Figure 1. 7 – NUAK1 gene alteration frequency in human cancer. 
The histogram represents the alteration frequency in NUAK1 gene across the four most 
lethal human cancers: pancreatic, breast, lung and colorectal cancer. NEPC, 
neuroendocrine prostate cancer; PAAC, Acinar Cell carcinoma of the pancreas; MBL, 
Mutational profiles of metastatic breast cancer. Graphic obtained from cBioportal and 
truncated from the right to omit non-relevant data. 
 
 
Multiple investigations have underlined a negative correlation between NUAK1 
expression levels and survival of patients affected by a number of cancer types. 
For example, analysis of samples derived from patients affected by colorectal 
cancer revealed higher levels of NUAK1 expression in the tumours compared to 
the normal adjacent tissue. Additionally, in agreement with a described role in 
invasion, NUAK1 was highly expressed in liver metastasis (Kusakai et al., 2004). 
Similarly, investigation of NUAK1 expression in tumour samples from patients 
affected by hepatocellular carcinoma and glioma indicated higher levels in the 
tumour tissue compared to normal adjacent tissue. Moreover, high expression 
levels of NUAK1 correlated with a poor prognosis for both glioma and 
hepatocellular carcinoma (Cui et al., 2013; Lu et al., 2013). The analysis of 
NUAK1 expression in human gastric and non-small cell lung cancer samples 
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similarly revealed high levels in the tumour samples, a negative correlation with 
prognosis and a positive correlation with the depth of invasion and lymph node 
metastasis (Chen et al., 2013; Ye et al., 2014).  
Most studies have highlighted a role of NUAK1 in invasion and metastasis. 
However, to date no genetically engineered mouse (GEM) models have been 
employed to characterize NUAK1 role in the early and late phases of tumour 
progression. In fact, given the variety of biological functions described, its role 
in cancer might not be limited to the metastatic process. In addition, the master 
upstream kinase LKB1 has been established as an important tumour suppressor in 
lung tumorigenesis, therefore we cannot exclude that NUAK1 might mediate 
some of tumour suppressive function in specific cancer types, such as lung 
cancer. Therefore, the use of GEM models could improve our understanding of 
NUAK1 role in cancer and suggest new therapeutic approaches.  
 
 
1.3.6 Exploiting the synthetic lethal interaction between NUAK1 
and MYC in cancer therapy 
The important finding of a synthetic lethal interaction between NUAK1 and MYC 
opened the door to a new therapeutic strategy for cancer.  
The proto-oncogene c-MYC, together with the family members N-MYC and L-
MYC, is a basic helix-loop- helix-leucine zipper (bHLH-LZ) transcription factor 
that controls the expression of a large number of genes. Upon dimerization with 
the protein partner MAX, MYC binds to the E‐box element CACGTG to induce 
gene expression, whereas upon interaction with the transcriptional activator 
Miz-1, MYC causes repression of Miz-1 target genes. Extensive studies carried out 
in the last decades have revealed that 15% of all genes belong to the network of 
targets regulated by MYC. These genes are involved in several biological 
processes, such as cell cycle regulation, anabolic metabolism (biosynthesis of 
amino acids, nucleotides and lipids), ribosome biogenesis, mitochondrial 
biogenesis and metabolic pathways (glycolysis, glutaminolysis) (Dang, 2012). 
Therefore, given its crucial role in cell metabolism and proliferation, it is not 
surprising that MYC is frequently dysregulated in human cancer. For example, 
MYC translocation to one of the immunoglobulin loci gives rise to Burkitt 
lymphoma (Dalla-Favera et al., 1982). In other cases, dysregulation of MYC 
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occurs via overexpression, while somatic mutations are not frequent events in 
cancer. In particular, MYC gene amplification has been frequently detected in 
many cancer types such as breast cancer, in which a correlation with disease 
progression has been suggested (Deming et al., 2000). Furthermore, upregulation 
of MYC can also be due to oncogenic activation of upstream signalling pathways 
that can promote MYC stability, i.e. RAS activation. Therefore, given its 
incontrovertible role in cancer, MYC targeting has been the focus of many 
therapeutic strategies. However, its inhibition has proved difficult to achieve 
because the lack of enzymatic activity limits the use pharmacological inhibitors 
and its localization in the nucleus prevents access to antibody-based therapies. 
Thus, the identification of synthetic lethal interactors, such as NUAK1, might 
represent a more successful strategy to challenge cancer addiction to MYC. 
 
 
1.4 Lung cancer 
1.4.1 Heterogeneity of lung cancer 
Lung cancer is the second most common cancer in both males and females, 
secondary for incidence to prostate and breast cancer, respectively. Although 
the incidence and mortality has experienced a reduction over the last 30 years, 
it still represents the leading cause of cancer-related death worldwide. 
Lung cancer can be classified in two major groups: Non-small cell lung cancer 
(NSCLC) and Small cell lung cancer (SCLC). The former accounts for the majority 
of cases (80%), and can be further classified in three groups based on histological 
characteristics: squamous cell carcinoma (SCC), adenocarcinoma (ADC) and 
large-cell carcinoma. Half of all cases of NSCLC are categorized as 
adenocarcinomas, which are malignant tumours with glandular histology and 
derive from the distal airways, particularly from bronchiolar and alveolar 
epithelial cells. Squamous cell carcinomas, which occurs in 40% of cases, 
typically derive from bronchial epithelial cells and are characterized by 
squamous differentiation, whereas large-cell carcinomas have a lower incidence 
and are diagnosed based on the lack of squamous or glandular differentiation. 
The specific cell or cells of origin is a contributor to the histological diversity of 
NSCLC. Although over the recent years the cell of origin for ADC has been 
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debated, the use of genetically engineered mouse models has facilitated the 
investigation of the topic. To date, three types of cells have been considered for 
their potential to give rise to ADC: Clara cells (or Club cells), alveolar epithelial 
type 2 (AT2) cells and bronchioalveolar stem cells (BASCs). Conversely, the 
limited availability of GEM models for the study of SCC has restricted the 
investigation of the histogenesis of this specific subtype, however basal cells are 
thought to be the at the origin of SCC (Chen et al., 2014) (Fig. 1.8). 
 
The classification of the multiple subtypes of NSCLC has been recently revisited 
by the World Health Organization, with the inclusion of several histological 
subtypes (Tab 1.1), and the recommendation for the use of 
immunohistochemistry along with morphological criteria for classification (Travis 
et al., 2015). In particular, in agreement with the protein expressed by the cell 
of origin, ADC displays positivity for markers like surfactant protein C (SPC), 
Keratin 7 (KRT7) and thyroid transcription factor 1 (TTF1), whereas SCC is 
characterized by expression of basal cells markers such as p63 and Keratin 5 
(KRT5) (Fig. 1.8). 
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Figure 1. 8 – Histogenesis and molecular markers of Adenocarcinoma and 
Squamous cell carcinoma. 
The distinct cell populations that give rise to Squamous cell carcinoma and 
Adenocarcinoma are depicted in the diagram. Squamous cell carcinoma typically origin 
from basal cells in the proximal lung whereas Adenocarcinoma is thought to arise from 
distal airways. TTF1, Thyroid transcription factor 1; KRT7, Keratin 7; SPC, surfactant 
protein C; KRT5, Keratin 5. Image adapted from (Chen et al., 2014) and generated using 
items from Servier Medical Art. 
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2015 WHO CLASSIFICATION OF LUNG TUMOURS 
Histological types and subtypes 
Adenocarcinoma Squamous cell carcinoma 
Lepidic adenocarcinoma Keratinizing squamous cell carcinoma 
Acinar adenocarcinoma Nonkeratinizing squamous cell 
carcinoma 
Papillary adenocarcinoma Basaloid squamous cell carcinoma 
Micropapillary adenocarcinoma Preinvasive lesion 
Solid adenocarcinoma Squamous cell carcinoma in situ 
Invasive mucinous adenocarcinoma Large cell carcinoma 
Mixed invasive mucinous and  
nonmucinous adenocarcinoma 
 
Colloid adenocarcinoma  
Fetal adenocarcinoma  
Enteric adenocarcinoma  
Minimally invasive adenocarcinoma  
Nonmucinous  
Mucinous  
Preinvasive lesions  
Atypical adenomatous hyperplasia  
Adenocarcinoma in situ  
Nonmucinous  
Mucinous  
 
Table 1. 1 - Histological types and subtypes of NSCLC. 
A summary of the histological types and subtypes of Non-small cell lung cancer (NSCLC) 
as for classification by the World Health Organization (Travis et al., 2015). 
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1.4.2 Molecular profiling of NSCLC 
The accumulation of genetic alterations leads ultimately to the dysregulation of 
the normal physiology of the cells and their transformation into cancerous cells. 
The development of new technologies such as Next Generation Sequencing has 
allowed the dissection of the genetic abnormalities in human cancer, providing 
us with a greater knowledge of the disease but simultaneously revealing its 
impressive complexity. The genetic investigation of SCC and ADC has added 
another level of separation between the two subtypes. Somatic mutations in 
PIK3CA, PTEN, are frequently detected in SCC, whereas mutations in EGFR, KRAS 
and ROS1 are more common in ADC. In addition, recent molecular profiling 
carried out on hundreds of tumour samples derived from patients with lung 
adenocarcinoma has uncovered several genetic aberrations and chromosomal 
rearrangements, placing lung ADC as one of the cancers with the highest 
mutation rate (The Cancer Genome Atlas Research, 2014). Interestingly, the 
mutation rates of some genes differ according to ethnicity and they also strongly 
correlate with tobacco smoke. For example, mutation in EGFR and ERBB2 are 
more frequent in never-smokers and Asian patients (Shigematsu et al., 2005), 
and tobacco smokers showed a higher number of mutations in comparison to 
never-smokers (Govindan et al., 2012).  
The study of genetically engineered mouse models for NSCLC has enormously 
contributed to our current knowledge of the molecular mechanisms that drive 
the disease. However, pre-clinical studies of lung adenocarcinoma have been 
primarily conducted at the expense of squamous cell carcinoma, due to the 
limited availability of mouse models for the latter. Although numerous genes are 
being investigated for their potential tumorigenic role in lung adenocarcinoma, 
activating mutations of EGFR and KRAS have been established as important 
drivers of the disease and targeting of their aberrant activity has been a major 
clinical goal in the recent years. 
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1.4.2.1 EGFR and the ERBB signalling network 
The dysregulation of the epidermal growth factor receptor (EGFR) in lung cancer 
was described already three decades ago (Veale et al., 1987), when 
immunostaining of tumour sections indicated higher levels of EGFR relative to 
normal lung tissue. Since then remarkable progresses have been made in the 
understanding of its role in lung cancer and overexpression of EGFR, detected in 
62% of cases, is now considered a common event in NSCLC, with activating 
mutations present in approximately 15% of lung adenocarcinoma. 
EGFR (also known as ERBB1 or HER1) belongs to the ERBB family of receptor 
tyrosine kinases together with ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4). 
These receptors are ubiquitously expressed as transmembrane proteins, 
characterized by an extracellular ligand-binding domain and an intracellular 
tyrosine kinase domain (Fig. 1.9). Although ERBB3 lacks a kinase domain and no 
ligand has been shown to bind to ERBB2, these two members can still function 
upon dimerization with EGFR and ERBB4. In addition, ERBB2-containg 
heterodimers have been shown to occur preferentially due to its peculiar 
conformation that resemble an active state that facilitates interaction with 
other ERBB receptors (Garrett et al., 2003).  
ERBB receptors are activated by several ligands that belong to the family of EGF-
related peptide growth factors (Fig. 1.9). These ligands are usually produced as 
transmembrane precursors that can be cleaved and released in the extracellular 
space by the enzymatic activity of the sheddases ADAMs (ADAM9, ADAM10, 
ADAM15 and ADAM17). Upon ligand binding, ERBB monomers form homo- and 
heterodimers, which triggers trans-phosphorylation of tyrosine residues of the 
intracellular kinase domain and stimulate the recruitment of effector proteins. 
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Figure 1. 9 – The ERBB signalling network. 
Representation of the homo- and heterodimers formed by the ERBB family of receptor 
tyrosine kinases (EGFR (1), ERBB2 (2), ERBB3 (3), ERBB4 (4)) and their ligands. Numbers 
below each ligand indicate the high-affinity for the respective ERBB receptors, but 
arrows are only shown for EGF and NRG4 for simplicity of the graph. The cross on the 
intracellular domain of ERBB3 indicates the lack of kinase activity, whereas the filled 
extracellular domain of ERBB2 indicates the absence of a ligand interacting with the 
receptor. Image adapted from (Yarden and Sliwkowski, 2001) and generated using items 
from Servier Medical Art. 
 
 
Multiple downstream signalling pathways are modulated by activation of the 
ERBB receptors and experimental evidence suggests that the type of ligand and 
heterodimer formed controls the selection of the effector proteins (Dankort et 
al., 2001; Sordella et al., 2004). Overall, the ERBB network modulates a number 
of biological processes: from cell proliferation and survival to cell migration and 
differentiation, with PI3K/AKT, RAS, PKC, JAK/STAT representing some of the 
several downstream effectors of the ERBB receptors. 
 
 
1.4.2.2 RAS signalling 
The story of the oncogene RAS goes back to 1960s, when Jennifer Harvey and 
Werner Kirsten discovered that a virus preparation from leukemic rat could 
induce sarcomas when injected in new-born rats (Ras= rat sarcoma). The 
homologous of the viral Ras sequence was identified in rat, mouse and humans in 
the following decades, and despite the extensive time and efforts spent in 
studying its function and, most importantly, its targeting, we are still in search 
of its Achilles’ heel.  
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The RAS family is frequently mutated in human cancer and consists of three 
genes: H-RAS, K-RAS and N-RAS. KRAS is the isoform more frequently mutated in 
lung cancer (30% of lung adenocarcinoma), with activating mutation first 
described in 1984 by Mariano Barbacid (Santos et al., 1984). 
RAS is a small GTPase that cycle between an off-state when bound to GDP to an 
on-state when bound to GTP. However, because of its poor intrinsic GTPase 
activity, it relies on two classes of proteins to switch between the on and off 
states: GTPase activating proteins (RASGAPs) and guanine nucleotide exchange 
factors (RASGEFs). In particular, RASGAPs stimulate the hydrolysis of GTP to 
GDP, promoting inactivation of RAS, whereas the RASGEFs induce the exchange 
of GDP for GTP, leading to RAS activation. Binding of GTP to RAS induces a 
conformational change in two regions, named Switch I and Switch II, resulting in 
an increased affinity and interaction of RAS with effector proteins (Vetter and 
Wittinghofer, 2001). Activating mutations impair RAS sensitivity to the activity of 
RASGAPs, which leads to a persistently active GTP-bound RAS (Malumbres and 
Barbacid, 2003).  
Mutations in KRAS frequently occur at codon 12, but the frequency of the type of 
substitution changes according to the type of cancer. In lung cancer, the 
mutation G12C is the most recurrent, followed by G12V and G12D (Cox et al., 
2014). Interestingly, the different substitutions have been shown to have a 
different correlation with cigarette smoke, with G12C and G12V being associated 
more with tobacco exposure than G12D (Riely et al., 2008), but also to engage 
different downstream effectors of RAS (Ihle et al., 2012). 
Regarding the downstream effectors, over 11 families have been identified as 
mediators of RAS function, but the Raf/MEK/ERK cascade and AKT pathway are 
among the major downstream effectors (Fig. 1.10). 
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Figure 1. 10 - Downstream targets of RAS. 
Active RAS in the GTP-bound state can stimulate multiple downstream pathways, among 
which the PI3K/AKT and the Raf/MEK/ERK cascade are the most important effectors. 
The PI3K/AKT axis support cell survival and proliferation through induction of mTORC1, 
the downregulation of the pro-apoptotic protein BAD and activation of MDM2, negative 
regulator of p53. On the other hand, RAS mediates activation of Raf, which culminates 
with the phosphorylation and activation of ERK, responsible for the regulation of several 
substrates located in the cytoplasm and in the nucleus, such as transcription factors, to 
support cell survival and proliferation. Only some of the targets are represented in the 
image. PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-
trisphosphate. Image generated using items from Servier Medical Art. 
 
 
The Raf/MEK/ERK signalling is one of the Mitogen-activated protein kinase 
(MAPK) cascade and transduces signals to regulate cell growth, differentiation 
and migration. The first step that triggers the pathway is the interaction and 
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phosphorylation of the Raf (MAPKKK) kinase by RAS. There are three isoforms of 
Raf (Raf-1, A-Raf, B-Raf), which differ not only in tissue distribution but also in 
their capability to activate the downstream effector MEK (Mitogen-activated 
protein kinase kinase or MAPKK). B-Raf is the isoform that most effectively 
activates the two isoforms of MEK (MEK1/2), followed by Raf-1, as opposed to 
the weak activation by A-Raf (Pritchard et al., 1995). This cascade of 
phosphorylation and activation events culminates with MEK catalysing a dual 
phosphorylation of a regulatory threonine and tyrosine on ERK. The 
serine/threonine kinase ERK (extracellular signal–regulated kinases or MAPK) is 
the only physiological substrate known of MEK and is encoded in two isoforms, 
ERK1 and ERK2, although several splicing forms are also produced. Once 
activated, ERK can regulate multiple targets located in the cytoplasm but also 
modulate nuclear transcription factors (Fig. 1.10). 
 
An additional and crucial downstream effector of RAS is the PI3K/AKT axis (Fig. 
1.10). This pathway is an important regulator of cell proliferation and survival 
and thus often dysregulated in cancer. Mechanisms of dysregulation include 
aberrant upstream signalling, i.e. EGFR or RAS mutation, as well as somatic 
mutations of its components (Vivanco and Sawyers, 2002). The first element of 
the signalling pathway is the Phosphoinositide 3‐kinase (PI3K), a family of lipid 
kinases that consists of three classes: class I (further divided into subclasses IA 
and IB), class II and class III. Class IA of the PI3K family is the best characterized 
and plays a prominent role in cancer (Thorpe et al., 2015). It is formed by a p85 
regulatory subunit and a p110 catalytic subunit, both of them being expressed as 
multiple isoforms. Active PI3K can phosphorylate phosphatidylinositol-4,5-
bisphosphate (PIP2) to form phosphatidylinositol-3,4,5-trisphosphate (PIP3), 
which functions as second messenger and activator of AKT and additional 
numerous effector proteins. There are three genes encoding as many forms of 
AKT: AKT1, AKT2 and AKT3. Upon activation of PI3K, AKT is recruited to the 
plasma membrane where the binding of PIP3 to the PH domain of AKT causes a 
change to an active conformation that facilitates the access of upstream kinases 
for phosphorylation. Phosphorylation of AKT1 at Thr308 and Ser473 by PDK1 and 
mTORC2, respectively, is required for the full activation of the kinase. 
Phosphorylation also occurs on the corresponding sites in AKT2 (Thr309 and 
Ser474) and AKT3 (Thr305 and Ser472). As phosphorylation and PIP3 are 
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important factors in triggering AKT activity, its inactivation is mediated by 
phosphatases and by the tumour suppressor PTEN, which is responsible for 
dephosphorylation of PIP3 (Manning and Toker, 2017). Although over 100 
substrates for AKT have been suggested, not all of them have been validated. 
Nonetheless, multiple effectors proteins belonging to a variety of signalling 
pathways have been established as key mediators of AKT function. For example, 
in its role to promote cell survival, AKT can phosphorylate and inhibit the pro-
apoptotic protein BAD and regulate the tumour suppressor p53 (Datta et al., 
1997; Ogawara et al., 2002); furthermore, AKT can stimulate cell growth by 
promoting mTORC1 activity through inhibition of the repressors TSC2 and PRAS40 
(Inoki et al., 2002; Sancak et al., 2007). 
 
 
1.4.3 Targeted therapies for NSCLC 
Despite the tremendous efforts made in the last decades to improve current 
treatments and introduce new therapies, patients affected by advanced lung 
cancer still have a 5-year survival rate of only 15%. However, the identification 
of genetic drivers of the disease has allowed the clinical use of targeted 
therapies that, in some instances, offer a better therapeutic outcome in 
comparisons to standard chemotherapy. For example, patients with activating 
mutations in EGFR can benefit from EGFR tyrosine kinase (TK) inhibitors. 
Responsiveness of patients with EGFR mutation to treatment with Gefitinib, an 
EGFR inhibitor, was firstly described in 2004 (Santos et al., 1984), almost twenty 
years after the discovery of EGFR dysregulation in lung cancer. Subsequent 
clinical studies have described the benefit of EGFR TK inhibitors, accountable for 
a longer median progression-free survival and also a higher response rate over 
standard chemotherapy in lung cancer patients selected based on EGFR 
mutations (Maemondo et al., 2010). However, the emergence of resistance to 
long-term treatments represents a major clinical problem, to which the response 
has involved the use of second and third generation TK inhibitors, mutant-
specific inhibitors or targeting additional upregulated kinases. A wide range of 
resistance mechanisms to EGFR inhibition has been identified over time, such as 
activation of collateral pathways (MET amplification or activation of ERBB2 
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signalling), but also secondary mutations in EGFR, such as the T790M 
substitution, which affects the binding of the small molecule inhibitors 
(Kobayashi et al., 2005; Turke et al., 2010; Yonesaka et al., 2011). Overall, 
introduction of TK inhibitors in combination with patients’ stratification based 
on mutation status has revolutionized the therapeutic strategy for non-small cell 
lung cancer and many other cancer types. Nevertheless, limited targeted 
therapies are available for patients bearing mutations in the alternative 
oncogenic driver KRAS, as its inhibition has been extremely challenging to 
achieve. In particular, the development of GTP-competitive inhibitors that could 
impair RAS activity has proved to be unsuccessful due to the picomolar affinity 
of GTP for RAS (Spiegel et al., 2014). In addition, a broad inhibition of RAS, 
without distinction between the mutant and wild type form, might exhibit 
significant toxicity given its fundamental role in the biology of normal tissues. 
Therefore, in the recent years researchers have been trying to develop inhibitors 
that specifically target the mutant forms of RAS, with some promising results 
that need to be evaluated in clinical trials (Ostrem et al., 2013).  
Alternatively, researchers have tried to impair RAS function by targeting those 
mechanisms that are required for its activity and its ability to engage with 
effector proteins. For example, localization of RAS to the plasma membrane is a 
key prerequisite for its function and requires the attachment of a farnesyl group 
to the CAXX motif that is present in all RAS isoforms. However, upon inhibition 
of the farnesyltransferase (FT) enzyme, which catalyses the farnesylation, RAS 
can be post-translationally modified by geranylgeranyltransferase (GGT). 
Simultaneous inhibition of both FT and GGT has proved to be highly toxic in 
preclinical models, limiting its clinical application (Lobell et al., 2001). 
Additionally, inhibition of the downstream effectors of RAS represents an 
alternative therapeutic strategy. A major effector of RAS is the MAPK pathway, 
which is hyper activated in 30% of cancers. Several pharmacological inhibitors of 
the components of the MAPK cascade have been developed and reached clinical 
evaluation over time. For example, MEK inhibitors have been approved for 
clinical use in B-RAF mutant metastatic melanoma and combination of 
Selumetinib (MEK inhibitor) with standard chemotherapy (docetaxel) resulted in 
an increase of the median progression-free survival in comparison to 
chemotherapy alone in a phase II trial in advanced KRAS-mutant NSCLC (Janne et 
al., 2013). However, a phase II trial suggested that inhibition of MEK using 
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Trametinib was not beneficial over chemotherapy with docetaxel in lung cancer 
patients selected for KRas mutation (Blumenschein et al., 2015). Further studies 
suggested the potential mechanism responsible for the lack of therapeutic 
efficacy of MEK inhibition alone. Specifically, Bernards group revealed that MEK 
inhibition resulted in upregulation of ERBB2 and ERBB3, which can sustain 
tumour cell growth through upregulation of the PI3K/AKT pathway. Therefore, a 
combinatorial therapy with ERBB receptors and MEK inhibitors was shown to be 
more effective and overcome resistance to MEK inhibition (Sun et al., 2014). 
Overall, preclinical and clinical data suggest that the success of a single-agent 
therapy is highly unlikely given the ability of tumour cells to rewire their 
signalling to support viability in the presence of inhibitory drugs. 
 
 
1.5 PhD objectives 
The great magnitude of studies in the cancer research field has contributed to 
make an impressive progress in the understanding and treatment of cancer. 
However, they have also highlighted the high complexity of cancer and how it 
cannot be defined as a single disease but as an extremely heterogeneous set of 
diseases. Although key oncogenes have been identified decades ago for their 
crucial role in the onset and maintenance of tumour cells viability, many of 
them still remain ‘undruggable’ and their targeting represents a major clinical 
goal. 
 
The recent finding of the requirement of NUAK1 in cells overexpressing the 
oncogene MYC gave rise to a new therapeutic potential of this AMPK related 
kinase. Although other studies have revealed a clinical relevance for NUAK1 
targeting in cancer, our knowledge about its regulation and biological function 
remains limited. In addition, experimental evidence has suggested a tumour 
promoter role for NUAK1, albeit its location downstream of the tumour 
suppressor LKB1. Therefore, the objective of this work are: 
• Improve our knowledge of the mechanisms of NUAK1 regulation; 
• Understand NUAK1’s role in metabolic homeostasis and specifically 
explore its involvement in lung tumorigenesis; 
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• Enhance our understanding of the molecular mechanisms of Non-small cell 
lung cancer to develop new therapeutic approaches. 
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Chapter 2 – Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
Reagent Supply 
2-mercaptoethanol Sigma-Aldrich 
2-propanol Fisher Scientific 
30% Acrylamide VWR 
96-Well PCR plates Biorad 
Ammonium persulfate (APS) Sigma-Aldrich 
Anti-FLAG M2 affinity gel Sigma-Aldrich 
APC Annexin V Biolegend 
BSA Sigma-Aldrich 
CaCl2 solution Sigma-Aldrich 
Captisol Selleckchem 
Chloroform Fisher Scientific 
DMSO Sigma-Aldrich 
DNAse/RNAse free water Qiagen 
Dulbecco’s Modified Eagle Medium (DMEM) Life Technologies 
ECL Western blotting substrate Pierce 
Fetal Bovine Serum (FBS) Thermo Fisher 
L-Glutamine Life Technologies 
Lipofectamine 3000 Thermo Fisher 
Lipofectamine RNAiMAX Thermo Fisher 
Milk powder Marvel 
Minimum Essential Media (MEM), powder Thermo Fisher 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Nitrocellulose membrane (0.2 m pore size) 
GE Healthcare Life 
Sciences 
Normal Goat Serum (NGS) Vector labs 
NP-40 Sigma-Aldrich 
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Table 2. 1 – Chemicals and Suppliers 
 
 
2.1.2 Kits 
Table 2. 2 – Kits 
 
Opti-MEM Thermo Fisher 
PageRuler Prestained Protein Ladder Thermo Fisher 
Peanut oil Sigma-Aldrich 
PEG 400 Sigma-Aldrich 
Penicillin/Streptomycin Life Technologies 
Phosphatase inhibitor cocktail 2 Sigma-Aldrich 
Phosphatase inhibitor cocktail 3 Sigma-Aldrich 
Polybrene Sigma-Aldrich 
Ponceau S Sigma-Aldrich 
Propidium Iodide Sigma-Aldrich 
Protease inhibitor cocktail Sigma-Aldrich 
Puromycin  
Spectra multicolour high range protein ladder Thermo Fisher 
SuperSignal West Dura Pierce 
Tris HCl Sigma-Aldrich 
Trizol Thermo Fisher 
Trypsin Life Technologies 
Tween-20 Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Kit Supplier 
ApopTag Peroxidase in situ Apoptosis Detection 
kit 
Millipore 
Pierce BCA Protein Assay kit Thermo Fisher 
Quantitect-Rev. transcription kit Qiagen 
Vectastain ABC HRP Kit Vector Laboratories 
SYBR green Fast Mix VWR 
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2.1.3 Solutions 
Solution Recipe 
Whole cell extract lysis 
buffer 
150 mM NaCl, 50 mM Tris (pH 7.5), 1% NP-40 
(v/v), 0.5% Sodium deoxycholic acid (w/v), 1% 
SDS (v/v), protease and phosphatase inhibitor 
cocktails 
IP lysis buffer 
50 mM Tris HCl (pH 7.5), 1% NP-40 (v/v), 0.27M 
sucrose, phosphatase and protease inhibitors 
IP washing buffer 50 mM Tris HCl (pH 7.5), phosphatase inhibitors 
Annexin V Binding Buffer 
10 mM HEPES (pH 7.4), 140 mM NaCl, 2.5 mM 
CaCl2 
5X Sample Buffer 
0.3 M Tris (pH 6.8), 50% Glycerol (v/v), 10% SDS 
(w/v), 0.5% Bromophenol Blue (w/v), 4% 2-
mercaptoethanol 
Ponceau S 0.1% Ponceau S (w/v), 5% acetic acid 
PBS 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
KH2PO4, 
PBS/T PBS, 0.1% Tween-20 (v/v) 
TBS 10 mM Tris HCl pH7.4, 150 mM NaCl 
TBS/T TBS, 0.1% Tween-20 (v/v) 
Sodium Citrate Buffer 10 mM Sodium citrate (pH 6.0) 
Running Buffer 10% SDS, 250 mM Tris, 1.92 M Glycine 
Transfer Buffer 
0.1% SDS, 25 mM Tris, 0.192 M Glycine, 20% 
Methanol 
Table 2. 3 – Recipes of solutions 
 
 
2.1.4 Primary Antibodies 
Protein Species Antibody Supplier 
Phospho-ACC (Ser79) Rabbit 3661 Cell Signaling 
ACC Rabbit 3676 Cell Signaling 
Phospho-RAPTOR (Ser792) Rabbit 2083 Cell Signaling 
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RAPTOR Rabbit 2280 Cell Signaling 
Phospho-4E-BP1 (Thr37/46) Rabbit 2855 Cell Signaling 
4E-BP1 Rabbit 9644 Cell Signaling 
Phospho-p70 S6 Kinase (Thr389) Rabbit 9234 Cell Signaling 
p70 S6 Kinase Rabbit 2708 Cell Signaling 
Phospho-AMPK (Thr172) Rabbit 2535 Cell Signaling 
AMPK1/2 Rabbit 2532 Cell Signaling 
AMPK1/2 Rabbit 4150 Cell Signaling 
AMPK1 Rabbit 32508 Abcam 
NUAK1 Rabbit 4458 Cell Signaling 
Phospho-NUAK1 (Thr211) Rabbit NA Eurogentec 
NUAK2 Sheep S225B MRC PPU 
Phospho-(Ser) PKC substrate Rabbit 2261 Cell Signaling 
Phospho-PKC/II (Thr638/641) Rabbit 9375 Cell Signaling 
PKC Rabbit 2056 Cell Signaling 
phospho-MARCKS (Ser159/163) Rabbit 11992 Cell Signaling 
anti-MARCKS Rabbit 72459 Abcam 
Phospho-MYPT1 (Ser445) Sheep S508C MRC PPU 
MYPT1 Rabbit 8574 Cell Signaling 
MYC Rabbit 32073 Abcam 
Phospho-EGFR (Tyr1068) Rabbit 3777 Cell Signaling 
EGFR Rabbit 06-847 Millipore 
Phospho-ERBB2 (tyr1248) Rabbit 06-229 Millipore 
ERBB2 Mouse OP15L Merk-Millipore 
Phospho-ERBB3 (Tyr1197) Rabbit 4561 Cell Signaling 
ERBB3 Mouse 05-390 Millipore 
Phospho-ERK (Tyr204) Mouse 7383 Santa Cruz 
ERK Rabbit 4695 Cell Signaling 
Phospho-AKT (Ser473) Rabbit 4060 Cell Signaling 
AKT Mouse 2920 Cell Signaling 
FLAG Mouse F1804 Sigma-Aldrich 
Vinculin Rabbit 129002 Abcam 
-Actin Mouse A5441 Sigma-Aldrich 
-Tubulin Mouse 173831 Abcam 
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H2B Rabbit 1790 Abcam 
Table 2. 4 – Primary antibodies 
 
 
2.1.5 Secondary Antibodies 
Protein Species Antibody Supplier 
HRP anti-rabbit Sheep NA934 Ge Healthcare  
HRP anti-mouse Sheep NA931 Ge Healthcare  
HRP anti-sheep Rabbit 31480 Pierce 
Table 2. 5 – Secondary antibodies 
 
 
2.1.6 siRNA  
Target SiRNA Supplier 
Non-targeting control FlexiTube 1022076 Qiagen 
NUAK1 1  FlexiTube SI00108388 Qiagen 
NUAK1 2  FlexiTube SI00108388 Qiagen 
NUAK2 FlexiTube SI02660224 Qiagen 
PKC 1  FlexiTube SI00605934 Qiagen 
PKC 2  FlexiTube SI00605927 Qiagen 
MYC #1 FlexiTube SI00300902 Qiagen 
MYC #2 FlexiTube SI02662611 Qiagen 
MYC #3 FlexiTube SI03101847 Qiagen 
Table 2. 6 – siRNA used for RNA interference experiments 
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2.1.7 shRNA 
Target Sequence Supplier 
Non-targeting control Renilla Mirimus Inc 
MYC 1  CTGAGTCTTGAGACTGAAAGAT Mirimus Inc 
MYC 2  CGCCTCCCTCCACTCGGAAGGA Mirimus Inc 
Table 2. 7 – shRNA used for RNA interference experiments 
 
 
2.1.8 Primers  
Primer Sequence 
ITPR1 forward 5’-GAAGGCATCTTTGGAGGAAGT-3’ 
ITPR1 reverse 5’-ACCCTGAGGAAGGTTCTG-3’ 
PKC forward 5’-CAAGGGATGAAATGTGACACC-3’ 
PKC reverse 5’-CCTCTTCTCTGTGTGATCCATTC-3’ 
NUAK1 forward 5’-CCGCTCACTGATGTAATC-3’ 
NUAK1 reverse 5’-GTCATCTCTCAACCATCCTCAT-3’ 
CaMKK forward 5’-GGAGGTCGAGAACTCAGTCAA-3’ 
CaMKK reverse 5’-CATGGTCTTCACCAGGATCA-3’ 
-Actin forward 5’-CCAACCGCGAGAAGATGA-3’ 
-Actin reverse 5’-CCAGAGGCGTACAGGGATAG-3’ 
2m forward 5’-ACCTCCATGATGCTGCTTAC-3’ 
2m reverse 5’-GGACTGGTCTTTCTATCTCTTGTAC-3’ 
Table 2. 8 – qPCR primer sequences 
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2.1.9 Acrylamide gels 
 Separating Gel Stacking Gel 
 7.5% 10% 13%  
30% 
Acrylamide 
3.75 ml 5.1 ml 6.8 ml 650 l 
1M Tris pH8.9 5.6 ml 5.6 ml 5.6 ml - 
1M Tris pH6.8 - - - 600 l 
H2O 5.5 ml 4.2 ml 2.5 ml 3.6 ml 
10% SDS 150 l 150 l 150 l 50 l 
20% APS 75 l 75 l 75 l 25 l 
TEMED 15 l 15 l 15 l 5 l 
Table 2. 9 – Acrylamide gels composition 
 
 
2.1.10 Drugs 
Reagent Supplier 
A23187 Abcam 
A769662 Abcam 
BAPTA-AM Tocris 
Erlotinib LC Labs 
Gö6976 Tocris 
HTH-01-015 Cambridge Bioscience 
Ionomycin Abcam 
MG132 Sigma-Aldrich 
Neratinib Carbosynth 
phenformin Sigma-Aldrich 
Rapamycin Sigma-Aldrich 
Sto-609 Sigma-Aldrich 
Trametinib Insight Biotechnology 
WZ 4003 Tocris 
Table 2. 10 – Drugs and Suppliers 
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Tumour Cells 
U2OS and HeLa cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 4.5 g/L glucose, 2 mM L-Glutamine, 100 U/ml of penicillin, 
100 g/ml of streptomycin, 10% foetal bovine serum (FBS) and incubated at 37 
C in 5% CO2. Cells were passaged when they reached 70% confluency and kept in 
culture until a maximum of 20 passages.  
To split cells, the medium was removed and cells were washed once with PBS. 
Cells were then incubated with Trypsin-EDTA at 37 C until complete 
detachment of the adherent cells was observed. Trypsin was then quenched by 
the addition of complete culture medium and cells were counted using a 
hemocytometer or an automated cell counter (Innovate) and re-seeded at the 
desired density for further experiments or for maintaining cells in culture. 
All cell lines were routinely tested for mycoplasma contamination and were 
validated by STR profiling using an in-house validation service (CRUK-BICR). 
 
 
2.2.1.2 Primary mouse embryonic fibroblasts 
Pregnant females were euthanized by CO2 at 13.5 days after plugging was 
observed. The uterus was dissected using dissecting forceps and each embryo 
was released from the yolk sac and placed in individual petri dishes containing 
PBS; embryos were then decapitated and a piece of tissue was used for 
genotyping purposes. After the removal of the embryonic internal organs, the 
embryo body was transferred into a fresh petri dish containing 2 ml of PBS and 
finely minced using a scalpel. Minced tissue was transferred to a falcon tube 
containing 1 ml of Trypsin-EDTA and incubated at room temperature for 15 
minutes with occasional shaking. The tissue suspension was then placed in a 10 
cm diameter petri dishes containing complete Dulbecco’s modified Eagle’s 
medium (DMEM) and incubated at 37 °C and 3% of Oxygen. The entire procedure 
was carried out in sterile conditions in a laminar flow hood. Cells were passaged 
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every 3 days using the same protocol as described in section 2.2.1.1, and re-
seeded at a density of 1.3x106 into a 10 cm petri dish. 
To induce recombination of the loxP-flanked regions, wild type and Rosa26-lsl-
MYC MEFs were infected with 300 multiplicity of infection (MOI) of Adenovirus 
(University of Iowa) expressing Cre recombinase. Briefly, Adenovirus Cre, stored 
at -80 °C, was thawed on ice and mixed with the minimum sufficient volume of 
DMEM complete medium to cover the plate. Polybrene (4 g/ml) was also added 
to the vector-medium solution to increase the transduction efficiency and the 
final mixture was added to the cells. Culture medium was removed after 6-8 
hours post-transduction and replaced with fresh complete medium. Nuak1FL/FL 
MEFs were infected with retrovirus expressing tamoxifen-inducible CreER and 
selected on 1g/mL puromycin.  
SV40 T antigen-immortalised Prkaa1FL/FL; Prkaa2FL/FL MEFs were generously 
provided by Russell Jones, McGill University, and infected with 300 MOI of 
Adenovirus-Cre or Adenovirus-LacZ.  
 
 
2.2.1.3 Cryopreservation and resuscitation of cells 
For long-term storage, cells were cryopreserved when in log-phase growth, i.e. 
when cells were below the confluent density. Culture medium was removed and 
cells were washed once with PBS. Trypsin-EDTA was then added to detach the 
cells, which were re-suspended in freezing medium (10% DMSO, 90% FBS). The 
cell suspension was aliquoted into cryovials, which were transferred into Mr 
Frosty freezing containers filled with 2-propanol and stored at -80 °C before 
long-term storage in liquid nitrogen. 
 
For resuscitation of frozen cells, cryovials containing cells were quickly thawed 
by incubation in a 37 °C water bath for 3-5 minutes. The cell suspension was 
then transferred to a 15 ml falcon tube containing complete culture medium and 
centrifuged at 1200 rpm for 5 minutes. After centrifugation, the supernatant was 
removed and the cell pellet was re-suspended in complete culture medium, 
transferred to appropriate culture plates and incubated at 37 °C. 
For resuscitation of Mouse Embryonic Fibroblasts, cryovials were quickly thawed 
as described above and the cell suspension was added drop-wise to culture 
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plates containing complete medium, avoiding the centrifugation step, and 
incubated at 3% Oxygen. 
 
 
2.2.2 Plasmid transfection 
Cells were seeded at 1.5x106 cells per 10 cm and incubated overnight at 37 °C. 
The next day, 3 g of DNA was re-suspended in 500 l OPTI-MEM, with the 
subsequent addition of 6 l of p3000 reagent. At the same time, 5 l of 
Lipofectamine 3000 was added to 500 l of Opti-MEM. Then, the two solutions 
were mixed together and incubated at room temperature for 15 min, as for 
manufacturer’s instructions. The DNA-lipid complex was added drop-wise to the 
cells in Pen/Strep free DMEM medium, following incubation at 37 °C. After 12 
hours, medium was replaced with complete DMEM and cells re-seeded for 
further experiments and analysed as per figure legends. 
shRNA-encoding plasmids, containing a puromycin resistance gene, were 
transfected as described above. In addition, cells were selected using 1g/mL of 
puromycin before subsequent experiments. Non-transfected cells treated with 
the same antibiotic were used as control to assess the antibiotic response. 
FLAG- tagged NUAK1 T211A mutant plasmid was generously provided by David 
Bernard, Cancer Research Center of Lyon, and was reverted to the wild type 
form using a mutagenesis kit (QuikChange XL Site-Directed Mutagenesis Kit, 
Agilent Technologies). 
 
 
2.2.3 siRNA transfection 
Cells were seeded at 1x106 cells per 10 cm and the incubated overnight at 37 °C. 
Next day, the desired volume of siRNA, as per figure legends, was re-suspended 
in 500 l OPTI-MEM and 10 l of Lipofectamine RNAiMAX was also diluted in a 
second vial containing 500 l Opti-MEM. The diluted siRNA was then added to the 
diluted Lipofectamine RNAiMAX and the solution obtained was incubated at room 
temperature for 5 minutes before adding it drop-wise to the cells in Pen/Strep 
free DMEM medium. Cells were incubated at 37 °C and re-seeded for further 
experiments as per figure legends.  
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2.2.4 RNA extraction and Quantitative Real-Time PCR 
2.2.4.1 RNA extraction 
Cells were seeded at 1x105 cells per well in a 6 well plate in triplicates. To 
isolate RNA, they were first rinsed in PBS and then harvested by adding 1 mL of 
Trizol. 200 l of Chloroform was then added and the cell suspension was 
centrifuged at 14,000 rpm for 15 minutes at 4 °C. The upper aqueous phase was 
transferred to a fresh tube and mixed with an equal volume of isopropanol. The 
mix was incubated on ice for 20 minutes before centrifugation at 15,000 rpm for 
10 minutes at 4 °C. The supernatant was removed and the RNA pellet was 
washed by the addition of 500 μl of 70% ethanol followed by centrifugation at 
8,000 rpm for 5 min at 4 °C. The washing step was repeated a second time 
before air-drying the RNA pellet to completely remove the residual ethanol. 
Finally, RNA was re-suspended in 30 μl of RNase and DNase free water and 
incubated at 56 °C for 10 min. RNA concentration was measured using NanoDrop 
2000c (ThermoFisher).  
 
 
2.2.4.2 cDNA synthesis 
Reverse transcription of 1 μg RNA into cDNA was carried out using QuantiTect 
Reverse Transcription Kit, according to manufacturer’s instructions. Briefly, 1 g 
of RNA was added to 2 l of gDNA Wipeout buffer and a final volume of 14 l was 
reached with the addition of RNase free water. The mixture was incubated at 42 
°C for 2 minutes to remove contamination with genomic DNA and then samples 
were transferred on ice. For the reverse transcription of RNA into cDNA, 1 l of 
Quantiscript Reverse Transcriptase, 4 l of Quantiscript RT buffer and 1 l of RT 
Primer mix were added to each RNA sample and incubated first at 42 °C for 15 
minutes and then at 95 °C for 3 minutes to inactivate the reverse transcriptase 
enzyme. 
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2.2.4.3 qPCR primers design and analysis 
Primers for amplification of the gene of interest were designed using the Assay 
Design Centre freely available from Roche website, using an intron spanning 
assay. They were then analysed for the formation of hairpins, self- and hetero-
dimers with the OligoAnalizer 3.1 freely available from IDT (Integrated DNA 
Technology).  
 
 
2.2.4.4 Quantitative Real-Time PCR 
Real time quantification was performed using SYBR Green Fast Mix. Specifically, 
1 μl of cDNA was added to a mix containing 5 μl of SYBR Green Fast MIX, 0.1 μl of 
each Reverse and Forward primers (10 M stock), and 3.8 μl of DNAase/RNAse 
free water to reach a final volume of 10 μl. Samples not containing the cDNA 
template were included to test the primer formation of homo- or heterodimers. 
Samples were plated in triplicates in a 96-well PCR plate and the qPCR reaction 
was carried out using a C1000 thermal cycler (Bio-Rad). A three-step protocol 
was used for the qPCR reaction:  
 
Temperature (°C) Time Cycle number 
95 5 minutes 1 
95 30 seconds  
60 20 seconds 35 
72 10 minutes 1 
65 10 seconds 1 
95 30 seconds 1 
Table 2. 11 – Cycling conditions for qPCR reaction 
 
The relative quantification of gene expression was performed using the 
comparative ΔΔCt method, with normalization of the target gene to the control 
genes β2-macroglobulin or Actin. 
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2.2.5 Immunoprecipitation and immunoblotting 
2.2.5.1 Immunoprecipitation 
FLAG-NUAK1 wild type, mutant (T211A) or empty vector transiently 
overexpressed HeLa cells were rinsed with ice-cold PBS and then lysed in IP Lysis 
Buffer (Tab. 2.3). Protein content of the cell lysates was quantified using the 
BCA quantification kit according to manufacturer’s instructions and 1 mg of 
proteins were incubated overnight at 4 C with anti-FLAG M2 Affinity gel. 
Immunoprecipitated were centrifuged at 2,000 rpm at 4 C for 1 minute, the 
supernatant was discarded and pellet washed twice with IP Washing Buffer (Tab. 
2.3). After the final washing step, the immunoprecipiated were re-suspended in 
30 μl of 2X SDS Sample Buffer. 
 
 
2.2.5.2 Preparation of whole cell proteins extracts 
For whole cell extracts, cells were rinsed twice with ice-cold PBS and then lysed 
in situ with ice-cold lysis buffer (Tab. 2.3). Lysates were then sonicated to 
reduce viscosity and diluted in 5X SDS Sample Buffer.  
 
 
2.2.5.3 SDS-PAGE 
Immunoprecipitated and whole cell extract proteins were resolved by SDS-PAGE. 
Samples were boiled at 95 C for 10 minutes and centrifuged at 5,000 rpm for 2 
minutes before loading onto hand-cast acrylamide gels of 1.5 mm thickness and 
of various percentage (Tab. 2.9) according to the molecular weights intended to 
separate. Electrophoresis was performed using a Bio-Rad Electrophoresis 
chamber containing Running Buffer (Tab. 2.3) and gels were run at 90 V until 
samples reached the separating gel and then the run was continued at 120 V 
until the visualization of the protein ladder indicated the preferred separation. 
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2.2.5.4 Western Blotting 
Proteins were transferred to nitrocellulose membrane using a Bio-Rad tank 
transfer system, in which gels and membranes are submerged under transfer 
buffer (Tab. 2.3). Transfer was performed at 250 mA for a maximum of 2.5 
hours.  
The membrane was quickly stained using a Ponceau S solution to observe the 
quality of the transfer process and then rinsed with TBS/T before adding a 
blocking solution of 5% milk in TBS/T for 1 hour at room temperature with gentle 
shacking. The membrane was then rinsed in TBS/T before the overnight 
incubation with primary antibodies diluted in either 5% BSA or 1% milk in TBS/T 
at 4 C. 
Membranes were then washed three times, for 10 minutes each, in TBS/T and 
incubated with gentle shacking for 1 hour at room temperature with a 1:5000 
dilution of the appropriate HRP-conjugated secondary antibody in 5% milk in 
TBS/T. Membranes were thoroughly washed three times in TBS/T to remove the 
secondary antibody and then incubated with the ECL Western blotting substrate 
for 1 minute. For detection of low intensity signal, membranes were incubated 
with SuperSignal West Dura Extended Duration Substrate in place of ECL Western 
blotting substrate. Membranes were then placed in a plastic sheet protector and 
transferred in a film cassette for detection of the chemiluminescent signal by 
autoradiography using X- ray film and a Kodak X-Omat 488 X-ray film processor. 
 
 
2.2.6 Cell death analysis 
Cells were seeded in triplicates at 10x104 cells per well in a 6-well plate and on 
the day of the analysis the supernatant was collected in round-bottom 
polystyrene tubes kept on ice. Cells were rinsed in PBS, following by the addition 
of 500 l of 1X trypsin. Trypsin was quenched with 100 l of FBS and cells were 
collected and transferred in to the polystyrene tubes for centrifugation at 300 g 
for 5 min at 4 C. The supernatant was discarded and the cell pellet was 
incubated in 200 l Annexin V Binding Buffer (Tab. 2.3) containing 2 l of APC 
Annexin V (5 g/ml stock) for 10 min at room temperature in the dark. 100 l of 
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a 1 mg/ml propidium iodide solution was added prior to the analysis with 
FACSCalibur (BD Biosciences). 
 
 
2.2.7 Determination of protein synthesis rates 
Cells were seeded in triplicates at 9x104 cells per well in a 12-well plate after 
siRNA transfection and incubated with 30 μCi/ml 35S-methionine label (EasyTag 
from Perkin Elmer) for 30 minutes. Medium was then removed and cells washed 
with ice cold PBS before lysis. Protein precipitation was performed using a final 
concentration of 12.5% trichloroacetic acid and precipitated collected by 
vacuum filtration onto glass filter paper (Whatmann). Filters were then washed 
with 70% ethanol and acetone before counting scintillation (Ecoscint) for 2 
minutes. An aliquot of the lysates was used for a BCA assay (Pierce) to normalise 
scintillation counts per minute to total protein. 
 
 
2.2.8 Animals 
2.2.8.1 Mouse Models 
Multiple Genetically Engineered Mouse (GEM) models were used for research 
purposes and provided by different research groups. Specifically, R26-lsl-MYC 
mice were generated by Daniel Murphy (Neidler and Murphy, unpublished), lsl-
KrasG12D mice (Jackson et al., 2001) were obtained from Jackson lab and 
Nuak1F/F mice were generously provided by Hiroyasu Esumi (Inazuka et al., 
2012). Lkb1F/F mice (Sakamoto et al., 2005) were provided by Owen Sansom and 
Hprt-lsl-Irfp mice were generated by Hock Andreas in collaboration with the 
Transgenic Production facility at the Beatson Institute (Hock et al., 2017). 
 
 
2.2.8.2 Breeding and Maintenance 
All animal work was carried out in accordance with UK Home Office guidelines in 
line with Animals (Scientific Procedures) Act 1986 and the European Directive 
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2010/63/EU. Experimental cohorts and breeding stocks were kept in a light/dark 
12 hours cycle, bred and maintained at the Beatson Institute Animal Facility. All 
breeding stocks and experimental cohorts were regularly checked for health 
concerns. Ear notching and general maintenance (food, water and housing) was 
carried out by the Biological Services Unit at the Beatson Institute. Animals were 
euthanized according to Schedule 1 techniques. Genotyping was carried out 
using ear notch tissue by Transnetyx (Cordova, TN, US). All experimental 
procedures were carried out under the Project Licence No. 70-7950 and my 
personal licence No. ICB9550E7. 
 
 
2.2.8.3 Intranasal instillation of Adenovirus  
Administration of Adenovirus Cre was carried out according to the following 
protocol in animals aged between 8 and 10 weeks.  
Minimum Essential Medium (MEM) was prepared by dissolving MEM powder in 
distillate water and pH was adjusted at 7.86 using NaOH. Medium was then 
filter-sterilised using a 0.22 m filter.  
Adenovirus expressing Cre recombinase, stored at -80 C, was thawed on ice and 
diluted to obtain the desired concentration in the prepared MEM medium. To 
create virus particle precipitates, CaCl2 was added to a final concentration of 4 
mM to the diluted virus and incubated at room temperature for approximatively 
30 minutes. 
Mice were anesthetized using a combination of Medetomidine (0.25 mg/Kg) and 
Ketamine (50 mg/Kg) diluted in 0.9% NaCl and administered by intraperitoneal 
injection. The depth of the anesthesia was checked by pinching animal’s feet 
before proceeding with the administration of 45 l of Adenovirus Cre 
precipitates through the nostrils. Animals were then kept in recovery cages 
placed on heated plates to help maintain their body temperature. Once mice 
were fully recovered from the anaesthesia, they were housed in filter-top cages 
and maintained in a contained room for two weeks. 
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2.2.8.4 Administration of drugs 
Rapamycin was administrated by intraperitoneal injection (i.p.) for 3 days at a 
dose of 10 mg/kg. A stock solution of 50 mg/ml was prepared in 100% Ethanol 
and 500 l was further diluted in 9.5 ml of vehicle (5% PEG400, 5% Tween 20, 
PBS). 
Neratinib and Trametinib were dissolved in peanut oil and sonicated in an 
ultrasonic bath. Both drugs were administered daily by i.p. injection, for the 
duration indicated as per figure legends, at a dose of 80 mg/Kg and 1 mg/Kg, 
respectively. 
Erlotinib was dissolved in 6% captisol (w/v) in water and administered at a dose 
of 100 mg/Kg for 4 weeks by daily gavage.  
Animals under treatment were frequently monitored for sides effects and 
sacrificed in case of excessive adverse response. 
 
 
2.2.8.5 In vivo imaging 
In vivo iRFP imaging was carried out using the Pearl Trilogy Small Animal Imaging 
System (LI-COR). To minimize the signal background originating from the 
stomach and intestine due to standard diet, mice were fed with alfalfa-free 
chow (AIN-93M, DBM Scotland) for at least 7 days prior to imaging. Briefly, 
animals were anesthetized under 2% isoflurane-mixed oxygen and the hair of the 
thorax and abdominal regions was removed using Nair depilatory cream. Animals 
were then imaged for the acquisition of the iRFP fluorescence in the 700 channel 
using the Pearl imaging system. Quantification of the iRFP signal intensity was 
performed with Image Studio v5 (LI-COR).  
 
 
2.2.8.6 Tissue collection 
To isolate the lungs for histological and pathological analysis, animals were 
euthanized according to Schedule 1 protocol by asphyxiation with carbon dioxide 
(CO2) followed by cervical dislocation. To clear the internal organs of red blood 
cells, a whole-body perfusion was carried out through the heart by injecting PBS 
solution in the left ventricle and making an incision in the right ventricle to 
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allow for the discharge of the blood flow. To ensure a proper fixation of the 
lungs, 10% neutral buffered formalin was injected through the trachea using a 
18g needle until the lungs were completely inflated. Lungs were then removed 
and placed in a conical tube containing 10% neutral buffered formalin. Tissue 
was fixed for approximately 16-20 hours before further histological processing 
was carried out by the Histology Service at the Beatson Institute. 
 
 
2.2.8.7 Protein isolations from lung tumours 
To isolate proteins from lung tumours, animals were sacrificed according to 
Schedule 1 protocol. Whole-body perfusion with PBS was carried out as 
described in paragraph 2.2.8.6 and lungs were quickly removed and placed in a 
petri dish containing PBS. Lung tumours were then dissected and placed in pre-
chilled tubes containing 10 volumes of ice-cold lysis buffer (Tab. 2.3) for 1 
volume of tissue sample. The tumour samples were homogenised using 
polypropylene pestles attached to a motor-driven grinder and then centrifuged 
at 12,000 rpm for 10 minutes at 4 C. Supernatant was transferred to a fresh 
tube and stored at -20 C for further analysis. Protein concentration was 
determined by BCA protein assay prior to Western blot analysis. 
 
 
2.2.9 Histology 
2.2.9.1 Immunohistochemistry 
Paraffin-embedded tissue sections of 4 m thickness were routinely cut and 
stained with Hematoxylin & Eosin by the Histology Service at the Beatson 
Institute.  
Immunohistochemical staining for specific antigens was performed by initial de-
paraffinization of the tissue sections through the incubation in three washes of 
xylene for 5 minutes each. Sections were then rehydrated by washing in a 
decreasing concentration of ethanol series (100%, 70%, 50%, 30%) for 2 minutes 
each, followed by incubation in dH2O for 5 minutes.  
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Heat-induced antigen retrieval was carried out to unmask the antigen and allow 
for its recognition by the primary antibody by placing the tissue sections in pre-
warmed sodium citrate buffer (pH 6.0) and heated for 6 minutes at 120 C in a 
pressure cooker using a microwave. Sections were left to cool down for at least 
30 minutes before washing in dH2O for 5 minutes.  
To prevent non-specific signal or high background staining due to endogenous 
peroxidase activity, sections were incubated in 3% hydrogen peroxide (H2O2) for 
10 minutes to block the endogenous peroxidase. Sections were then washed for 5 
minutes in TBS/T before incubation in the appropriate blocking solution for 30 
minutes at room temperature.  
Primary antibodies were diluted as indicated in Table 2.12 and sections 
incubated overnight at 4 C in a humidified chamber. To remove the excess of 
primary antibody, sections were washed twice in TBS/T for 5 minutes per wash. 
Detection of the primary antibody bound to the antigen was carried out using 
the Vectastain ABC HRP Kit, which allows the amplification of the signal by 
exploiting the Avidin/Biotin complex formation. In particular, the use of a 
protein with high affinity-binding to biotin (avidin), allows the formation of a 
molecular bridge between the biotinylated secondary antibody and the 
biotinylated peroxidase enzyme, resulting in an enhanced signal detection upon 
addition of the enzyme substrate.  
Tissue sections were incubated for 30 minutes with the appropriate biotinylated 
secondary antibody (Vectastain ABC HRP Kit) diluted in 5% Normal goat serum 
(NGS) diluted in TBS/T. At the same time, the ABC (Avidin/Biotinylated enzyme 
Complex) reagent was prepared as for manufacturer’s instructions (Vectastain 
ABC HRP Kit) and incubated at room temperature for 30 minutes. 
Sections were washed twice in TBS/T for 5 minutes each and incubated with the 
ABC reagent for 30 minutes in a humidified chamber. They were rinsed twice in 
TBS/T for 5 minutes and then DAB (3,3'-diaminobenzidine) was applied to each 
section and the staining monitored closely using a bright field microscope to 
establish the optimal incubation time. The peroxidase enzyme, in complex with 
Avidin and the biotinylated secondary antibody, determines the oxidation of DAB 
resulting in the deposition of a brown, alcohol-insoluble precipitate at the site of 
enzymatic activity. As soon as the signal of the desired intensity was developed, 
sections were rinsed in dH2O and then counterstained for 1-2 minutes with a 
solution of Hematoxylin to stain cell’s nucleus. They were then rinsed in gently 
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running tap water before and after dipping into a differentiation solution (Acid 
Alcohol) to remove excess staining and define nuclei, following by 30 seconds 
incubation in a blueing reagent (Scott’s tap water) to transform the initial 
soluble colour of the Hematoxylin within the nucleus to an insoluble blue colour. 
Finally, tissue sections were dehydrated by washing in an increasing 
concentration of ethanol series (70%, 95%, 100%) for 2 minutes each and then 
incubated in two washes of xylene for 5 minutes per wash. Coverslips were 
mounted using a drop of DPX mounting media. 
 
Antigen Antibody (Supplier) Blocking Buffer Dilution 
Ki67 
RM-9106-SO (Fisher 
Scientific) 
1% BSA in TBS/T 1:200 
BrdU  
1% NGS in 
TBS/T 
1:200 
p-ERK 4370 (Cell Signaling) 5% NGS in PBS 1:500 
p-AKT 
(Ser473) 
4060 (Cell Signaling) 
5% NGS in 
TBS/T 
1:25 
p-4E-BP1 
(Thr37/46) 
2855 (Cell Signaling) 
5% NGS in 
TBS/T 
1:500 
p-S6 
(Ser235/236) 
4858 (Cell Signaling) 
5% NGS in 
TBS/T 
1:800 
p63 Sc-8431 (Santa Cruz) No blocking 1:1000 
SPC AB3786 (Millipore) 3% NGS in PBS 1:1000 
CD31 28364 (Abcam) No blocking 1:75 
Table 2. 12 – Primary antibodies used for Immunohistochemestry 
 
 
2.2.9.2 TUNEL staining 
Detection of apoptosis was performed using the ApopTag Peroxidase In Situ 
Apoptosis detection kit which consists of digoxigenin-conjugated nucleotide and 
the terminal deoxynucleotidyl transferase (TdT) enzyme. Apoptotic cells are 
characterized by fragmented DNA with free 3’-OH ends. The TdT enzyme can 
incorporate digoxigenin-conjugated nucleotide to the free 3’-OH ends, labelling 
the DNA fragments localized in apoptotic bodies. The digoxigenin-nucleotide can 
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then be detected by an HRP conjugated anti-digoxigenin antibody. Therefore, 
upon the addition of DAB, the HRP enzyme will catalyse the conversion of the 
chromogenic substrate into a visible brown coloured product, identifying the 
fragmented DNA.  
Briefly, tissue sections were de-paraffinised and re-hydrated as already 
described in section 2.2.9.1, and antigen retrieval was carried out by incubation 
in a Coplin jar containing a solution of proteinase K (20 g/ml in PBS) for 15 
minutes at room temperature with gentle shacking. Sections were washed twice 
with dH2O for 2 minutes per wash and endogenous peroxidase activity was 
blocked by incubation in 3% H2O2 in PBS for 5 minutes at room temperature. 
After rinsing twice in PBS for 5 minutes each, 75 l of Equilibration buffer was 
added to each section and incubated for 10 seconds. The TdT Enzyme was 
diluted 1:10 in Reaction Buffer and, after aspiration of the Equilibration buffer, 
60 l of the solution was added to each section for incubation at 37 C for 30 
minutes in a humidified chamber. Sections were incubated in a Coplin jar 
containing the STOP Buffer (1 ml STOP buffer+ 34 ml dH2O) for 10 minutes at 
room temperature and then washed three times in PBS for 1 minute per wash. 
The HRP- conjugate anti-digoxigenin antibody was applied to each section and 
incubated at room temperature for 30 minutes in a humidified chamber. 
Sections were rinsed three times in PBS for two minutes per wash before 
addition of the DAB substrate for 2-3 minutes. Optimal staining time was 
established by monitoring the brown colour development under the microscope. 
Counterstaining with hematoxylin and coverslip mounting were performed as 
described in section 2.2.9.1. 
 
 
2.2.10 Tumour burden quantification and Immunohistochemistry 
scoring 
Lung tissue sections were scanned using the Aperio Digital Pathology Slides 
Scanner (Leica) and tumour burden (n3 per genotype) was quantified with 
SlidePath Digital Image Hub. 
For quantification of Ki67 and TUNEL staining, images of lung tissue sections at 
20X magnification were taken of at least 5 fields of view (n=3 per genotype) and 
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scoring was performed by counting the percentage of positively stained nuclei 
within tumours using ImageJ software.  
Quantification of BrdU and CD31 staining was performed using SlidePath Digital 
Image Hub. 
 
 
2.2.11 Laser-Capture Microdissection and RNA-SEQ analysis 
Formalin-fixed paraffin-embedded (FFPE) sections of 10 m thickness were 
mounted on framed membrane slides (Leica). To identify phospho-ERK positive 
regions, adjacent sections were mounted on standard glass slides and stained for 
phospho-ERK. Tissue mounted on membrane slides was stained with ice-cold 1% 
cresyl violet after de-paraffinization and rehydration. Selected phospho-ErkLow 
and phospho-ErkHigh tumour regions were micro-dissected using a Leica DM 6000B 
microscope and harvested into separate tubes before combining tissue obtained 
from multiple sections for each of 4 mice. RNA was then isolated using the 
RNEasy FFPE kit (Qiagen) according to manufacturer’s instructions and depletion 
of ribosomal RNA was achieved using Ribo-Zero (Epicentre). Synthesis of cDNA 
was performed using the SMARTER Stranded random primed RNA-SEQ kit 
(Takara/Clontech), resulting in cDNA libraries flanked by Illumina indexing 
primers. Libraries were standardized to 10 nM after quantification (Quant-IT Pico 
green kit, Invitrogen), denatured and diluted to 10 pM for subsequent analysis by 
paired-end sequencing using an Illumina GA11X deep sequencer. Statistical 
analysis was performed by a combination of HTSeq and the R 3.0.2 environment, 
utilizing packages from the Bioconductor data analysis suite and differential 
gene expression analysis based on the negative binomial distribution using the 
EdgeR package (Robinson et al., 2010). Pathway modulation analysis was 
performed using Metacore GeneGO (Thompson Reuters). For analysis of 
individual gene expression, data were normalized internally to B2M for each 
mouse, and fold change and false discovery rates were recalculated.  
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2.2.12 Statistical analysis 
Statistical analysis was carried out by GraphPad 6.0 software. Comparison of two 
data sets was performed with unpaired or paired t-tests, as indicated per figure 
legend. To compare more than two data sets, ANOVA with a post-hoc Tukey’s 
multiple comparison test was used. 
Log-rank Mantel-Cox test was used for statistical analysis of survival data. 
Statistical significance is indicated in each figure legend, with p<0.05 considered 
as significant.  
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Chapter 3 – Investigating the role of NUAK1 in cell 
survival under metabolic stress 
In this chapter, we elucidate the contribution of NUAK1 to AMPK activation. In 
addition, we examine the activity of NUAK1 in the absence of the upstream 
kinase LKB1 and investigate an alternative pathway in NUAK1 activation that 
involves PKC. Finally, we give more insights on the mechanism contributing to 
the synthetic lethal interaction between NUAK1 and MYC and further explore 
how NUAK1 sustains cell viability in MYC-overexpressing cells.  
Some of the results of the presented work have been published in (Monteverde 
et al., 2017). 
 
 
3.1 Introduction 
NUAK1, also known as ARK5, is a serine/threonine kinase belonging to the AMPK 
family (Suzuki et al., 2003a). LKB1, in complex with STRAD-MO25, is the major 
upstream kinase of the family, responsible for the activation of NUAK1 through 
phosphorylation of the Thr211 in the active T loop (Lizcano et al., 2004b). 
NUAK1 has been involved in a variety of biological processes: from cell adhesion 
(Zagorska et al., 2010) to proliferation (Hou et al., 2011) and axon branching 
(Courchet et al., 2013). Interestingly, Liu et al. identified NUAK1 as being 
required for survival of tumour cells that overexpress MYC. Particularly, the 
study revealed that depletion of NUAK1 led to an increase in mTORC1 activity 
and a collapse in ATP levels, resulting in apoptotic cell death (Liu et al., 2012).  
 
Rapidly growing cells, like cancer cells, require an enhanced production of 
building blocks, such as amino acids and nucleotides, to sustain cell growth and 
proliferation. As these processes are energy-demanding, the maintenance of the 
energetic balance is essential for the survival of cells under metabolic stress. 
AMP-activated protein kinase is a key regulator of energy homeostasis and its 
activation to re-establish the energetic balance is crucial for cell survival 
(Hardie et al., 2012; Shaw et al., 2004b). In fact, it has been shown that cells 
that overexpress the oncogene c-MYC undergo metabolic stress that triggers the 
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activation of AMPK. Importantly, NUAK1 was shown to be required for activation 
of AMPK as downregulation of NUAK1 resulted in an impaired AMPK response to 
MYC-induced metabolic stress (Liu et al., 2012).  
MYC is found to be amplified or, less frequently, mutated in multiple cancers 
and its role in tumour initiation as well as in tumour maintenance has been well 
documented (Beroukhim et al., 2010; Nesbit et al., 1999) but the lack of 
enzymatic activity has limited the application of pharmacological inhibitors as a 
therapeutic approach. Therefore, the synthetic lethal interaction between 
NUAK1 and MYC is an attractive strategy for cancer therapy. However, a better 
understanding of the biological roles of NUAK1 might shed more lights on its 
potential to be used as therapeutic target.  
 
LKB1, the master upstream regulator of NUAK1, is recognised as a critical 
tumour-suppressor gene responsible for the Peutz–Jeghers syndrome, a 
hereditary disorder characterized by gastrointestinal hamartomatous polyps and 
a higher risk of cancer. In addition, LKB1 is frequently mutated in lung cancer 
and occasionally mutated in other sporadic cancers (Monteverde et al., 2015). 
Loss of Lkb1 has been shown to accelerate KRas-driven lung cancer as well as 
enhance the metastatic process (Ji et al., 2007). Although other kinases have 
been suggested to contribute to NUAK1 activation, such as AKT (Suzuki et al., 
2003a), an alternative kinase that could regulate NUAK1 in the absence of LKB1 
has not been identified. 
 
Protein Kinase C (PKC) is a family of serine/threonine kinase that consists of 
numerous isozymes divided in three major groups: conventional PKC (cPKC: 
PKC, PKCI, PKCII and PKC), novel PKC (nPKC: PKC, PKC, PKC PKC) and 
atypical PKC (aPKc: PKC and PKC). cPKC isozymes are activated by Ca2+ and 
phorbol esters or diacylglycerol (DAG), whereas nPKCs require DAG but not Ca2+ 
for activation and aPKC do not respond to either Ca2+ nor DAG. Remarkably, the 
PKC family regulates a diverse set of cellular processes including cell 
proliferation, survival and migration. However, although multiple isozymes share 
some common functions and substrates, the physiological role of each of them 
can completely differ depending on the specific cell type. Thus, two isoforms 
can exert opposite roles in the same setting and the same isoform can behave 
differently in two distinct cell types (Garg et al., 2014b). For example, 
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proliferative and anti-proliferative roles have been attributed to PKC. In 
particular, PKC was described to promote cell cycle arrest at the G1 phase in 
intestinal epithelial cells by induction of the cyclin-dependent kinase inhibitors 
p21Cip1 and p27Kip (Frey et al., 1997) and to mediate downregulation of cyclin D1 
(Guan et al., 2007). Similarly, activation of PKC was shown to induce cell cycle 
arrest through p21Cip1 in pancreatic cancer cells (Detjen et al., 2000). 
Conversely, PKC downregulation was reported to reduce proliferation of human 
hepatocellular carcinoma cells (Wu et al., 2008) and its overexpression resulted 
in increased proliferation of glioma and breast cancer cells (Mandil et al., 2001; 
Ways et al., 1995).  
Multiple studies have established a positive role of PKC in the regulation of cell 
invasion and metastasis. Specifically, PKC downregulation was described to 
impair the migration of several cancer cell lines (Byers et al., 2010; Haughian 
and Bradford, 2009; Wu et al., 2008) and its activation was shown to promote 
motility and invasion of breast cancer cells through downregulation of E-
cadherin and upregulation of matrix metalloproteinase protein 1 and 9 (MMP-
1/9) (Kim et al., 2012a). In addition, through the phosphorylation of the 
myristoylated alanine-rich C-kinase substrate (MARCKS), which is an actin- and 
membrane-binding protein, PKC can further exert a control role on cell motility 
and morphogenesis (Disatnik et al., 2002; Ott et al., 2013). 
 
A link between PKC and cancer was already identified three decades ago, when 
cells transformed with KRas or HRas were shown to have higher levels of DAG as 
well as increased activity of PKC (Wolfman and Macara, 1987). Moreover, cells 
with increased levels of PKC were found to be more inclined to transformation 
with KRas (Hsiao et al., 1989). However, the specific contribution to the 
tumorigenic aspect of each PKC isozymes has been difficult to delineate due to 
the context-dependent and diversity of their functions. Indeed, until now 
researchers have been debating on their actual value as therapeutic targets in 
cancer. In addition, the lack of a clear description of PKCs substrates and the 
difficulties encountered in the identification of isoform-specific targets has 
challenged a comprehensive understanding of the biology of PKCs and, 
consequently, of their role in cancer.  
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3.2 Results 
3.2.1 NUAK1 does not regulate AMPK subunits nor basal activity 
To elucidate the molecular mechanism of the role played by NUAK1 in the 
activation of AMPK (Liu et al., 2012), we first analysed the effect of NUAK1 
inhibition and downregulation on the catalytic (1/2) and the regulatory 
subunits (1/2, 1, 2, 3) of the AMPK complex. As shown in figure 3.1A, acute 
treatment up to 4 hours with the selective inhibitor of NUAK1, HTH-01-015, 
identified by Gray and colleagues (Banerjee et al., 2014a), did not affect the 
protein levels of the regulatory and catalytic subunits of AMPK. Note that no 
signal was detected for the 2, 3 subunits as probably they are not expressed in 
U2OS cells (data not shown). NUAK1 downregulation by two independent siRNAs 
resulted in a modest increase of AMPK2 protein levels but only one siRNA 
caused a slight increase of AMPK1/2 and AMPK1 protein levels (Fig. 3.1B). 
Therefore, the overall analysis suggested that NUAK1 does not influence the 
protein levels of the AMPK subunits. 
 
 
 
 
Figure 3. 1 - NUAK1 is not required for the maintenance of AMPK subunits. 
A, U2OS cells were treated for the indicated time points with HTH-01-015 (10 M) and 
lysates immunoblotted with the indicated antibodies. B, U2OS cells were transfected 
with 10 nM of two siRNAs targeting NUAK1 or control siRNA (nt). After 48 hours, cells 
were harvested in lysis buffer and lysates immunoblotted with the indicated antibodies. 
All images are representative of at least 3 independent experiments. 
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Alternatively, we asked if acute NUAK1 inhibition could have a more prominent 
effect on the activation of AMPK rather than the subunit protein levels. As shown 
in figure 3.2, treatment of U2OS cells with HTH-01-015 for 1 hour was sufficient 
to efficiently reduce levels of MYPT1 phosphorylation at Ser445, a known and 
validated NUAK1 substrate (Zagorska et al., 2010), in a dose-dependent manner. 
In contrast, the basal levels of AMPK activation were not affected upon 
Inhibition of NUAK1, as revealed by the unchanged phosphorylation of Acetyl-
CoA Carboxylase (ACC), a well characterized substrate of AMPK (Ha et al., 1994).   
 
 
 
Figure 3. 2 - NUAK1 is not required for the maintenance of AMPK basal activity. 
U20S cells were treated with the indicated concentrations of HTH-01-015 for 1 hour and 
whole cell extracts were immunoblotted with the indicated antibodies. The antibody 
against ACC may cross react with ACC2. Images are representative of at least 3 
independent experiments. 
 
 
3.2.2 NUAK1 is specifically required for Ca2+-mediated activation 
of AMPK 
After excluding a role of NUAK1 on influencing the basal activity of AMPK, we 
were interested to investigate if NUAK1 regulation of AMPK activation was 
context-specific rather than a general phenomenon. Therefore, we analysed the 
AMPK response to multiple activators that mimic the different activation 
pathways in the presence of NUAK1 inhibition. Particularly, we employed 
phenformin, an inhibitor of the mitochondrial complex I that activates AMPK 
through the generation of an energetic imbalance; A769662, a synthetic 
compound that can directly interact with the AMPK complex causing its allosteric 
activation; finally, we used the calcium ionophore A23187 to increase the 
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intracellular levels of Ca2+ and study the aspect of Ca2+-mediated activation of 
AMPK. As expected, the different activators could induce the activation of 
AMPK, as shown by the increased phosphorylation of ACC. Interestingly, NUAK1 
inhibition did not affect the response to A769662 whereas the efficiency of ACC 
phosphorylation in response to A23187 and phenformin was impaired (Fig. 3.3).  
 
 
 
 
Figure 3. 3 - AMPK response to increase in intracellular Ca2+ is impaired by NUAK1 
inhibition. 
U2OS cells were pre-treated with HTH-01-015 (10 M) for 1 hour and then stimulated 
with phenformin (10 mM), A769662 (100 M) for 1 hour and with A23187 (3 M) for 10 
min. Whole cell protein extracts were immunoblotted for the detection of phospho-
ACCS79 and total ACC. Densitometric analysis shown in the bar graph. All images are 
representative of at least 3 independent experiments. 
 
 
LKB1 is known to be the major upstream kinase for NUAK1 (Lizcano et al., 
2004b). However, the contribution of NUAK1 to Ca2+-dependent activation of 
AMPK suggested an LKB1-independent regulation of the kinase. Therefore, we 
repeated the analysis of NUAK1 contribution to AMPK activation in HeLa cells, 
which do not express LKB1 (Fig. 3.4A). As already documented by others (Fogarty 
et al., 2010), stimulation of HeLa cells with phenformin did not induce a 
significant phosphorylation of ACC, and only a moderate increase was observed 
following A769662 treatment. Nevertheless, in both instances the levels of ACC 
phosphorylation were not affected by NUAK1 inhibition. In contrast, A23187 was 
more effective in inducing ACC phosphorylation, which was reduced by NUAK1 
inhibition (Fig. 3.4B). Overall, the analysis carried out in U2OS and HeLa cells, 
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strongly pointed towards a role of NUAK1 in Ca2+ signalling and independent of 
LKB1. 
 
 
 
Figure 3. 4 - NUAK1 is still required for AMPK response to increase in intracellular 
Ca2+ in the absence of LKB1. 
A, Western blot showing LKB1 protein expression in U2OS and HeLa cells. Images are 
from the same gel & immunoblot, but rearranged to omit extraneous data. B, HeLa cells 
were pre-treated with HTH-01-015 (10 M) for 1 hour and then stimulated with 
phenformin (10 mM), A769662 (100 M) for 1 hour and with A23187 (3 M) for 10 min. 
Whole cell protein extracts were immunoblotted for the detection of phospho-ACCS79 
and total ACC. Densitometric analysis shown in the bar graph. All images are 
representative of at least 3 independent experiments. 
 
 
3.2.3 NUAK1 is activated by Ca2+ signalling by an LKB1-
independent pathway 
To further elucidate the activity of NUAK1 in the absence of LKB1, we assessed 
the phosphorylation levels of its substrate, MYPT1, following NUAK1 inhibition. 
As shown in figure 3.5A, treatment of HeLa cells with HTH-01-015 resulted in a 
dose-dependent decrease of MYPT1 phosphorylation at Ser445. In addition, 
MYPT1 phosphorylation was also affected by NUAK1 downregulation in the same 
cells by two independent siRNAs, confirming that NUAK1 is indeed active in 
LKB1-null cells (Fig.3.5B). 
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Figure 3. 5 - NUAK1 is active and can be modulated in LKB1-null cells. 
A, HeLa cells were treated with the indicated concentrations of HTH-01-015 for 1 hour 
and whole cell protein extracts were immunoblotted for phospho-MYPT1S445 and total 
MYPT1. Densitometric analysis shown in the bar graph. B, HeLa cells were transfected 
with 10 nM of two siRNAs targeting NUAK1 or control siRNA (nt). After 48 hours, cells 
were harvested in lysis buffer and lysates immunoblotted with the indicated antibodies. 
Densitometric analysis shown in the bar graph. All images are representative of at least 
3 independent experiments. 
 
 
3.2.4 CaMKKβ does not mediate Ca2+-induced activation of 
NUAK1 
Having established the activity of NUAK1 in the absence of the upstream kinase 
LKB1, we asked which alternative pathway could be engaged to regulate the 
kinase activity.  
It is known that AMPK can be activated by CaMKKβ in response to increase in 
intracellular Ca2+ levels (Woods et al., 2005). Given the observed role of NUAK1-
mediated activation of AMPK during Ca2+ signalling, we asked if CaMKKβ could be 
an alternative upstream kinase for NUAK1 as it is for AMPK. To test the 
hypothesis, we treated HeLa cells with the CaMKKβ inhibitor Sto-609. Inhibition 
of CaMKKβ efficiently reduced the phosphorylation of AMPK and its target ACC, 
but no effect was observed on the basal levels of MYPT1S445 phosphorylation (Fig 
3.6). Moreover, stimulation of cells with the Ca2+ ionophore A23187 induced a 
striking increase in phospho-MYPT1S445 that was not affected by Sto-609 
treatment. 
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Figure 3. 6 - CaMKKβ is not an upstream kinase for NUAK1. 
HeLa cells were pre-treated with Sto-609 (5 g/mL) for 1 hour and then stimulated with 
A23187 (3 M) for 10 min. Whole cell protein extracts were immunoblotted with the 
indicated antibodies. Image representative of at least 3 independent experiments. 
 
 
In agreement with the observed Ca2+-mediated activation of NUAK1, treatment 
of HeLa cells with two different Ca2+ ionophores, Ionomycin and A23187, induced 
an increase in MYPT1S445 phosphorylation that was attenuated by NUAK1 
inhibition with HTH-01-015 (Fig. 3.7A). Conversely, chelation of the intracellular 
Ca2+ by treatment with BAPTA-AM resulted in the decrease of phopsho-MYPT1S445 
(Fig. 3.7B). Taken together, these results revealed that Ca2+ signalling could 
modulate NUAK1 activation, but not through CaMKKβ.  
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Figure 3. 7 - Modulation of intracellular Ca2+ levels impacts on NUAK1 activation. 
A, HeLa cells were pre-treated with HTH-01-015 (10 M) for 1 hour and then stimulated 
with A23187 (3 M) or Ionomycin (3 M) for 10 min. Whole cell protein extracts were 
immunoblotted for phospho-MYPT1S445 and total MYPT1. N=3. Densitometric analysis 
shown in the bar graph. B, HeLa cells were treated with BAPTA-AM (20 M) for 30 min. 
Whole cell extracts were prepared and immunoblotted with the indicated antibodies. 
N=2. 
 
 
3.2.5 Both NUAK1 and NUAK2 phosphorylate MYPT1S445 in 
response to increased intracellular Ca2+ 
The observation that NUAK1 inhibition could not completely abrogate MYPT1S445 
phosphorylation in response to increase in intracellular Ca2+ levels suggested 
that other kinases might be involved in the same pathway. Particularly, NUAK2 
has been previously shown to phosphorylate MYPT1 at Ser445 (Zagorska et al., 
2010). Therefore, we asked if the remaining phosphorylation of MYPT1 after 
NUAK1 inhibition could be attributed to NUAK2 activation. As shown in figure 
3.8A, downregulation of NUAK2 by siRNA resulted in a partial decrease of 
phospho-MYPT1S445. However, the combination of NUAK2 downregulation with 
inhibition of NUAK1 by HTH-01-015 resulted in a striking decrease of phospho-
MYPT1S445, confirming that the two kinases share the same target. In addition, 
the phosphorylation of MYPT1S445 in response to A23187 could be more efficiently 
prevented when both NUAK1 and NUAK2 were inhibited and downregulated, 
respectively (Fig. 3.8A). Similarly, the simultaneous inhibition of NUAK1 and 
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NUAK2 using WZ4003, an inhibitor previously shown to have high selectivity for 
both kinases (Banerjee et al., 2014a), led to the abrogation of phosphorylation 
of MYPT1S445 in response to increased Ca2+ signalling compared to the partial 
effect obtained with NUAK1 inhibition alone using HTH-01-015 (Fig. 3.8B). 
Therefore, NUAK1 and NUAK2 are both induced by Ca2+ and mediate the increase 
in phospho-MYPT1S455 in response to stimulation with A23187. 
 
 
 
 
Figure 3. 8 - Simultaneous depletion of NUAK1 and NUAK2 abrogates modulation of 
phospho-MYPT1S445 in response to calcium. 
A, HeLa cells were transfected with siRNA targeting NUAK2 (20 nM) and pre-treated 
with HTH-01-015 (10 M) for 1 hour and then stimulated with A23187 (3 M) for 10 min. 
N=3. Densitometric analysis shown in the bar graph. B, HeLa cells were pre-treated with 
HTH-01-015 (10 M) or WZ4003 for 1 hour and then stimulated with A23187 (3 M) for 10 
min. Whole cell protein extracts were immunoblotted for phospho-MYPT1S445 and total 
MYPT1. N=2.  
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3.2.6 MYC modulates activation of PKC 
Calcium ions are extremely important second messengers in eukaryotic cells and 
they can activate a number of kinases that mediate the signal transduction to 
modulate various cellular processes that range from gene transcription to muscle 
contraction (Clapham, 2007). Multiple studies have suggested an interconnection 
between MYC and Calcium signalling. It has been reported that MYC expression 
can induce an increase in intracellular Ca2+ in B cells (Habib et al., 2007) but 
also that Ca2+ can drive MYC gene expression in various settings (Quesada et al., 
2002) (Todorova et al., 2009). Considering the link between Ca2+ and MYC and 
also the previously described synthetic lethal interaction between NUAK1 and 
MYC, we wondered if MYC could regulate the expression of a kinase, which is 
part of the Ca2+ signalling pathways, that could also be involved in NUAK1 
activation. To test that, we compared the transcriptome of wild type and MYC-
overexpressing Mouse Embryonic Fibroblasts (MEFs). Interestingly, the 
transcriptome analysis (data not shown) revealed that components of the Ca2+ 
signalling pathway, such as Pkcα, Itpr1 and CaMKK, were upregulated and the 
same results were confirmed by qPCR analysis (Fig. 3.9A). Enhancement of Ca2+ 
signalling in MYC-overexpressing cells was further reflected by the increased 
phosphorylation levels of ACC, downstream of AMPK, upon A23187 stimulation 
(Fig. 3.9B). In addition, MYC overexpression resulted in a Ca2+-dependent 
increase in PKC activity, as shown by the higher phosphorylation levels of its 
downstream target MARCKS (Aderem, 1992), which were sensitive to Ca2+ 
chelation and PKC inhibition with BAPTA and Gö6976, respectively (Fig. 3.9C). 
Moreover, MARCKS phosphorylation levels were diminished upon downregulation 
of MYC by three independent siRNAs in HeLa cells, indicating that MYC-
dependent activation of PKC is conserved across species (Fig. 3.9D). 
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Figure 3. 9 - Overexpression of MYC induces upregulation of components of the 
Ca2+ signalling pathway. 
A, R26-lsl-MYC or wild type MEFs were infected with 300 MOI of Adenovirus-Cre and 24 
hours later analysed for mRNA expression levels of Pkcα, Itpr1 and CaMKK. Bar graph 
representing the Mean and SD from biological triplicates. * p<0.05 and *** p<0.001 
determined by two-tailed unpaired T-tests. B, Adenovirus-Cre infected R26lsl-MYC or wild 
type MEFs were stimulated with A23187 (6 M) for 10 min and whole cell protein 
extracts were immunoblotted with the indicated antibodies. C, Adenovirus-Cre infected 
R26lsl-MYC or wild type MEFs were treated with BAPTA (10 M) or Gö6976 (1 M) for 3 
hours prior to lysis. Whole cell protein extracts were immunoblotted with the indicated 
antibodies. D, HeLa cells were transfected with three independent siRNAs (20 nM) 
targeting MYC and whole cell protein extracts immunoblotted with the indicated 
antibodies. All images are representative of at least 3 independent experiments, except 
(D) where n=2. 
 
 
3.2.7 PKC mediates NUAK1 activation by Ca2+ signalling 
The conventional class of PKC (cPKC) is a subgroup of the PKC family known for 
being activated by Ca2+ and includes four isozymes: PKCα, PKCI, PKCII and 
PKC. Therefore, cPKC represented a good candidate for the upstream calcium-
mediated regulation of NUAK1. To test if that was the case, HeLa cells were 
treated acutely with Gö6976, a potent PKCα and PKCI inhibitor, which induced a 
dose-dependent decrease of phospho-MYPT1S445 (Fig. 3.10A). Phospho-(Ser) PKC 
substrate antibody was used as readout of PKC activity in response of Gö6976 
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treatment. Notably, whereas HTH-01-015 could sustain MYPT1S445 inhibition over 
a treatment period of 16 hours, phosphorylation levels of MYPT1S445 and 
Phospho-(Ser) PKC substrates recovered after treatment with Gö6976 for the 
same time frame, suggesting a transient effect of the PKC inhibitor (Fig. 3.10B).  
Additionally, acute inhibition of PKC resulted in an attenuation of Ca2+-induced 
MYPT1S445 phosphorylation (Fig.3.10C), indicating its contribution to the pathway 
that leads to MYPT1 phosphorylation. 
 
 
 
 
Figure 3. 10 - Inhibition of PKC impairs MYPT1S445 phosphorylation. 
A, HeLa cells were treated with the indicated concentrations of Gö6976 for 1 hour and 
whole cell protein extracts were immunoblotted with the indicated antibodies. B, HeLa 
cells were treated with HTH-01-015 (10 M) or Gö6976 (0.5 M) for 1 hour and 16 hours 
and whole cell protein extracts were immunoblotted with the indicated antibodies. C, 
HeLa cells were pre-treated with Gö6976 (0.5 M) for 1 hour and then stimulated with 
A23187 (3 M) for 10 min. Lysates were immunoblotted for phospho-MYPT1S445 and total 
MYPT1. All images are representative of at least 3 independent experiments. 
 
 
Given that Gö6976 can inhibit two of the four conventional PKC isoforms, PKCα 
and PKCI, we sought to determine whether one or both isoforms were mediating 
the observed effect of Ca2+-induced phosphorylation of MYPT1S445. 
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Downregulation of PKCα by two different siRNAs (Fig. 3.11A) resulted in a 
decrease of MYPT1S455 phosphorylation, which was not further reduced by 
simultaneous depletion of PKCI (Fig. 3.11B). Note that downregulation of PKCI 
could not be confirmed, as no protein or mRNA expression could be detected in 
HeLa cells, probably indicating that this isoform is not expressed in this cell line 
(data not shown). 
 
 
 
 
Figure 3. 11 - PKCα and not PKCI regulates downstream phosphorylation of 
MYPT1S445. 
HeLa cells were transfected with 20 nM of two siRNAs targeting PKC and control siRNA 
(nt) (A) or with a combination of siRNAs targeting PKC (20 nM) and PKC (20nM) (B). 
After 48 hours, cells were harvested in lysis buffer and lysates immunoblotted for 
phospho-MYPT1S445, total MYPT1 and PKC. Densitometric analysis shown in the bar 
graph (A). All images are representative of at least 3 independent experiments. 
 
 
Phosphorylation of MYTP1S455 has proved to be mediated by both NUAK1 and 
NUAK2, therefore, we sought to obtain a more direct indication of the effect of 
PKC inhibition on NUAK1 phosphorylation at Thr211 in the activation loop. Thus, 
to study phospho-NUAK1T211 we made use of an antibody against phospho-
AMPKT172 that was previously shown to detect phosphorylation at Thr211 of 
overexpressed NUAK1 (Fisher et al., 2005). A23187 treatment induced an 
increase in the phosphorylation of the immunoprecipitated FLAG-tagged NUAK1 
that was prevented by treatment with Gö6976, whereas no signal was detected 
for the T211A mutant, confirming the specificity of the antibody (Fig. 3.12A). 
The same results could be reproduced with a newly developed polyclonal 
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antibody raised against Thr211 of human NUAK1 (Fig. 3.12B). Overall, we 
obtained strong evidence for PKCα regulation of NUAK1 activity and its ability to 
phosphorylate the downstream target MYPT1 in response to Ca2+ signalling.  
 
 
 
 
 
Figure 3. 12 - Phosphorylation of NUAK1 is decreased by PKC inhibition. 
A-B, HeLa cells were transfected with expression plasmids encoding either wild type or 
mutant (T211A) FLAG-NUAK1. Forty-eight hours post-transfection, FLAG-NUAK1 wild 
type cells were pre-treated with Gö6976 (0.5 M) for 1 hour and then stimulated with 
A23187 (3 M) for 10 min. Cells were then lysed and FLAG-tagged proteins were 
immunoprecipitated and immunoblotted with the indicated antibodies. Detection of 
phospho-NUAK1T211 was performed by cross-reaction of the phospho-AMPKT172 antibody 
(n=3) (A) or by a newly developed antibody raised against phospho-NUAK1T211 (n=2) (B). 
Cells transfected with Empty Vector were use as negative control. 
 
 
3.2.8 PKC regulates NUAK1 protein levels 
Upon depletion of PKC by two independent siRNAs we observed a marked 
reduction of NUAK1 protein levels, suggesting that PKC regulates NUAK1 
protein stability. Indeed, as shown in Figure 3.13A-B, the decrease in NUAK1 
protein levels upon PKC downregulation was rescued by proteasome inhibition 
using MG132. In addition, NUAK1 mRNA expression levels were not significantly 
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affected by PKC depletion, confirming a regulation at protein levels as opposed 
to a transcriptional modulation (Fig. 3.13C). 
 
 
 
 
Figure 3. 13 - PKC depletion induces NUAK1 degradation. 
A, HeLa cells were transfected with 20 nM of two siRNAs targeting PKC or control 
siRNA (nt) and treated with MG132 (20 M) for 5 hours prior to lysis. Whole cell protein 
extracts were then immunoblotted with the indicated antibodies. N=2. B, Bar graph 
indicating the Mean and SD fold decrease in NUAK1 protein expression in HeLa cells 
depleted for PKC and treated with MG132 (20 M) or DMSO control. N=3. ns= not 
significant. P value calculated with one-way ANOVA, Tukey’s multiple comparison. C, 
Hela cells were transfected with two independent siRNAs targeting PKC (20 nM) or 
control siRNA (nt) and NUAK1 mRNA levels analysed by qPCR. Bar graph indicating the 
Mean and SD fold change of NUAK1 mRNA expression relative to control (nt). ns= not 
significant. P value calculated with one-way ANOVA, Tukey’s multiple comparison. 
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3.2.9 NUAK1 and NUAK2 reside in two distinct pathways for the 
regulation of MYPT1S445 phosphorylation in response to Ca2+ 
signalling 
Notably, PKC downregulation only induced a partial reduction of MYPT1S445 
phosphorylation (Fig. 3.11A) and treatment with the PKC inhibitor Gö6976 did 
not completely abrogate phospho-MYPT1S445 levels in response to A23187 
stimulation (Fig. 3.10C). In light of our data showing a contribution of NUAK2 to 
Ca2+-induced phosphorylation of MYPT1S445 (Fig. 3.8A-B), we asked if the 
incomplete inhibition of phospho-MYPT1S445 upon PKC depletion and inhibition 
could be attributed to NUAK2. Co-depletion of NUAK1 and PKC in HeLa cells 
minimally affected phospho-MYPT1S445 levels in comparison to NUAK1 depletion 
alone, consistent with the two kinases residing in the same pathway. Conversely, 
phospho-MYPT1S445 levels were further reduced upon co-depletion of NUAK2 and 
PKC in comparison to their individual downregulation, indicating that NUAK2 
and PKC mediate Ca2+-dependent phosphorylation of MYPT1 from two different 
signal axes (Fig. 3.14). 
 
 
Figure 3. 14 – PKC and NUAK2 co-depletion further decreases phospho-MYPT1S445 
levels. 
HeLa cells were transfected with siRNA targeting PKC (20 nM) and/or NUAK1 (10 nM) or 
NUAK2 (20 nM). Whole cell protein extracts were then immunoblotted with the 
indicated antibodies. N=2. The arrow indicates the correct band for NUAK2. 
Densitometric analysis shown in the bar graph. 
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3.2.10 The PKCα-NUAK1 pathway supports viability of MYC 
overexpressing cells  
A previous synthetic lethality screening carried out by Liu et al., identified 
NUAK1 as being required to support survival of MYC-overexpressing cells (Liu et 
al., 2012). In agreement with that, inhibition of NUAK1 by HTH-01-015 treatment 
in HeLa cells, which express high levels of MYC (Shen et al., 2017), induced a 
significant increase in apoptotic cell death compared to control cells. 
Interestingly, cell death was observed only at 10 μM of HTH-01-015, whereas 
partial inhibition of NUAK1 with a lower concentration of the inhibitor did not 
affect cell survival (Fig. 3.15A). Similarly, in the same cells, downregulation of 
NUAK1 with two different siRNAs resulted in a significant increase in cell death 
only when NUAK1 expression was more strongly suppressed (Fig. 3.15B).  
 
 
Figure 3. 15 - NUAK1 inhibition and depletion is lethal in HeLa cells. 
A, HeLa cells were treated with the indicated concentrations of HTH-01-015. Forty-
eight hours later, induction of apoptosis was analysed by Annexin V/Propidium iodide 
FACS (top) and whole cell protein extracts were immunoblotted with the indicated 
antibodies (bottom). Error bars represent the SD of the mean of three independent 
experiments. ***p<0.001 calculated with one-way ANOVA, Tukey’s multiple comparison. 
B, HeLa cells were transfected with 10 nM of two siRNAs targeting NUAK1 or control 
siRNA. At day 3 post-transfection, induction of apoptosis was analysed by Annexin V/PI 
staining (top) and whole cell protein extracts were immunoblotted with the indicated 
antibodies (bottom). Error bars represent the SD of the mean of three independent 
experiments. ***p<0.001 calculated with one-way ANOVA, Tukey’s multiple comparison. 
Chapter 3  104 
Thus, our results suggested that NUAK1 expression at low levels was still able to 
support cell survival, establishing a threshold of NUAK1 expression below which 
cells are no longer able to sustain viability. Next, we asked if the synthetic 
lethal interaction of NUAK1 and MYC was indeed responsible for the observed 
cell death upon NUAK1 inhibition in HeLa cells. MYC reduction by two 
independent shRNAs (Fig. 3.16B) significantly decreased the levels of cell death 
caused by NUAK1 inhibition, consistent with a synthetic lethal interaction (Fig. 
3.16A).  
 
 
 
 
Figure 3. 16 - Cell death induced by NUAK1 inhibition is rescued by MYC 
downregulation. 
HeLa cells were transfected with two shRNA-encoding plasmids targeting MYC or a non-
targeting control (shRen). After puromycin selection, cells were treated with HTH-01-
015 (10 M) and 48 hours after treatment analysed by Annexin V/PI staining for 
apoptosis induction (A). Error bars reflect the standard deviation of biological triplicate 
samples from one experiment and statistical analysis was performed on a total of five 
independent experiments. **p<0.01, *p<0.05 calculated with one-way ANOVA, Tukey’s 
multiple comparison. Whole cell protein extracts were immunoblotted with the 
indicated antibodies (B). 
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Furthermore, PKCα downregulation by two independent siRNAs also induced a 
significant increase in cell death in HeLa cells (Fig. 3.17A), and PKC inhibition 
with Gö6976 more efficiently induced death in cell treated with a low dose of 
HTH-01-015 (Fig. 3.17B-C), corroborating a role of PKCα upstream of NUAK1. 
 
 
 
 
Figure 3. 17 - PKCα depletion and inhibition is lethal in HeLa cells. 
A, HeLa cells were transfected with 20 nM of two siRNAs targeting PKC or control 
siRNA (nt). At day 3 post-transfection, induction of apoptosis was analysed by Annexin 
V/PI staining (top) and whole cell protein extracts were immunoblotted with the 
indicated antibodies (bottom). Error bars represent the SD of the mean of three 
independent experiments. ***p<0.001, **p<0.01 calculated with one-way ANOVA, 
Tukey’s multiple comparison. B, HeLa cells were treated with Gö6976 (1 M) and HTH-
01-015 (5 M) and, 48 hours post treatment, induction of apoptosis was analysed by 
Annexin V/PI staining. Error bars represent the SD of the mean of three independent 
experiments. Ns= not significant, **p<0.01 calculated with one-way ANOVA, Tukey’s 
multiple comparison. C, Whole cell protein extracts from HeLa cells stimulated as per 
B, were isolated after 1 hour of treatment and immunoblotted with the indicated 
antibodies. Densitometric analysis shown in the bar graph. 
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3.2.11 The PKCα-NUAK1 pathway regulates activation of mTORC1 
via Raptor 
Cell that express higher levels of MYC are characterized by increased protein 
synthesis, which is required to sustain the increase in proliferation (van Riggelen 
et al., 2010). Therefore, cells in those conditions are high metabolically 
demanding and the activation of metabolic checkpoints becomes crucial to cope 
with energetic stress. Restraining mTOR activity is a mechanism that protects 
cells form metabolic stress and AMPK is well known to control mTORC1 
activation for the maintenance of energetic balance. Particularly, it has been 
shown that AMPK can inhibit Raptor through phosphorylation of Ser792 (Gwinn et 
al., 2008). Indeed, as shown in figure 3.18, stimulation of HeLa cells with A23187 
induced activation of AMPK and phosphorylation of RaptorS792, which resulted in 
a dynamic response of mTORC1. In particular, whereas phospho-RaptorS792 levels 
increased steadily over time, phosphorylation levels of S6K and 4EBP1, mTORC1 
substrates, decreased after an initial increase, in agreement with a dual effect 
of Ca2+ in activating mTORC1 (Li et al., 2016; Zhou et al., 2015) as well as 
inhibiting Raptor through activation of AMPK. 
 
 
 
Figure 3. 18 – Dynamic Ca2+-dependent modulation of mTORC1. 
HeLa cells were treated for the indicated time points with A23187 (3 M) and whole cell 
protein extracts immunoblotted with the indicated antibodies. 
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Surprisingly, downregulation of PKCα and NUAK1 in HeLa cells resulted in an 
impaired inhibition of Raptor at basal levels as well as in response to A23187 
treatment, as observed by the decreased phosphorylation at Ser792 (Fig. 3.19A).  
Furthermore, NUAK1-mediated regulation of RaptorS792 phosphorylation was 
similarly observed in U2OS cells, which retain LKB1 function. Particularly, as 
shown in Figure 3.19B-C, acute inhibition of NUAK1 with HTH-01-015 or 
downregulation by two independent siRNAs significantly impaired the inhibitory 
phosphorylation of Raptor in response to multiple AMPK activators, such as 
phenformin, Salicylate and A23187, suggesting a higher mTORC1 basal activity 
but also the inability of AMPK to efficiently control Raptor in the absence of 
NUAK1. 
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Figure 3. 19 - PKCα and NUAK1 depletion impairs Raptor inhibition at basal levels 
and in response to AMPK stimulation. 
A, HeLa cells were transfected with siRNA targeting PKC (20 nM), NUAK1 (10 nM) or 
control siRNA. At day 1 post-transfection, cells were stimulated with A23187 6 M for 10 
minutes and whole cell protein extracts were immunoblotted with the indicated 
antibodies. B, U2OS cells were pre-treated with HTH-01-015 (10 M) for 1 hour and then 
stimulated with phenformin (10 mM), Salicylate (10 mM) for 1 hour and with A23187 (3 
M) for 10 min. Whole cell protein extracts were immunoblotted with the indicated 
antibodies. Images are from the same gel & immunoblot, but rearranged to omit 
extraneous data. C, U2OS cells were transfected with 10 nM of two independent siRNAs 
targeting NUAK1 (10 nM) or control siRNA. At day 2 post-transfection, cells were 
stimulated with phenformin (10 mM), Salicylate (10 mM) for 1 hour and with A23187 and 
Ionomycin (3 M) for 10 min. Whole cell protein extracts were immunoblotted with the 
indicated antibodies. The star in B and C indicates a cross-reacting band. 
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Consistent with a role of NUAK1 in regulating mTORC1 activity, its 
downregulation in HeLa and U2OS cells resulted in a significant increase in 
protein synthesis, as underlined by an increase in 35S-Methionine incorporation in 
comparisons to control cells (Fig. 3.20). In addition, depletion of PKC in HeLa 
cells also caused a significant increase in protein synthesis, corroborating its 
involvement in NUAK1 signalling pathway. 
 
 
 
 
Figure 3. 20 - NUAK1 downregulation increases protein translation. 
HeLa were transfected with siRNA targeting PKC (20 nM), NUAK1 (10 nM) or a non-
targeting control (nt); U2OS cells were transfected with siRNA targeting NUAK1 (10 nM) 
or control siRNA (nt). At day 2 post-transfection, both cell lines were analysed for 35S-
Methionine incorporation. Bar graph represents Mean and SD from 3 independent 
experiments. *p<0.05 and **p<0.01 calculated with one-tailed unpaired T-test. Data 
generated in collaboration with Dr John Knight from the Beatson Institute. 
 
 
In agreement with a role of the PKC/NUAK1 axis to support cell viability by 
restraining mTORC1 activity through inhibition of Raptor, treatment of HeLa 
cells with the mTORC1 inhibitor Rapamycin could significantly rescue the cell 
death induced by either NUAK1 or PKCα downregulation (Fig. 3.21). 
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Figure 3. 21 - mTORC1 inhibition rescues cell death induced by PKC or NUAK1 
depletion. 
HeLa cells were transfected with siRNA targeting PKC (20 nM) and NUAK1 (10 nM) and 
treated with Rapamycin (100 nM) at day 1 post-transfection. 48 hours after treatment 
cells were analysed by Annexin V/PI staining for apoptosis induction. Error bars 
represent the SD of the mean of three independent experiments. ***p<0.001, **p<0.01 
calculated with 2-way ANOVA, Sidak’s multiple comparison test. 
 
 
Among the family members only AMPK has previously been described to inhibit 
Raptor by phosphorylation at Ser792 (Gwinn et al., 2008). Therefore, we asked if 
NUAK1 was mediating AMPK phosphorylation of Raptor or if it could regulate 
Raptor independently of AMPK. Thus, we studied the effect of NUAK1 inhibition 
on RAPTORS792 phosphorylation in Mouse Embryonic Fibroblast depleted of both 
α1 and α2 catalytic subunits of AMPK. As shown in figure 3.22, AMPK depletion 
moderately reduced phosphorylation of RAPTORS792. However, inhibition of 
NUAK1 by HTH-01-015 decreased phospho-RAPTORS792 levels both in wild type 
and AMPK depleted cells, suggesting an AMPK-independent regulation of Raptor 
by NUAK1. 
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Figure 3. 22 - NUAK1 regulates RaptorS792 phosphorylation in the absence of AMPK. 
AMPK1/2 floxed MEFs were infected with 300 MOI of Adenovirus expressing Cre (Ad-
Cre) or LacZ (Ad-LacZ). Cells were pre-treated with HTH-01-015 (10 M) for 1 hour and 
then stimulated with Salicylate (10 mM) for 1 hour and with A23187 (3 M) for 10 min. 
Whole cell extracts were immunoblotted with the indicated antibodies.  
 
 
3.3 Discussion 
NUAK1 was identified as a member of the AMPK family based on its 47% and 45% 
sequence homology to AMPK1 and 2, respectively. Since its discovery, few 
research groups have worked on understanding its biological functions, and 
NUAK1 role in migration and invasion together with cell proliferation and 
metabolic homeostasis has suggested an application of its targeting in cancer 
therapy. However, not many of the suggested targets or upstream kinases of 
NUAK1 have been further validated and a more comprehensive understanding of 
its function and regulation is needed to effectively and fully exploit its 
therapeutic potential. 
The discovery of a synthetic lethal interaction between NUAK1 and MYC opened 
the door to a novel approach of targeting NUAK1 in MYC-driven cancers. Results 
reported in this chapter have further investigated the mechanism through which 
NUAK1 contributes to survival of MYC-overexpressing cells, uncovering a novel 
Calcium-mediated activation of NUAK1 through PKC.  
 
Cells overexpressing the oncogene MYC were shown to upregulate AMPK activity, 
possibly as a mechanism of protection from the energetic stress resulting from 
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MYC induction (Liu et al., 2012). In addition, the same study suggested that 
AMPK increased activity was dependent on NUAK1, as its depletion was reported 
to prevent AMPK phosphorylation at Thr172 and also to decrease the protein 
levels of the regulatory subunit AMPK1. However, we have shown that 
inhibition or downregulation of NUAK1 in U2OS cells did not affect the protein 
levels of either the regulatory or catalytic subunits of AMPK (Fig. 3.1A-B). 
Therefore, data obtained in our study exclude the modulation of the AMPK 
subunits as part of the mechanism of NUAK1-mediated regulation of AMPK. 
However, the analysis performed by Liu and colleagues employed a type of U2OS 
cells in which a modified form of MYC (MYC-ER) is constitutively overexpressed 
but can only translocate to the nucleus, thus being activated, upon treatment 
with 4-Hydroxytamoxifen (4-OHT). Therefore, the discrepancy between our 
results and data from Liu and colleagues might reside in a basal induction of MYC 
activity in the absence of 4-OHT treatment, due to a leakiness of the system, 
that could change the dynamic of the effect of NUAK1 depletion on the AMPK 
complex, a hypothesis that will require further analysis. 
 
Our data revealed that the requirement for NUAK1 with regards to AMPK 
activation is context dependent, as NUAK1 inhibition could consistently impair 
activation of AMPK specifically in response to modulation of intracellular Ca2+ 
levels in the two cell lines tested, U2OS and HeLa (Fig. 3.3 & Fig. 3.4B). We have 
not currently characterized the mechanism of the observed phenomenon and 
additional investigations will be required to understand if NUAK1 can mediate 
AMPK activation by promoting its phosphorylation by upstream kinases, or 
perhaps through its own kinase activity, or protect AMPK from 
dephosphorylation. 
Notably, the requirement of NUAK1 for a complete response of AMPK to 
increased intracellular Ca2+ levels was preserved in LKB1-null cells (HeLa, Fig. 
3.4A-B). Moreover, the observations that NUAK1 activity could be efficiently 
modulated in HeLa cells (Fig. 3.5A-B) and that it was responsive to Ca2+ 
modulation (Fig. 3.7A-B) strengthen the theory of a novel Ca2+-dependent and 
LKB1-independent regulation of NUAK1. In particular, upon treatment with two 
Ca2+ ionophores, A23187 and Ionomycin, we observed an increase in phospho-
MYPT1S445 (Fig. 3.7A), which is a downstream target shared by both NUAK1 and 
NUAK2 (Zagorska et al., 2010). Indeed, our data indicate that both kinases can 
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be activated by Ca2+ and mediate the increase in phospho-MYPT1S445 (Fig. 3.8A-
B). 
In our search for an upstream kinase mediating NUAK1 activation by Ca2+ 
signalling we could firstly exclude the involvement of CaMKK (Fig. 3.6), which is 
known to mediate the Ca2+-dependent phosphorylation of AMPK (Woods et al., 
2005). A role of Ca2+ and CaMKK in the activation of other AMPK-related kinases 
(ARKs) has been previously investigated and excluded based on the inability of 
the ARKs to phosphorylate the AMARA peptide in response to A23187 treatment 
or expression of CaMKK (Fogarty et al., 2010). Our data partially agree with the 
experimental evidence provided by Fogarty and colleagues, as we have excluded 
a role for CaMKK in mediating the Ca2+-dependent activation of NUAK1 and 
NUAK2, assessed by the unchanged phosphorylation of their downstream target 
MYPT1 upon CaMKK inhibition (Fig.3.6). However, our observations support an 
effect of Ca2+ in NUAK1 and NUAK2 activation as an optimal phosphorylation of 
MYPT1 in response to A23187 was impaired when both kinases were inhibited 
(Fig. 3.8A-B), which was rejected by Fogarty et al. with regards to NUAK2, 
whereas NUAK1 was not included in their biochemical analysis. This 
inconsistency might be attributed to the use of the AMARA peptide, which was 
initially considered as a common substrate for all the ARKs but that has been 
since revisited as a preferential substrate for SIK and AMPK. 
 
Interestingly, multiple experimental evidence suggested a reciprocal regulation 
between Ca2+ and MYC. The calcium ionophore A23187 was shown to induce MYC 
expression in Human promyelocytic leukemia cells (HL-60) (Salehi and Niedel, 
1990). More recently, calcium was shown to affect MYC activity in addition to its 
expression, as Ca2+-loaded Calmodulin was described to interact with MYC and 
enhance its transcription activity (Raffeiner et al., 2017). On the other hand, 
MYC was shown to amplify calcium signalling through the downregulation of the 
Ca2+ efflux pump PMCA4b (Habib et al., 2007) and to bind the promoter of 
components of the Ca2+-signalling pathway, such as CaMKK, ITPR1 and PKC 
(Walz et al., 2014). In agreement with Walz et al., upon MYC overexpression we 
obsevrved an increase in mRNA levels of CaMKK, Itpr1 and Pkc (Fig. 3.9A), a 
higher sensitivity of AMPK to calcium modulation, as shown by the increased 
levels of ACC phosphorylation upon A23187 treatment (Fig. 3.9B) and, most 
importantly, an increased Ca2+-dependent activity of PKC, as revealed by the 
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increased phosphorylation levels of the downstream target MARCKS (Fig. 3.9C). 
Taken together these results agree with the previously reported role of MYC in 
the amplification of Ca2+ signalling and established a new important link 
between MYC and NUAK1 through PKC (Fig. 3.23). 
 
We identified PKC as a novel regulator of NUAK1 activity and protein levels. 
Specifically, downregulation or inhibition of PKC resulted in decreased 
phosphorylation levels of MYPT1S445 (Fig. 3.10A & 3.11A). In addition, PKC 
inhibition could prevent phosphorylation of NUAK1 at Thr211 in response to 
A23187 (Fig. 3.12 A-B) and PKC downregulation induced proteasome-dependent 
degradation of NUAK1 (Fig. 3.13 A-B). Overall, our data strongly indicate that 
PKC is the upstream kinase regulating NUAK1 basal activity and in response to 
Calcium, while we additionally report that NUAK2, although it is responsive to 
Ca2+, is not similarly regulated by PKC (Fig. 3.14). 
Notably, phospho-NUAK1T211 levels were not completely abolished by inhibition 
of PKC using Gö6976, but nevertheless they did not increase upon combination of 
Gö6976 and A23187 (Fig. 3.12 A-B). Taken together, this evidence suggests that 
PKC is the only kinase mediating NUAK1 phosphorylation in response to A23187 
but also that NUAK1 maintains a basal level of phosphorylation at the Thr211 
site. This residual phosphorylation might be explained by the presence of an 
additional upstream kinase or by an auto-phosphorylation activity of NUAK1, 
thus further biochemical investigations are needed to confirm any of the 
hypothesis. Interestingly, AMPK has been shown to undergo auto-phosphorylation 
in response to oxidation induced by peroxide (Zmijewski et al., 2010) and 
unpublished data from our laboratory suggest a similar mechanism of activation 
of NUAK1 by oxidative stress, opening to the possibility of an auto-
phosphorylation reaction for NUAK1. 
 
The Thr211 in the activation loop of NUAK1 (QKDKFLQtFCGSPLY) does not 
conform to the canonical phospho-PKC Substrate Motif (K/RXpSXK/R). However, 
other sites appear to be a more suitable match for PKC, such as Ser367 
(VMLERQRsLKKSKKE) on human NUAK1, which opens to the possibility of PKC 
phosphorylating an alternative site that could influence phosphorylation of 
Thr211 and support protein stability due to regulatory mechanisms that are not 
yet understood.  
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The regulation of NUAK1 activity by an alternative phosphorylation would not be 
surprising, as AKT has been previously suggested to modulate NUAK1 activity by 
phosphorylation at Ser600 (Suzuki et al., 2003a). Furthermore, phosphorylation 
of additional sites to the threonine residue in the T loop for the modulation of 
the activity of other ARKs has been reported by multiple experimental evidence 
(Henriksson et al., 2012; Timm et al., 2008). In any case, further investigations 
will be required to identify phosphorylation sites on NUAK1 upon Ca2+ stimulation 
and understand which of them might be regulated by PKC, contemplating also 
the possibility of a second kinase, downstream of PKC, mediating the observed 
effects. 
 
Inhibition or downregulation of NUAK1 resulted in a significant increase in death 
of HeLa cells (Fig. 3.15A-B), which express high levels of MYC due to the 
upstream genomic integration of the Human papilloma virus 18 (HPV-18) (Adey 
et al., 2013; Shen et al., 2017). Similarly, downregulation of PKC caused a 
significant increase in cell death (Fig. 3.17A), consistent with a role of PKC 
upstream of NUAK1. In agreement with the synthetic lethality interaction 
between NUAK1 and MYC, downregulation of MYC in HeLa cells decreased the 
cell death induced by NUAK1 inhibition (Fig. 3.16A-B). The synthetic lethal 
interaction between MYC and NUAK1 appears to be independent of LKB1 status, 
as it was firstly identified in U2OS cells that are proficient for LKB1 (Liu et al., 
2012) and confirmed in this thesis in HeLa cells, which are LKB1-deficient. 
Therefore, given the observed requirement of PKC for survival of HeLa cells, 
additional investigations could be carried out to elucidate if PKC depletion 
might be synthetic lethal with MYC overexpression in the presence of LKB1. 
 
Depletion of NUAK1 was described to be lethal in combination with MYC 
overexpression and the mechanism for the synthetic lethality interaction 
involved an unrestrained mTORC1 activity, attributed to the impaired activation 
of AMPK in the absence of NUAK1 (Liu et al., 2012). However, our data indicated 
that NUAK1 itself can regulate mTORC1 activity, as downregulation of the 
PKC/NUAK1 axis resulted in increased protein synthesis (Fig. 3.20). In addition, 
our data suggested that NUAK1 regulation of mTORC1 involved the inhibition of 
Raptor, a positive regulator of the mTORC1 complex, although this mechanism 
has been previously attributed to AMPK (Gwinn et al., 2008). Specifically, 
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inhibition or downregulation of NUAK1 resulted in a decreased phosphorylation 
of Raptor at Ser792, a function that was conserved among cell lines and not 
dependent on LKB1 status (Fig. 3.19). Importantly, RaptorS792 phosphorylation in 
AMPK1/2-depleted MEFs was still sensitive to NUAK1 inhibition (Fig. 3.22), 
indicating that NUAK1 exerts a direct and prominent role in the mechanism 
rather than simply assisting AMPK-mediated regulation of mTORC1.  
Activation of metabolic checkpoints that restrain mTORC1, particularly under 
energy stress conditions, has been shown to be required for cell survival, as 
failure in mTORC1 inhibition ultimately leads to apoptotic cell death (Gwinn et 
al., 2008). Thus, taken together, our data indicate an active role of NUAK1 in 
the inhibition of Raptor to modulate a metabolic checkpoint that favours survival 
of MYC-overexpressing cells. As the regulation of Raptor by NUAK1 is 
independent of LKB1 status, it would be interesting to explore the contribution 
of PKC to the regulation of NUAK1 in the presence of LKB1. Previously 
published data have highlighted how deletion of Lkb1 strikingly reduced the 
levels of MYPT1S445 phosphorylation, indicating a major control exerted by LKB1 
(Zagorska et al., 2010). However, the analysis of a single substrate might not be 
representative of the kinase activity as the specificity towards substrates might 
differ according to the type of stimulus or conditions. In addition, the 
physiological relevance of Ca2+-mediated activation of NUAK1 should be explored 
in other conditions, as activation of receptors such as the Epidermal growth 
factor receptor (EGFR) by the binding of growth factors is known to generate an 
acute increase in intracellular Ca2+ levels that contributes to the downstream 
signal propagation. Therefore, further biochemical investigations are needed to 
explore additional physiological roles of the PKC/NUAK1 axis and understand its 
contribution to various cellular process also in the presence of LKB1. 
 
 
 
 
Chapter 3  117 
 
 
Figure 3. 23 – Proposed model for the MYC-PKC-NUAK1 signalling pathway. 
MYC amplification of Ca2+ signalling results in activation of downstream pathways that 
include the Ca2+-sensitive kinases CaMKK and PKC. The former leads to activation of 
AMPK, whereas the latter modulates NUAK1 activity. Activation of NUAK1 and AMPK, in 
part mediated by NUAK1, contributes to restrain mTORC1 activity through the inhibition 
of Raptor. In addition, Ca2+ signalling mediates the phosphorylation of MYPT1 through 
the induction of the PKC/NUAK1 axis and NUAK2, for which the upstream kinase has 
not been identified. 
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Chapter 4 – Investigation of NUAK1 role in lung 
tumorigenesis 
4.1 Introduction 
Lung cancer is currently the leading cause of cancer-related deaths worldwide, 
with about 46,000 new cases being diagnosed in the United Kingdom every year. 
It can be classified in two major groups: small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC), the latter representing the 80% of all lung cancer 
cases. Adenocarcinoma is the predominant histological subtype of non-small cell 
lung cancer and it shows a high rate of somatic mutations and genomic 
rearrangements, making it a very complex disease. Particularly, mutations in 
KRAS, found in approximately 30% of patients with lung adenocarcinoma, can 
drive the tumorigenic process and are associated with poor prognosis and a high 
risk of cancer recurrence (Meng et al., 2013). Among frequently mutated genes 
in lung adenocarcinoma, LKB1, also known as STK11, has the third highest 
mutation rate after TP53 and KRAS (Ding et al., 2008). Specifically, it is altered 
in about 20-30% of cases of NSCLC, with a tendency towards co-occurrence with 
KRAS mutations (The Cancer Genome Atlas Research, 2014). In addition, pre-
clinical models have established the important function of LKB1 as tumour 
suppressor in lung cancer (Ji et al., 2007; Sanchez-Cespedes et al., 2002).  
The AMPK family is a key downstream effector of LKB1, which can positively 
modulate the AMPK-related kinases (ARKs) (Lizcano et al., 2004b). Through the 
activation of multiple ARKs, LKB1 can regulate a wide range of biological 
processes: from cell polarity and metabolism to angiogenesis and chromosome 
segregation (Bonaccorsi et al., 2007; Kottakis et al., 2016; Londesborough et al., 
2008). Despite the tumour suppressor role of LKB1, multiples members of the 
AMPK family have been associated with a tumour-promoting role. For example, 
expression of NUAK1 has been linked to poor prognosis in various cancer types, 
such as ovarian and colorectal cancer and hepatocellular carcinoma (Cui et al., 
2013; Kusakai et al., 2004; Phippen et al., 2016). In addition, the role of NUAK1 
in cell adhesion and migration has been shown to contribute to tumour invasion 
and metastasis (Chen et al., 2017). Shi and colleagues have shown a tumour-
promoting role of NUAK1 in lung cancer, as it was found to promote migration 
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and invasion of NSCLC cells (Shi et al., 2014). Therefore, NUAK1 represents a 
promising target for cancer therapy. 
 
Although a tumour-promoting role of NUAK1 has been suggested in various 
cancer settings, with particular emphasis to its contribution to migration and 
invasion, the role of NUAK1 in the early phases of the lung tumorigenic process 
has not been elucidated yet. Therefore, in this chapter we investigate the role 
of NUAK1 in KRas-driven non-small cell lung cancer and try to understand if 
NUAK1 exerts some of the tumour suppressor function attributed to its upstream 
kinase LKB1. In addition, given that MYC is dysregulated in lung cancer as result 
of KRAS hyperactivation (Sears et al., 2000), and also found to be amplified in a 
fraction of lung adenocarcinomas (Iwakawa et al., 2011), we sought to 
determine if the synthetic lethal interaction of NUAK1 and MYC could be 
beneficial from a therapeutic perspective in a mouse model of NSCLC 
characterized by MYC overexpression. 
 
 
4.1.1 Mouse models 
To study the mechanism of progression of lung adenocarcinoma and investigate 
the contribution of NUAK1 to the tumorigenic process, we made use of a mouse 
model in which lung tumorigenesis is driven by KRas mutation. In particular, we 
used a conditional strain characterized by a G12D point mutation in the exon 1 
of the endogenous KRas gene. Expression of mutant KRas is prevented by a lox-
stop-lox (lsl) cassette inserted in the first intron of the gene, which generates a 
loss of function of endogenous KRas (Jackson et al., 2001). Since homozygosity 
for loss of KRas is embryonically lethal, only heterozygous animals with KRas 
G12D mutation were obtained for the experiments. KRasG12D was then bred to a 
conditional knockout of Nuak1 (Nuak1F/F), in which the exon 3 of endogenous 
Nuak1 is flanked by loxP sites (Inazuka et al., 2012), to generate lsl-
KRasG12D/Nuak1F/F mice (Fig. 4.1). KRasG12D/Lkb1F/F mice, in which the exon 4 of 
endogenous Lkb1 and a cDNA construct encoding the remainder of the LKB1 
sequence, inserted in replacement of exons 5–7, are flanked by loxP sites 
(Sakamoto et al., 2005), were additionally used for phenotypic comparison of 
Lkb1 loss with Nuak1 loss. 
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Adenovirus-Cre, delivered intranasally, mediates the recombination of the loxP 
sites causing the excision of either the stop cassette preceding mutant KRas or 
the floxed exon of Nuak1 or Lkb1, resulting in the induction of KRasG12D and 
deletion of Nuak1 or Lkb1 specifically in the lungs and in a time-controlled 
manner. 
 
 
Figure 4. 1 – Schematic representation of conditional lsl-KRasG12D and lsl-
KRasG12D;Nuak1F/F mouse model. 
 
 
4.2 Results 
4.2.1 KRas-mutant lung tumours develop as adenocarcinoma 
even in the absence of Nuak1 
Squamous cell carcinoma (SCC) and Adenocarcinoma (ADC) are the two major 
histological types of non-small cell lung cancer. Previous studies have indicated 
that KRasG12D and KRasG12D/p53F/F mice develop only adenocarcinoma (Jackson et 
al., 2005; Jackson et al., 2001; Rekhtman et al., 2012) whereas loss of function 
of the tumour suppressor LKB1, the major upstream kinase of NUAK1, has been 
observed in both lung adenocarcinoma and squamous cell carcinoma (Ji et al., 
2007; Sanchez-Cespedes et al., 2002). In addition, it has been shown that Lkb1 
deletion resulted in trans-differentiation of adenocarcinoma into squamous cell 
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carcinoma in a mouse model of non-small cell lung cancer driven by KRasG12D 
mutation, giving rise to a more complex phenotype (Li et al., 2015a). Therefore, 
we asked if Nuak1 deletion could phenotypically resemble Lkb1 deletion and 
contribute to tumour heterogeneity.  
KRasG12D only, KRasG12D/Lkb1F/F and KRasG12D/Nuak1F/F mice were induced with 
the same dose of Adenovirus-Cre and lungs were harvested at 16 weeks post 
Adeno-Cre infection. As expected, histological examination of lung lesions from 
KRasG12D/Lkb1F/F revealed a heterogeneity of tumours, some characterized by 
solid or papillary growth, typical of the adenocarcinoma subtype (Fig. 4.2, panel 
A), and others characterized by keratin pearls and cell nests forming round 
nodules, typical of squamous cell carcinoma (Fig. 4.2, panel B). Contrariwise, 
KRasG12D only and KRasG12D/Nuak1F/F tumours displayed characteristics of the ADC 
subtype (Fig. 4.2, panel C and D, respectively). The histological subtypes were 
then confirmed by immunohistochemical staining for SCC and ADC markers: p63 
and the surfactant apoprotein-C (SP-C), respectively. Indeed, KRasG12D/Lkb1F/F 
tumours with SCC features were positive for p63 staining while ADC stained 
positively for SP-C; all KRasG12D only and KRasG12D/Nuak1F/F tumours were 
negative for p63 but positive for SP-C (Fig. 4.2). Therefore, Nuak1 deletion did 
not contribute to the trans-differentiation from ADC to SCC driven by Lkb1 loss, 
as ADC was the only histological subtype observed in KRasG12D/Nuak1F/F lung 
tumours. 
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Figure 4. 2 – KRasG12D/Nuak1F/F mice develop only lung adenocarcinoma. 
Representative images of lsl-KRasG12D;Lkb1F/F, lsl-KRasG12D;Nuak1F/F and lsl-KRasG12D lung 
tumour sections stained with Hematoxylin & Eosin, SP-C and p63. Scale bars = 200 µm. 
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4.2.2 Deletion of Nuak1 does not affect the cell of origin of KRas-
mutant lung adenocarcinoma 
Although multiple studies have tried to identify the cell of origin of lung 
adenocarcinoma, there is still some controversy on its histogenesis. Alveolar 
type 2 cells (AT2) and Clara cells are the two cell types that have been debated 
for being the initiating cells in KRas-mutant lung adenocarcinoma, as tumours 
stain positively for AT2 and Clara cells markers such as SP-C and CC10, 
respectively (Jackson et al., 2001; Sutherland et al., 2014). To investigate if 
Nuak1 deletion could influence the cell of origin of KRas-driven lung 
adenocarcinoma, tissue sections of KRasG12D/Nuak1F/F and KRasG12D tumours were 
stained for SP-C and CC10 markers. As already shown in figure 4.2, KRasG12D and 
KRasG12D/Nuak1F/F adenomas stained positive for SP-C, whereas epithelial 
hyperplasia of the bronchioles (EH) showed positivity for the CC10 marker (Fig. 
4.3A). In addition, as previously revealed by Jackson and colleagues (Jackson et 
al., 2001), regions of epithelial hyperplasia that were continuous with atypical 
adenomatous hyperplasia (AAH) in KRasG12D/Nuak1F/F and KRasG12D mice stained 
positive for both SP-C and CC10 (Fig.4.3B). Overall, Nuak1 deletion does not 
appear to influence the histogenesis of KRasG12D tumours.  
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Figure 4. 3 – Nuak1 deletion does not affect the histogenesis of KRasG12D lung 
adenocarcinoma. 
A, Representative pictures of epithelial hyperplasia of the bronchioles (EH) in lsl-
KRasG12D;Nuak1F/F and lsl-KRasG12D lung tumour sections at 16 weeks post Adeno-Cre 
infection stained for H&E and CC10. Scale bars = 200 µm. B, Representative pictures of 
EH lesions continuous with atypical adenomatous hyperplasia (AAH) in lsl-
KRasG12D;Nuak1F/F and lsl-KRasG12D lung tumour sections stained with SP-C and CC10. 
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4.2.3 Nuak1 deletion does not affect KRas-driven tumorigenic 
process 
The tumour suppressor LKB1, which is the master upstream kinase of NUAK1, has 
been previously shown to exert an important tumour suppressor role in lung 
tumorigenesis, as loss of Lkb1 gave rise to a more aggressive disease in a mouse 
model of non-small cell lung cancer driven by KRasG12D mutation (Ji et al., 2007). 
Therefore, we sought to investigate if Nuak1 could also function as tumour 
suppressor in the same setting. The tumour burden of KRasG12D/Nuak1F/F and 
KRasG12D only mice, infected with the same dose of Adenovirus-Cre, was analysed 
at 16 weeks post infection. The analysis revealed that Nuak1 deletion did not 
affect the tumorigenic process driven by KRasG12D, as no significant difference in 
tumour burden was observed in KRasG12D/Nuak1F/F mice compared to KRasG12D 
only (Fig. 4.4). 
 
 
 
 
Figure 4. 4 – Nuak1 deletion does not affect KRasG12D-driven lung tumorigenesis. 
Box plots representing the tumour burden (Mean ± SEM) of KRasG12D (n=4) and lsl-
KRasG12D;Nuak1F/F (n=4) mice at 16 weeks post Adeno-Cre infection. ns = not significant. 
P value calculated with two-tailed unpaired T test. 
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4.2.4 Characterization of Nuak1 deletion in KRasG12D/MYC lung 
adenocarcinoma 
Given the previously described synthetic lethal interaction between MYC and 
NUAK1 in MYC-overexpressing cells (Liu et al., 2012), we were interested in 
exploring the effect of Nuak1 deletion in a mouse model driven by KRas G12D 
mutation with the addition of MYC overexpression. Therefore, KRasG12D mice 
were bred with a conditional model of MYC overexpression, in which lsl-human 
MYC is expressed under the control of the Rosa26 (R26) locus. Homozygous 
animals for the R26-lsl-MYC allele were used in all the experiments. 
The lsl-KRasG12D/R26-lsl-MYC NSCLC mouse model (referred to as KM) has been 
previously characterized by a former colleague, Dr Sarah Neidler, who showed 
how a moderate overexpression of MYC can drastically accelerate the lung 
tumorigenic process driven by KRas G12D mutation, as indicated by the 
significant increase in tumour burden in KM mice compared to KRasG12D only (Fig. 
4.5A-B). 
 
 
 
 
Figure 4. 5 - Moderate overexpression of MYC accelerate KRasG12D-driven lung 
cancer. 
A, Mouse Embryonic Fibroblasts of the indicated genotypes were infected with 
Adenovirus-Cre and whole cell protein extracts immunoblotted for c-MYC and H2B. B, 
Box plots representing the tumour burden (Mean ± SEM) of lsl-KRasG12D (n=4) and lsl-
KRasG12D;R26-lsl-MYC (n=4) mice at 6 weeks post Adeno-Cre infection (data generated by 
Sarah Neidler). **p<0.01 value calculated with two-tailed unpaired T test. 
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To investigate the role of Nuak1 in lung tumorigenesis in a setting of MYC 
overexpression, KRasG12D/MYC and KRasG12D/MYC/Nuak1F/F mice (referred to as 
KMN) were infected with the same dose of Adenovirus-Cre and lungs harvested 
at 6 weeks post infection.  
Histological examination of KRasG12D/MYC lungs revealed the presence of 
multiple lesions: from epithelial hyperplasia of the bronchioles (EH) to atypical 
adenomatous hyperplasia and adenomas (Fig. 4.6, panel A, B, C, respectively). 
Furthermore, the observed adenomas were characterized by a predominant 
papillary structure, displaying a fibrovascular core lined by tumour cells with 
slightly enlarged nuclei and prominent nucleoli. Similarly, lesions observed in 
KRasG12D/MYC/Nuak1F/F mice were also represented by EH, atypical adenomatous 
hyperplasia and adenomas (Fig. 4.6, panel D, E, F). However, upon Nuak1 
deletion adenomas presented an acinar-predominant pattern, in which tumours 
formed glandular structures and presented cord-like arranged tumour cells (Fig. 
4.6, panel F). 
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Figure 4. 6 – Histological examintaion of KM and KMN tumours. 
Representative H&E pictures of epithelial hyperplasia of the bronchioles (EH, A-D), 
adenomatous hyperplasia (B-E) and adenoma (C-F) of lsl-KRasG12D;R26-lsl-MYC;Nuak1F/F 
and lsl-KRasG12D;R26-lsl-MYC lung sections at 6 weeks post Adeno-Cre infection. Scale 
bars = 200 µm. 
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4.2.5 MYC overexpression is not synthetically lethal with Nuak1 
deletion in KRas-driven NSCLC 
To further characterize the effect of Nuak1 deletion in KRasG12D/MYC lung 
tumours, the analysis of the proliferation rate was carried out by examination of 
the incorporation of Bromodeoxyuridine (BrdU), the synthetic analogue of 
thymidine, into newly synthetized DNA of cancer cells. KMN tumours did not 
differ in the levels of BrdU incorporation in comparison to KM tumours, as 
indicated by the quantification of the immunohistochemistry staining (Fig. 4.7A). 
In agreement with the comparable levels of proliferation, the tumour burden at 
6 weeks post infection was not significantly different in KMN mice compared to 
KM (Fig. 4.7B). 
 
Figure 4. 7 – Deletion of Nuak1 does not affect growth of KRas/MYC lung tumours. 
A, Bar graphs representing the Mean ± SEM of BrdU positively stained cells from KM 
(n=3) and KMN (n=3) lung tumours at 6 weeks post Adeno-Cre infection. B, Box plots 
representing the tumour burden (Mean ± SEM) of KM (n=7) and KMN (n=7) mice at 6 
weeks post Adeno-Cre infection. ns = not significant. P value calculated with two-tailed 
unpaired T test. 
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4.2.6 Upregulation of the PI3K/AKT pathway in Nuak1 deleted 
lung tumours 
The Raf/MEK/ERK cascade is a major effector downstream of RAS and is a very 
important contributor to cell survival and proliferation, often dysregulated in 
cancer. In addition, increased activation of ERK1/2, as indicated by increased 
phosphorylation levels, has been correlated with more advanced and aggressive 
tumours in patients with NSCLC (Vicent et al., 2004). Therefore, we sought to 
assess ERK1/2 activation status in KRasG12D/MYC lung tumours and we observed a 
minority of adenomas characterized by areas that were positive for 
immunohistochemical staining with phospho-ERK (Fig. 4.8A, panel ii). 
Interestingly, those specific regions also featured a distinctive morphology, 
indicative of a more aggressive phenotype: a much lower degree of organization 
and a loss of cell polarity (Fig. 4.8A, panel i). Furthermore, histological 
examinations of lungs after 4-5 months from Adeno-Cre infection revealed a 
higher and wider occurrence of phospho-ERK positive regions, suggesting that 
the distinctive tumour regions identified at 6 weeks are aggressive sub-clones 
that predominate as tumours progress to a more advanced disease (Fig. 4.8B). In 
contrast, analysis of phospho-ERK in KRasG12D/MYC/Nuak1F/F adenomas at 6 
weeks post infection showed a significant reduction of the number of phospho-
ERK positive tumours (Fig. 4.8C).  
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Figure 4. 8 – Nuak1 deletion decreases signalling through ERK. 
A, Representative pictures of KM lung tumours stained for H&E and phospho-ERK at 6 
weeks post Adeno-Cre infection, depicting the morphological changes associated with 
progression (panel i and ii). Scale bars = 50 µm. B, Representative pictures of KM lung 
tumours stained for phospho-ERK at 6 weeks (panel i and ii) in comparison to 5 months 
post Adeno-Cre infection (panel iii). Scale bars = 1 mm (i and iii), 200 µm (ii) . C, 
Scatter dot plot representing the number ± SEM of phospho-ERK positive lung tumours 
per mouse from KM (n=5) and KMN (n=5) mice at 6 weeks post Adeno-Cre infection. * 
p<0.05 calculated with two-tailed unpaired T test. 
 
 
A similar phenotype has been previously observed in KRasG12D/Lkb1F/F lung 
tumours, which showed decreased phospho-ERK levels in comparison to KRasG12D 
tumours (Chen et al., 2012). In addition, the same study revealed an increased 
activity of the AKT and SRC pathways, suggesting that Lkb1 deleted tumours 
rewire their dependency from MEK/ERK to AKT and SRC pathways to sustain their 
growth. Therefore, given the observed decrease in phospho-ERK levels upon 
Nuak1 deletion, we were interested in exploring if upregulation of the PI3K/AKT 
pathway represented an alternative mechanism to sustain tumour growth in 
KRasG12D/MYC/Nuak1F/F as in KRasG12D/Lkb1F/F mice. 
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Staining for phospho-AKTS473 revealed an increased positivity of lung tumours 
when Nuak1 was deleted compared to wild type controls (Fig. 4.9).  
 
 
 
 
Figure 4. 9 – Nuak1 deletion results in increased AKT phosphorylation in lung 
tumours. 
Representative pictures of phospho-AKT (Ser473) staining of KM and KMN lung tumours 
at 6 weeks post Adeno-Cre infection. Scale bars = 200 µm. 
 
 
4.2.7 Deletion of Nuak1 does not sensitize lung tumours to 
mTORC1 inhibition 
One of the major effectors of the PI3K/AKT signalling cascade is mTORC1, which 
positively regulates protein synthesis to sustain cell growth. Given the higher 
AKT phosphorylation observed in Nuak1 deleted lung tumours and considering 
the regulation of the mTORC1 subunit Raptor by NUAK1, highlighted in our 
studies (Chapter 3), we decided to investigate the activation of mTORC1 in our 
tumour model. Thus, we performed immuhistochemical staining for downstream 
effectors of mTORC1: phospho-4E-BP1 and phospho-S6. As shown in figure 4.10, 
deletion of Nuak1 resulted in an increase in phospho-4E-BP1 staining compared 
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to wild type tumours, whereas no significant difference was observed regarding 
phospho-S6. 
 
 
 
Figure 4. 10 – Nuak1 deletion results in increased phosphorylation of 4E-BP1. 
Representative pictures of KM and KMN lung tumour sections at 6 weeks post Adeno-Cre 
infection stained with H&E, phospho-S6 (Ser235/236) and phospho-4E-BP1 (Thr37/46). 
Scale bars = 200 µm. 
 
 
LKB1 has been shown to negatively regulate mTORC1 (Shaw et al., 2004a) and 
LKB1-deficient NSCLC cells displayed a higher sensitivity to inhibition of the 
PI3K-mTORC1 signalling pathways (Whang et al., 2016). Thus, in light of the 
higher mTORC1 activity observed in Nuak1 deleted tumours, we sought to test 
the effect of mTORC1 inhibition. 
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KMN and KM mice at 6 weeks post Adeno-Cre infection were treated acutely with 
the mTORC1 inhibitor Rapamycin. As shown in figure 4.11A, Rapamycin could 
efficiently inhibit tumour cell proliferation in both KM and KMN lung tumours, as 
assessed by BrdU incorporation, but no increased sensitivity was observed in 
correlation to Nuak1 deletion. In addition, apoptotic levels in response to 
rapamycin treatment were not significantly different between KM and KMN 
tumours (Fig. 4.11B), suggesting overall that Nuak1 deletion did not confer 
higher sensitivity to inhibition of mTORC1 activity. 
 
 
 
Figure 4. 11 – Nuak1 deletion does not senstize tumours to mTORC1 inhibition. 
Bar graphs representing the Mean ± SEM of BrdU (A) and TUNEL (B) positively stained 
lung tumour cells from KM (n=3) and KMN (n=3) mice treated with vehicle or Rapamycin 
for 3 days at 6 weeks post Adeno-Cre infection. ns= not significant. P value calculated 
with one-way ANOVA, Tukey’s multiple comparison. 
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4.2.8 Deletion of Nuak1 confers a survival advantage to 
KRasG12D/MYC mice 
Although the tumour burden analysed at 6 weeks post infection did not 
significantly differ between KM and KMN mice, the observation of phospho-ERK 
positive regions in KM adenomas, which were absent in KMN tumours, suggested 
that Nuak1 deletion affected the onset of aggressive tumour sub-clones. 
Interestingly, a negative correlation between high cytoplasmic phospho-ERK 
levels and survival of patients with NSCLC has been previously described (Vicent 
et al., 2004). In addition, preliminary data on the immunohistochemical analysis 
of CD31 staining, marker of endothelial cells, at 6 weeks post infection revealed 
a significant reduction in the number of blood vessels in KMN tumours in 
comparison to KM (Fig. 4.12). 
 
 
 
 
Figure 4. 12 – Nuak1 deletion affects tumour blood vessels. 
Bar graphs representing the Mean ± SEM of CD31 positively stained lung tumour blood 
vessels from KM (n=2) and KMN (n=3) mice at 6 weeks post Adeno-Cre infection. * p<0.05 
calculated with two-tailed unpaired T test. Data generated in collaboration with Lisa 
Neilson and Dr Sara Zanivan from the Beatson Institute. 
 
 
Thus, we sought to determine if Nuak1 deletion could have an impact on overall 
survival in our tumour model. Given the asphyxia caused by the large tumour 
load obtained with the high dose of Adenovirus-Cre used in the previous 
experiments, which limits an adequate study of long term survival benefits, KM 
and KMN mice were infected with a lower dose of Adenovirus-Cre and sacrificed 
at clinical end-point, i.e. when animals showed signs of respiratory distress, 
deterioration of body conditions and behavioural changes. As shown in figure 
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4.13, Nuak1 deletion resulted in a significant increase in survival of KM mice, 
suggesting a long-term benefit of Nuak1 deletion in NSCLC.  
 
 
 
Figure 4. 13 – Nuak1 deletion enhances survival of KRasG12D/MYC lung tumours-
bearing mice. 
Kaplan-Meier survival analysis of KM (n=12) and KMN (n=9) mice induced with a low titer 
of Adenovirus-Cre (3x105 pfu). * p<0.05 determined by log-rank (Mantel-Cox) test. 
 
 
4.3 Discussion 
The Liver Kinase B1 (LKB1), also known as STK11, has been identified as the 
third most frequently mutated gene in lung adenocarcinoma. In addition, the 
tumour suppressor role of LKB1 in lung cancer has been compellingly determined 
in pre-clinical models of lung cancer. Specifically, deletion of Lkb1 in a mouse 
model of NSCLC driven by KRasG12D showed an acceleration of the disease with 
enhanced metastatic potential (Ji et al., 2007). However, the data described in 
this chapter suggest that NUAK1, as downstream effector of LKB1, does not 
reflect the potent tumour suppressor role of its upstream kinase. Our results 
indicate that Nuak1 deletion in the lungs does not accelerate the tumorigenic 
process driven by mutant KRas, as simultaneous deletion of Nuak1 and 
expression of KRasG12D did not affect the tumour burden in comparison to 
KRasG12D only (Fig. 4.4). Also, whereas Lkb1 deletion has been shown to mediate 
trans-differentiation of lung adenocarcinoma into squamous cell carcinoma (Li et 
al., 2015a), here we provide evidence that Nuak1 deletion does not recapitulate 
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a similar phenotype as only the adenocarcinoma subtype was detected in 
KRasG12D/Nuak1F/F lungs at 16 weeks post Adeno-Cre infection (Fig. 4.2). 
Although deletion of Nuak1 did not have an impact on the tumorigenic process 
driven by mutant KRas in the lungs, other studies have suggested a beneficial 
effect of NUAK1 inhibition in multiple cancer settings. Particularly, a previous 
synthetic lethality screening done by Liu and colleagues identified NUAK1 as 
being required for survival of MYC-overexpressing cells (Liu et al., 2012). 
Interestingly, the study showed that depletion of NUAK1 impaired the graft of 
hepatoma cells expressing MYC and resulted in a significant extension in survival 
of tumour-bearing mice. We characterized the effect of Nuak1 deletion in a 
genetically engineered mouse model for NSCLC driven by KRasG12D mutation and 
accelerated by MYC overexpression (KM model). Remarkably, upon Nuak1 
deletion (KMN model) we observed a change of the histological features of lung 
adenomas, which were characterized by predominant acinar structures in 
contrast to Nuak1 wild type tumours that presented a papillary predominant 
growth. Despite these morphological differences, at 6 weeks post infection the 
levels of tumour cells proliferation did not significantly differ between KM and 
KMN lung tumours (Fig. 4.7A), in agreement with the observation of the 
unchanged tumour burden (Fig. 4.7B). Clinical data have suggested that there is 
not a significant difference in terms of survival between the papillary and acinar 
types of tumours, whereas the micropapillary subtype has been reported to have 
the worst survival outcome (Russell et al., 2011). Therefore, currently the 
biological meaning and clinical implications of the transition from a papillary to 
an acinar subtype are not yet understood. 
 
The MEK/ERK cascade downstream of Ras is frequently dysregulated in cancer 
and we identified enhanced ERK activation, suggested by increased 
phosphorylation levels, as KM tumours progress to more advanced stages. 
Furthermore, increased phospho-ERK levels were associated with tumour regions 
featuring morphological hallmarks of progression, such as loss of cell polarity 
and enlarged nuclei (Fig. 4.8A-B). Although Nuak1 deletion did not affect the 
tumour burden of KM mice at 6 weeks post Adeno-Cre infection, it resulted in a 
reduced level of ERK activation while increasing AKT phosphorylation (Fig. 4.8C 
and 4.9). AKT has been suggested as an alternative kinase for NUAK1 but a 
reciprocal role of NUAK1 regulating AKT has not been described yet. Further 
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analyses are needed to uncover the mechanism of the observed upregulation of 
AKT in the absence of NUAK1. Moreover, analysis of phospho-4E-BP1 and 
phospho-S6, which are targets of mTORC1, a downstream effector of AKT, 
revealed higher phosphorylation levels of 4E-BP1 in KMN tumours in comparison 
to KM tumours (Fig. 4.10).  
Raptor has been shown to recruit 4E-BP1 to the mTORC1 complex, facilitating its 
phosphorylation (Hara et al., 2002). Therefore, as we uncovered that NUAK1 
contributes to Raptor inhibition (Fig. 3.15), it is possible that the preferential 
phosphorylation of 4E-BP1 over S6 is a result of Raptor activation in Nuak1 
deleted lung tumours.  
The LKB1/AMPK axis is well known for regulating protein synthesis (Shaw et al., 
2004a). In particular, AMPK can modulate mTORC1 activity through the negative 
regulation of Raptor and the positive regulation of TSC2, an inhibitor of 
mTORC1. In addition, Lkb1 deletion has been shown to increase mTORC1 
activation both in vitro and in vivo and our data suggested a similar role for 
Nuak1 (Fig. 3.10 and Fig. 4.10). Therefore, targeting the increased protein 
synthesis that is required for highly proliferative cells, such as tumour cells, to 
sustain their growth appeared as a potential therapeutic strategy. Although 
Nuak1 deletion resulted in an increase of mTORC1 activity it did not sensitise 
tumour cells to Rapamycin. However, there is discordant evidence on the 
efficacy of mTORC1 inhibition in inducing cell death of LKB1-null cancer cells. 
Particularly, an in vitro study carried out by Whang and colleagues using wild 
type and LKB1-null human lung cancer cell lines highlighted the higher sensitivity 
of the latter to mTORC1 inhibition using Rapamycin, as demonstrated by the 
decreased viability and colony formation of LKB1-null cells as compared to LKB1 
wild type cells upon treatment (Whang et al., 2016). Conversely, other studies 
have disproved the increased sensitivity of LKB1-null cells to mTOR inhibitors, 
suggesting a feedback activation of the AKT pathway that overcomes mTOR 
inhibition (Xiao et al., 2015). Similarly, Momcilovic and colleagues have shown 
the lack of relation between LKB1 status and sensitivity to the mTOR inhibitor 
MLN0128 (Momcilovic et al., 2015). Moreover, multiple studies have suggested 
that Rapamycin has a differential effect on 4E-BP1 and S6K, which is the 
upstream kinase of S6. Treatment with Rapamycin was shown to repress S6K 
activity in a sustained manner, whereas phosphorylation levels of 4E-BP1 were 
re-established after an initial inhibition (Choo et al., 2008). Given the increase 
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of phospho-4E-BP1 but not of phosho-S6 observed in Nuak1 deleted tumour, one 
possibility is that the inefficiency of Rapamycin to inhibit 4E-PB1 is the cause of 
the lack of enhanced sensitivity of KMN tumours. We have not established 
whether phosphorylation of 4E-BP1 occurs independently of mTORC1 activation 
in our model, as it has been suggested an AKT-dependent modulation of the 
substrate, in which case inhibition of AKT might represent a better therapeutic 
approach. However, testing of ATP-competitors for mTORC1 that more 
efficiently inhibit 4E-BP1 phosphorylation might give more information on the 
contribution of mTORC1 to proliferation and survival of Nuak1 deleted tumour 
cells. 
 
An important finding of this study that will be confirmed and further explored is 
the potential role of NUAK1 in tumour angiogenesis, as the percentage of tumour 
blood vessels was decreased in Nuak1 deleted lung tumours in comparison to 
wild type (Fig. 4.12). Interestingly, a role of LKB1 in angiogenesis has been 
previously highlighted by multiple research groups, although with conflicting 
findings. In particular, deletion of Lkb1 was reported to cause vascular 
abnormalities, among others, in the developing embryos, with alterations in 
sprouting and maturation of blood vessels (Ylikorkala et al., 2001). An additional 
study carried out in adult mice described a similar role of LKB1 in supporting 
angiogenesis, since it was observed that formation of new blood vessels 
following an ischemic insult was impaired in mice bearing Lkb1 deletion in 
endothelial cells (Ohashi et al., 2010). However, other studies have provided 
evidence towards an antiagionenic role of LKB1. For example, it was recently 
described that tumour implanted in mice with endothelial deletion of Lkb1 
displayed increased angiogenesis in comparison to Lkb1 wild type endothelial 
cells (Zhang et al., 2017). Additional investigations have corroborated an 
antiagiogenic function of LKB1, proposing multiple mechanisms: from regulation 
of VEGF to degradation of the angiogenic receptor neuropilin-1 (NRP-1) (Liang et 
al., 2014; Okon et al., 2014). Overall, LKB1 might play a dual role in 
angiogenesis, which could differ according to tissues or development stage.  
We have not established if the angiogenic role of NUAK1 in our tumour model is 
dependent on the upstream kinase LKB1, which will require additional analysis. 
However, we also need to consider that the observed involvement of NUAK1 in 
tumour angiogenesis might not be related to LKB1 because, as highlighted by 
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data obtained in this chapter, LKB1 does not seem to mediate its tumour 
suppression functions in lung tumorigenesis through NUAK1. Moreover, some 
functions exerted by NUAK1 are not shared by LKB1 but actually contradicting 
with it. For example, whereas LKB1 has been shown to suppress cell invasion and 
its deletion to increase the metastatic potential, NUAK1 role in promoting 
invasion and metastasis has been compellingly established in multiple settings. 
Therefore, it appears that the two kinases may not lie within the same path for 
all their functions.  
Further investigations in our KMN model might clarify NUAK1’s involvement in 
angiogenesis and elucidate the mechanisms through which its deletion 
contributed to the observed extension of survival (Fig. 4.13). Deletion of Nuak1 
did not affect tumour cells proliferation in the presence of MYC overexpression 
at 6 weeks post infection. However, previous studies and also unpublished data 
from our laboratory indicate that NUAK1 expression increases with tumour 
progression. Therefore, the progression to more advanced stages and the related 
increase in metabolic stress might impose a more prominent and long-term 
dependence on NUAK1 for survival of MYC overexpressing cells. Furthermore, 
Nuak1 deletion might contribute to the inhibition of the metastatic process and 
together with an impairment in tumour vasculature, which is essential in 
providing oxygen and nutrients to tumour cells as well as a route for metastatic 
dissemination, oppose cancer progression, establishing itself as tumour promoter 
in NSCLC as opposed to LKB1. 
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Chapter 5 – The role of the ERBB network in 
supporting KRas mutant lung adenocarcinoma 
5.1 Introduction 
KRAS is a member of the RAS family of small GTPase together with the H- and N-
RAS isoforms. The RAS family of genes is often mutated in cancer, with 
activating mutations in KRAS frequently found in three of the four most lethal 
cancers: pancreatic adenocarcinoma, colorectal adenocarcinoma and lung 
adenocarcinoma (Oikonomou et al., 2014). Most mutations are found at the 
residue G12 of KRAS and they cause the formation of a persistent GTP-bound 
form, which represents a constitutively active state. Interestingly, alterations of 
RAS genes are events that occur in the early phases of tumour initiation but 
multiple experimental evidence point towards a role of continued expression of 
mutant RAS in tumour maintenance as well, corroborating its important role in 
the different stages of cancer progression (Brummelkamp et al., 2002; Singh et 
al., 2009).  
Despite the significant progress made in the understanding of RAS biology since 
the first detection of its activating mutations in human cancer in 1982 (Parada et 
al., 1982; Santos et al., 1982), targeted therapies for KRAS mutant cancers are 
lacking and they still represent a challenge for clinical oncology. Many attempts 
have been made to inhibit RAS and over time the efforts have been broadened 
from targeting RAS activity to affecting RAS function by interfering with its 
localization or by inhibiting RAS effectors. However, whereas patients with 
EGFR-mutant lung cancer can benefit from therapy with EGFR tyrosine kinase 
inhibitors (TKI), KRAS mutations have been suggested as negative predictors of 
response to therapies with EGFR TKI (Linardou et al., 2008; Massarelli et al., 
2007). 
 
The study of the role of Nuak1 in the tumorigenic process driven by KRas shed 
some light on the potential benefit of NUAK1 inhibition. However, it is unlikely 
that targeting of NUAK1 alone would be therapeutically sufficient in lung cancer. 
Therefore, we focused on the investigation of the mechanisms associated with 
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tumour progression of a KRasG12D/MYC NSCLC mouse model in order to identify 
new therapeutic targets. 
In this chapter, we elucidate the role of the ERBB network in the lung 
tumorigenic process driven by KRas, challenging the dogma that inhibition of 
ERBB receptors is not beneficial in patients affected by KRAS mutant NSCLC. 
Data provided in this chapter are part of a broader study carried out in 
collaboration with Björn Kruspig and Sarah Neidler. 
 
 
5.1.1 Mouse models 
Most of the experiments were performed using a lsl-KRasG12D/R26-lsl-MYCHom 
NSCLC mouse model (referred to as KRasG12D/MYC or KM), in which the KRas 
G12D point mutation is preceded by a lox-stop-lox (lsl) sequence, and lsl-human 
MYC is expressed under the control of the Rosa26 (R26) locus. In addition, to 
monitor tumour growth in live animals we employed the near-infrared 
fluorescent protein encoded by the Irfp gene, which was inserted in the 
endogenous Hprt locus and preceded by a lox-stop-lox cassette to control its 
expression (Hock et al., 2017). Upon administration of Adenovirus-Cre, the 
simultaneous induction of mutant KRas, exogenous MYC and iRFP, when present, 
was achieved (Fig.5.1). 
 
 
  
Figure 5. 1 – Schematic representation of the lsl-KRasG12D/R26-lsl-MYC/Hprt-lsl-Irfp 
mouse model. 
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5.2 Results 
5.2.1 Upregulation of the ERBB network during progression of 
KRas mutant lung adenocarcinoma 
As mentioned in Chapter 4, histological examination of lungs of KRasG12D/MYC 
(KM) mice after six weeks from Adeno-Cre infection revealed the presence of 
more aggressive sub-populations within the tumour, characterized by different 
morphological features (Fig. 4.8A). In addition, exclusively these tumour areas 
were positive for immunohistochemical staining with phospho-ERK, a 
downstream effector of KRAS and a marker associated with tumour progression 
(Vicent et al., 2004). To identify the underlying molecular events involved in the 
observed morphological transition to a more advanced phenotype, we compared 
the transcriptome of isolated phospho-ERKhigh regions to phospho-ERKlow regions 
of lung adenomas after 6 weeks from Adeno-Cre infection. GeneGO analysis of 
the data set obtained from the RNA sequencing analysis revealed that multiple 
pathways associated with regulation of cell adhesion, cell motility and 
cytoskeletal remodelling were upregulated in phospho-ERKhigh regions (data not 
shown). Surprisingly, multiple components of the ERBB signalling network were 
found to be enriched in the phospho-ERKhigh regions (Table 5.1). In particular, 
expression of ERBB receptors such as ERBB2 and ERBB3 was increased, together 
with multiple ERBB ligands such as Epiregulin, Amphiregulin and Tgf. 
Upregulation of LamC2, Fabp5 and Keratine 19, all shown to enhance signalling 
through EGFR/ERBB family RTKs (Garg et al., 2014a; Powell et al., 2015), was 
also identified. Furthermore, increased expression of the sheddase ADAM9 and 
ADAM10, proteolytic enzymes responsible for the release of soluble form of 
receptor ligands, was observed. Overall, the analysis strikingly indicated a 
potential role of the ERBB network in the progression of KRasG12D/MYC lung 
adenomas.  
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High phospho-ERK associated gene expression ∆ (fold) FDR 
ERBB family ligands 
Epiregulin 
Amphiregulin 
Transforming Growth Factor alpha 
Heparin-bound EGF 
 
24.82 
4.25 
2.69 
2.31 
 
2.78e-13 
4.98e-11 
0.0048 
0.020 
ERBB ligand sheddases 
Adam9 
Adam10 
 
2.00 
1.89 
 
0.0001 
0.0016 
ERBB Receptors/Receptor Tyrosine Kinases 
Erbb2 
Erbb3 
 
1.55 
1.53 
 
0.060 
0.054 
ERBB Accessory proteins 
IQGAP2 
LamC2 
Keratin 19 
FABP5 
 
5.30 
3.48 
2.96 
2.79 
 
0.0004 
2.56e-9 
2.06e-6 
6.15e-3 
RAS pathway 
Raf1 
BRaf 
CRaf 
 
1.86 
1.52 
1.80 
 
0.0178 
0.063 
0.0037 
 
 
Table 5. 1- Overexpression of genes belonging to the ERBB network in phospho-
ERKhigh tumour regions. 
Phospho-ErkHigh and phospho-ERKlow tumour regions from KM mice (n = 4) were isolated 
by laser-capture microdissection and gene expression measured by RNA-SEQ. The table 
represents normalized Ras and ERBB network gene expression in phospho-ErkHigh relative 
to phospho-ErkLow tumour regions. FDR = false discovery rate. Data generated by Sarah 
Neidler. 
 
 
Interestingly, Western blot analysis of protein lysates isolated from multiple lung 
tumours at 6 weeks post infection showed detectable levels of phospho-EGFR, 
phospho-ERBB2 and phosho-ERBB3, indicating activity of the ERBB receptors in 
the developing adenomas (Fig. 5.2). 
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Figure 5. 2 – ERBB receptors are active in KRasG12D/MYC lung adenomas.  
Protein extracts were isolated from KM lung tumours at 6 weeks post Adeno-Cre 
infection and were immunoblotted with the indicated antibodies. Each lane represents 
an individual lung tumour; all the ten tumours were harvested from a single mouse. 
 
 
5.2.2 KRasG12D/MYC lung tumours are sensitive to ERBB inhibition  
The observed upregulation of the ERBB network in developing KRas/MYC lung 
tumours indicated a potential contribution of the ERBB signalling in sustaining 
tumour progression. To test the sensitivity of ERBB receptors inhibition in our 
KRasG12D/MYC NSCLC mouse model, we made use of the clinically approved drug 
Neratinib, which is an irreversible inhibitor of EGFR and ERBB2 (Subramaniam et 
al., 2015). As shown in figure 5.3A, acute Neratinib treatment resulted in an 
efficient inhibition of EGFR and ERBB2, as suggested by their decreased 
phosphorylation levels in comparisons to vehicle treated controls. Most 
importantly, Neratinib treatment caused a significant decrease of tumour cell 
proliferation, as suggested by the reduction of the proliferation marker Ki67, 
and in a significant increase of apoptosis, as indicated by TUNEL staining, 
compared to vehicle treated controls (Fig. 5.3B-C). 
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Figure 5. 3 – ERBB inhibition induces growth arrest and cell death in KM lung 
tumours. 
A, KM mice at 6 weeks post Adeno-Cre infection were treated with Neratinib (n=3) or 
vehicle control (n=3) for three days before harvesting tumour tissue for protein 
isolation. Whole cell protein extracts were immunoblotted with the indicated 
antibodies. B, Representative images of lung tissue sections of KM mice at 6 weeks post 
Adeno-Cre infection treated for three days with Neratinib or vehicle control 
immunostained for Ki67 and TUNEL. Scale bars = 100 µm. C, Bar graphs representing the 
Mean ± SEM of Ki67 and TUNEL positively stained lung tumour cells from KM mice 
treated with vehicle (n=3) or Neratinib (n=3) for three days. ***p<0.01 calculated with 
two-tailed unpaired T test.  
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5.2.3 Inhibition of the ERBB receptors impairs KRas-driven 
tumorigenesis 
Having established the sensitivity of KM tumours to inhibition of ERBB receptors 
by Neratinib treatment, we sought to investigate the extent of the contribution 
of the ERBB signalling to the tumorigenic process driven by mutant KRas. To 
achieve that, KRasG12D/MYC mice were treated daily with Neratinib for 4 weeks, 
starting at 2 weeks post infection, a time point when only early lesions such as 
atypical adenomatous hyperplasia and epithelial hyperplasia of the bronchioles 
could be detected. Strikingly, continuous Neratinib treatment impaired the 
tumorigenic process driven by mutant KRas as shown by the significant decrease 
in tumour burden in KM treated mice compared to control mice. Conversely, 
prolonged inhibition of EGFR only, by treatment with a daily dose of Erlotinib, 
did not have a significant impact on tumour burden in comparison to vehicle 
treatment (Fig. 5.4A-B). Overall, these results suggested that multiple ERBB 
receptors are required since the early stages of the tumorigenic process of 
KRasG12D/MYC lung cancer. 
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Figure 5. 4 – Neratinib but not Erlotinib treatment reduces lung tumour burden of 
KM mice. 
A, Box plots indicating the tumour burden (Mean ± SEM) and B, representative H&E 
images of KM mice treated with either Neratinib (n=3), Erlotinib (n=4) or vehicle control 
(n=6) for 4 weeks, starting at 2 weeks post Adeno-Cre infection (PI). ns= not significant, 
*p<0.05 calculated with one-way ANOVA, Tukey’s multiple comparison. Scale bars = 1 
mm. 
 
 
5.2.4 ERBB blockade enhances therapeutic impact of MEK 
inhibition in KRas mutant lung adenocarcinoma 
The observed tumour preventive effect of the ERBB receptors inhibition in 
KRasG12D/MYC lung tumorigenesis prompted us to investigate the therapeutic 
outcome of Neratinib treatment. However, daily treatment of established 
KRasG12D/MYC lung tumours for 7 days with Neratinib did not have a significant 
effect on overall survival in comparison to vehicle treatment (Fig. 5.5).  
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Figure 5. 5 – Neratinib treatment does not increase the overall survival of KM mice. 
Kaplan-Meier survival analysis of KM mice treated with Neratinib (n=7) or vehicle control 
(n=9) for 7 days starting at 6 weeks post Adeno-Cre infection, which is indicated as time 
0 in the graph. ns= not significant. P value determined by log-rank (Mantel-Cox) test. 
 
 
Further in vitro studies on KRAS mutant human lung cancer cell lines (H2009, 
H358, A549) revealed that Neratinib treatment did not induce a significant 
increase in cell death in two of three cell lines. However, the achievement of a 
more pronounced inhibition of the MEK/ERK cascade by combination of ERBB and 
MEK inhibition using Neratinib and Trametinib, respectively, could efficiently 
and significantly enhance cell death in all the lines tested, as compared to single 
drugs and vehicle control treatment (Fig. 5.6).  
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Figure 5. 6 – Combination of ERBB and MEK inhibition more efficiently induces cell 
death in KRas mutant human lung cancer cell lines. 
Bar graph representing the Mean ± SEM of cell death induced by the indicated doses of 
Neratinib and/or Trametinib in human NSCLC cells, measured 48hrs after treatment. 
Cell death was analysed by Incucyte live-cell imaging system in the presence of Sytox 
green and corrected for confluence. N=3. Data generated by Björn Kruspig. 
 
 
Given the efficacy of the combination of Neratinib with Trametinib in inducing 
cell death in the human lung cancer cell lines tested in vitro, we sought to 
determine the therapeutic effect of the combinatorial treatment in our 
KRasG12D/MYC NSCLC in vivo model.  
Following Adenovirus-Cre administration, KRasG12D/MYC/Irfp animals were 
monitored weekly for detection of iRFP signal using the PEARL system for near-
infrared fluorescent imaging (LI-COR), starting at 2 weeks post infection. When 
the intensity of the iRFP signal, which correlates with tumour burden, reached a 
threshold of approximately 800 units, daily treatment with Neratinib in 
combination with Trametinib was carried out for 5 consecutive days.  
As shown by quantification in figure 5.7A, we could attest that the tumour 
growth followed an exponential trend in untreated mice, as suggested by the 
exponential increase of the iRFP signal intensity over time. On the contrary, 
treatment with the combination of Neratinib and Trametinib caused a plateau of 
the iRFP signal, indicating an arrest in the tumour growth during the treatment 
period. Similarly, representative pictures in figure 5.7B indicated an increase of 
the iRFP signal intensity over the treatment period in mice that received the 
vehicle control whereas the iRFP signal was reduced in the presence of the 
combinatorial therapy.  
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Figure 5. 7 – iRFP signal detection identified impaired growth of lung tumours 
treated with Neratinib in combination with Trametinib. 
A, iRFP signal in KM mice was monitored using a PEARL imaging system (LI-COR) and 
intensity curves calculated using the Weibull growth equation. iRFP signal is 
represented as baseline corrected values. Treatment with Neratinib & Trametinib was 
started when the signal threshold (800 arbitrary units) was reached and continued for 
five days. Each dot represents a day of imaging. B, Representative LI-COR PEARL images 
of lung tumours from KM mice treated with Neratinib & Trametinib or vehicle control. 
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Furthermore, in agreement with the observed arrest in tumour growth, the 
combination of Trametinib and Neratinib could significantly further extended 
overall survival, in comparisons to single treatments and vehicle control (Fig. 
5.8). 
 
 
 
 
Figure 5. 8 – Combination of Neratinib with Trametinib enhances survival of KM 
mice. 
Kaplan-Meier survival analysis of KM mice treated with vehicle control (n=9), Neratinib 
(n=7), Trametinib (n=10) or a combination of the two drugs (n=10) for 7 days starting at 
6 weeks post Adeno-Cre infection,which is indicated as time 0 in the graph. *p<0.05, 
**p<0.001 determined by log-rank (Mantel-Cox) test. 
 
 
Western blot analysis of tumour samples isolated from KM mice treated acutely 
with Neratinib and/or Trametinib revealed an increase in AKT phosphorylation 
upon Trametinib treatment, which has been previously documented by Sun and 
colleagues (Sun et al., 2014). Moreover, Neratinib treatment could reduce the 
Trametinib-mediated increase in AKT phosphorylation to basal levels and, 
whereas the levels of phospho-ERK were only modestly reduced by Neratinib, 
combination with Trametinib efficiently abrogated phosphorylation of ERK (Fig. 
5.9). Overall, combination of Neratinib with Trametinib appeared to be more 
effective than the single treatments in inhibiting two key pathways that sustain 
tumour cell survival and proliferation downstream of ERBB receptors and KRAS, 
the mitogen-activated protein kinase (MAPK)- and the PI3K/AKT pathways. 
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Figure 5. 9 – Simultaneous inhibition of the ERBB receptors and MEK impacts on 
AKT activation. 
Protein extracts were isolated from lung tumours of KM mice treated for three days with 
Neratinib (n=2), Trametinib (n=2), a combination of both drugs (n=2) or vehicle control 
(n=2) at 6 weeks post Adeno-Cre infection, and immunoblotted with the indicated 
antibodies. 
 
 
5.3 Discussion 
Activating mutations of the oncogene Ras are among the main drivers of the 
tumorigenic process in several tissues. In particular, somatic mutations in RAS 
are detected in 20% of human tumours, of which more than 80% are related to 
KRAS isoform. Although RAS was the first mutated gene to be identified in 
human cancer and its biological functions extensively studied over the years, we 
are still battling with the search of a successful therapeutic strategy that tackles 
its oncogenic activity. Therefore, the investigations reported in this chapter 
intended to provide with a better understanding of the molecular mechanisms at 
the base of KRas-driven tumour progression in the lung to develop novel 
therapeutic approaches. 
Experimental evidence obtained in this study have surprisingly uncovered a 
functional role of the ERBB signalling in supporting KRas driven tumorigenesis. 
Specifically, tumour regions with morphological and molecular features of 
progression were found to be characterized by the upregulation of multiple 
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components of the ERBB network, such as the ERBB receptors and their ligands 
(Tab. 5.1). In addition, inhibition of the ERBB receptors with Neratinib 
significantly reduced tumour cell proliferation and increased apoptotic levels in 
established tumours (Fig. 5.3), and most strikingly, it impaired tumour initiation 
when treatment was started at an early stage of tumorigenesis (2 weeks post-
Adeno-Cre infection) (Fig. 5.4). Overall, these findings not only support a 
functional requirement of the ERBB signalling in developing KRas mutant lung 
tumours but also in the tumour initiation process.  
These surprising but important observations challenge the current field on 
several aspects and are supported by recently published data that change our 
understanding of Ras biology. Firstly, as the three common KRAS mutations in 
lung cancer (G12C, G12D, G12V) confer a persistent activation status, it has 
been inferred that upstream signals, such as modulation by the ERBB receptors, 
can no longer influence RAS activity. However, a recent study has questioned 
that concept by providing evidence of a maintained basal GTPase activity of 
mutant KRasG12C that could be targeted with high affinity by a novel small 
molecule inhibitor (ARS853), which was able to reduce the levels of GTP-bound 
RAS and impair the signalling to the downstream effectors Raf and ERK (Lito et 
al., 2016). Thus, the new finding of mutant KRas still cycling between an on and 
off state has indicated that its activity can be modulated by upstream signalling. 
In addition, the mutual exclusive occurrence of KRAS and EGFR activating 
mutations has been attributed to their redundant function due to localization in 
the same or overlapping signalling pathways. Therefore, the mutual exclusivity 
would further support that hyperactivation of the ERBB receptors would not be 
required due to their redundancy in a setting of KRAS mutation. However, two 
recent studies have revealed an alternative and intriguing explanation for the 
absence of concomitant mutations in KRAS and EGFR. In particular, co-
expression of mutant KRAS and EGFR in human lung cancer cell lines induced 
hyperactivation of the MAPK pathway (ERK, p38 and JNK) and cell death, 
suggesting a synthetic lethal interaction between the two mutant oncogenes 
(Unni et al., 2015). Additionally, by using an elegant double-inducible in vivo 
system of KRasG12V and EGFRL858R, Santamaria’s group has described how 
induction of mutant EGFR in established KRas-driven lung adenocarcinoma 
caused an initial increase in tumour cells death that was followed by restoration 
of tumour progression together with a decreased activity of the MAPK and PI3K 
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pathways (Ambrogio et al., 2017). Therefore, it is possible that a distinct 
threshold of the ERBB signalling influences tumour survival and progression 
outcome. Thus, despite constitutive activation of EGFR, i.e. in case of 
mutations, might be detrimental to KRas driven tumours due to unsustainable 
levels of oncogenic signalling, our data suggested that a modest increase of ERBB 
signalling could support KRas driven tumorigenesis. 
 
Secondly, the sensitivity of KRas mutant lung tumours to ERBB inhibition therapy 
addresses the reported clinical failure of EGFR inhibition in patients with KRAS 
mutant NSCLC. In particular, EGFR tyrosine kinases inhibitors (TKI) and anti-
EGFR monoclonal antibodies have been successfully used in cancer patients with 
EGFR mutations, whereas KRAS mutations have been suggested as a negative 
predictor for the response to both therapies. Data from our KM mouse model 
reported in this chapter agree with the clinical observation that EGFR-inhibition 
alone, using Erlotinib, does not affect the tumorigenic process driven by mutant 
KRas (Fig. 5.4). However, the observed reduction of tumour burden upon 
inhibition of multiple ERBB receptors using Neratinib, suggests that the clinical 
outcome could be improved by the inhibition of multiple ERBB receptors.  
 
Continuous treatment of established tumours with Neratinib for seven days did 
not result in a survival advantage in comparison to vehicle control (Fig. 5.5). 
Although a more prolonged treatment could improve the therapeutic outcome, 
the inability of Neratinib to induce a significant increase in cell death in human 
lung cancer cell lines (Fig. 5.6) suggested that inhibition of ERBB signalling was 
not sufficient to impair tumour growth.  
The increased ERK phosphorylation as tumours progressed to more advanced 
stages (Chapter 4, Fig. 4.8) indicated the importance of the MAPK cascade in 
support of this process. Indeed, components of the cascade, such as the three 
isoforms of Raf, were modestly upregulated in the phospho-ERKHigh tumour 
regions together with the ERBB network (Tab. 5.1). Therefore, a more profound 
inhibition of the MAPK cascade by dual targeting of ERBB signalling and the 
downstream effector MEK could more efficiently induce cell death in the human 
cancer cell lines tested (Fig. 5.6) and, most importantly, cause an arrest in 
tumour growth in vivo (Fig. 5.7) that translated in an increased overall survival 
of KM mice in comparisons to single treatments (Fig. 5.8). 
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Although MEK inhibition alone induced a significant increase in cell death in all 
cell lines tested (Fig. 5.6) and significantly increased KM survival in comparison 
to vehicle treatment (p<0.05) (Fig. 5.8), clinical studies have obtained 
discouraging results for lung cancer. For example, Trametinib was shown to 
induce a similar response rate and progression-free survival as standard 
chemotherapy with docetaxel in patients with previously treated KRAS mutant 
NSCLC (Blumenschein et al., 2015). Further studies have tried to address the 
lack of therapeutic effect of MEK inhibition and combine it with the targeting of 
additional pathways for an improved outcome. Recent experimental evidence 
has suggested that inhibition of MEK results in upregulation of the Fibroblast 
growth factor 1 (FGFR1) as a compensatory response mechanism. Thus, a 
combinatorial therapy with inhibition of MEK and FGFR1 was proposed to be 
more effective for treating KRAS-mutant lung cancer (Manchado et al., 2016). An 
alternative mechanism of resistance to MEK inhibition was suggested to be 
mediated by the transcriptional induction of ERBB2 and ERBB3. Indeed, ERBB 
inhibition was shown to have a synergistic effect with MEK inhibition with a more 
efficient induction of cell death in colon and lung cancer cells (Sun et al., 2014). 
Therefore, although originating from a different contextualization of the ERBB 
network function in KRas mutant lung cancer as in our model upregulation of the 
receptors represents an intrinsic property of KM tumours rather than an induced 
consequence of MEK inhibition, our data are in agreement with the findings of 
Sun and colleagues in supporting the use of a combinatorial ERBB and MEK 
inhibition therapy. In particular, the increase in AKT activity observed due to 
MEK inhibition using Trametinib was prevented by combination with Neratinib 
(Fig. 5.9), suggesting that inhibition of the AKT pathway could be part of the 
synergistic mechanism of Trametinib and Neratinib treatment. However, further 
studies will be required to delineate the molecular details of the combinatorial 
therapy, assess the potential emergence of resistance, as it represents a major 
mechanism of failure of long term treatments, and establish the possible 
molecular mechanisms of resistance. 
 
MYC gene amplifications are detected in approximately 10% of lung 
adenocarcinoma (cBioPortal) and we have shown that a moderate overexpression 
of MYC could significantly contribute to accelerate KRas driven lung 
tumorigenesis (Chapter 4, Fig. 4.5). Therefore, combination of KRasG12D with 
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MYC overexpression provided with a good model to study both the initial and 
later phases of the tumorigenic process. However, we can exclude that the 
molecular phenotype described in this chapter is an artificial result of the 
engagement of the ERBB receptors to sustain exogenous MYC overexpression as 
we have previously reported that expression from the Rosa26 locus is refractory 
to growth factor signalling (Murphy et al., 2008). In addition, we can also 
exclude that the tumour regions featuring signs of progression reflect a 
differential expression efficiency of the exogenous MYC, as RNA-SEQ analysis did 
not reveal any difference in MYC expression levels between phospho-ERKHigh and 
phospho-ERKLow regions (data not shown). Therefore, we can conclude that the 
phenotype observed is not simply driven by exogenous MYC and that our 
findings, in support to available data, strongly suggest a renewed potential of 
targeting the ERBB network in KRAS mutant NSCLC. 
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Chapter 6 – Final Discussion 
Since the relatively recent identification of NUAK1 in 2003 (Suzuki et al., 2003a), 
multiple studies have revealed its role in a variety of cellular processes that 
established a connection with cancer. Enhancement of proliferative signalling, 
resistance to cell death and activation of invasion and metastasis are some of 
the so called “hallmarks of cancer” in which NUAK1 has been shown to play a 
role. In addition, NUAK1 expression has been reported to correlate with tumour 
stage and survival outcome in many cancer types (Cui et al., 2013; Kusakai et 
al., 2004; Lu et al., 2013), indicating that its targeting could be clinically 
relevant. However, our knowledge of NUAK1 regulation and function can be 
considered still limited particularly in comparison to AMPK, which has been the 
main focus of investigation among all the AMPK related kinases (ARKs). Indeed, 
currently only a restricted number of NUAK1 substrates and upstream regulators 
are well characterized, while a more in depth understanding of NUAK1 network 
is lacking.  
 
Data presented in this thesis describe a novel modality of regulation of NUAK1 
that involves modulation by Ca2+ levels. This activation modality was initially 
considered a peculiarity of AMPK, not shared by other AMPK related kinases 
(Fogarty et al., 2010). However, recent published data reported a Ca2+-mediated 
activation of SIK2 (Miranda et al., 2016) and we propose a similar activation for 
NUAK1 and NUAK2. Therefore, increase in intracellular Ca2+ levels might 
represent an activation modality common for the AMPK family or at least shared 
by multiple ARKs.  
The Ca2+/calmodulin-dependent protein kinase kinase-beta (CaMKK) has been 
established as the upstream kinase regulating AMPK activation in response to 
Ca2+ (Woods et al., 2005), whereas the kinase mediating the activation of SIK2 
has not been identified yet. Our experimental evidence has indicated that 
Protein Kinase C  (PKC) is the Ca2+-responsive kinase that regulates NUAK1 
activation, whereas NUAK2 does not appear to be modulated by the same 
kinase.  
 
The tumour suppressor LKB1 has been described as the master kinase for the 
AMPK family members and deletion of Lkb1 was shown to abolish NUAK1 activity 
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in non-transformed MEFs (Zagorska et al., 2010). However, a dominant 
regulation of NUAK1 by LKB1 is puzzling to some extent. Some aspects of NUAK1 
cellular functions are in agreement with the reported roles of LKB1 and 
experimental evidence has compellingly demonstrated that NUAK1 mediates 
some of LKB1 physiological functions. For example, LKB1 was described for its 
role in axon specification during neuronal polarization (Barnes et al., 2007; 
Shelly et al., 2007) and subsequent studies have underlined its role in axon 
branching of cortical neurons through activation of NUAK1 (Courchet et al., 
2013). In addition, the LKB1/NUAK1 axis has been involved in the regulation of 
phosphorylation of Myosin Light chain 2 (MLC2) (Zagorska et al., 2010), which 
plays an important role in cell adhesion and polarity (Vicente-Manzanares et al., 
2009). However, molecular connections between LKB1 and NUAK1 in the control 
of metastasis have not been recognised. Several studies have established the 
incontrovertible role of NUAK1 as a positive regulator of cell migration and 
invasion (Chang et al., 2012; Chen et al., 2017; Chen et al., 2013), whereas most 
data available indicate an opposite role for LKB1 (Chan et al., 2014; Deguchi et 
al., 2010; Goodwin et al., 2014). Therefore, it is possible that the function of 
NUAK1 in migration might be regulated by an alternative kinase.  
In particular, our identification of PKC as a kinase modulating NUAK1 activation 
in response to Ca2+ stimulation opens new frontiers to the understanding of the 
biology of NUAK1. Notably, PKC, which has been established as a positive 
regulator of cell migration and invasion, might regulate NUAK1 in regard to the 
metastatic process and potentially many others. As new biological roles for 
NUAK1 continue to emerge, more aspects of its tumour promoter role are being 
described but also additional degrees of separation from LKB1 are revealed. For 
example, NUAK1 has been recently involved in the induction of epithelial-to-
mesenchymal transition (EMT) (Obayashi et al., 2016; Xu et al., 2016), which has 
been debated for playing a role in the metastatic process but also implicated in 
the mechanisms of drug resistance (Fischer et al., 2015; Shibue and Weinberg, 
2017). Similarly to NUAK1, PKC has been shown to promote EMT and mediate 
drug resistance (Abera and Kazanietz, 2015), whereas LKB1 has been suggested 
to inhibit EMT (Carretero et al., 2010; Roy et al., 2010). Therefore, evaluation of 
the PKC/NUAK1 axis in the induction of EMT might be an additional aspect to 
consider from a physiological point of view but also as therapeutic approach to 
chemoresistance. 
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Intriguingly, we have exposed a new role of PKC in its function as a linker 
between NUAK1 and MYC. Particularly, MYC was found to amplify Ca2+ signalling 
through the transcriptional upregulation of multiple components such as ITPR1, 
CaMKK and PKC. Importantly, MYC overexpression induced a more prominent 
effect at the level of activity of PKC rather than at expression levels. In 
addition, depletion of either NUAK1 or PKC was shown to be lethal in HeLa 
cells, which express high levels of the oncogene MYC, consistent with a role of 
the PKC/NUAK1 axis in supporting the survival of MYC overexpressing cells.  
NUAK1 has already been described to promote survival of MYC-overexpressing 
cells by restraining mTORC1 activity (Liu et al., 2012). In our studies, we were 
further able to delineate the mechanism underling the involvement of NUAK1 in 
the regulation of mTORC1. Particularly, our data revealed a direct role of NUAK1 
in the inhibition of Raptor, which might represent an important metabolic 
checkpoint that contributes to the pro-survival mechanism in the setting of MYC 
oncogene-induced stress.  
 
MYC is an emblematic oncogene in its function as it is known to drive 
proliferation but also to induce apoptosis. In particular, a threshold level of MYC 
has been suggested to determine cell fate. Indeed, whereas low expression 
levels of MYC can sustain aberrant proliferation, elevated levels of MYC trigger a 
tumour suppressive function with the induction of ARF/p53 and apoptotic 
pathways (Murphy et al., 2008). PKC has been suggested to exert a pro-survival 
function through phosphorylation of the anti-apoptotic protein BCL-2 (Ruvolo et 
al., 1998) and enhancement of AKT activity (Li et al., 1999). Therefore, a 
potential function of PKC would be to protect cells from death induced by high 
levels of MYC, mitigating MYC tumour suppressive role in favour of its oncogenic 
activity. 
Overall, our data strengthen the rationale for the therapeutic targeting of 
NUAK1 and provide insights for the inhibition of PKC, which so far has produced 
mixed and largely negative outcomes in clinical oncology (Marshall et al., 2004; 
Paz-Ares et al., 2006; Villalona-Calero et al., 2004), as a potential therapeutic 
strategy in MYC-deregulated cancers. 
 
NUAK1 has been indicated to act as a tumour promoter, since an increased 
expression has been reported in more advanced tumour stages and has been 
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associated with poor survival for different cancer types. Our studies conducted 
in a mouse model of Non-small cell lung cancer (NSCLC) driven by mutant 
KRasG12D have demonstrated that NUAK1 does not share the tumour suppressive 
role of LKB1, whose deletion has been reported to accelerate lung tumorigenesis 
(Ji et al., 2007). At 16 weeks post infection, deletion of Nuak1 did not affect the 
tumour burden in the lungs of KasG12D mice, although a survival analysis might 
offer a more exhaustive interpretation of its role. Indeed, Nuak1 deletion 
increased the survival of mice in which lung tumorigenesis was driven by 
KRasG12D and accelerated by MYC overexpression. The synthetic lethal interaction 
between MYC and Nuak1 might contribute to the observed survival benefit but it 
is also possible that deletion of Nuak1 results in the loss of its intrinsic tumour 
supportive mechanisms. For example, preliminary results have suggested a 
potential role of NUAK1 in tumour angiogenesis, as we observed a decrease in 
tumour blood vessels formation upon Nuak1 deletion, which might represent a 
novel biological function of NUAK1, not related to MYC. The pro-angiogenic role 
of NUAK1 could be partially responsible for the observed increase in survival of 
Nuak1 deleted mice, as blood vessels are essential in providing nutrients and 
oxygen to the highly metabolic tumour cells, other than representing the 
preferential way for tumour dissemination to distant sites. On the other hand, a 
reduction in tumour blood vessel might represent an obstacle for an efficient 
systemic delivery of chemotherapeutic agents. However, an analysis of the 
structure and permeability of the remaining blood vessels together with a 
pharmacokinetics and tumor uptake study might indicate if the observed 
reduction in tumour blood vessels could considerably affect drug delivery.  
 
We observed a decrease of phospho-ERK levels in KRasG12D/MYC/Nuak1F/F 
tumours, which might delay the development of aggressive sub-clones, 
responsible for a rapid progression of the disease, and reflect the observed 
survival benefit. Notably, Nuak1 deletion also resulted in an increase in AKT 
activation, which might be supported by an enhanced insulin sensitivity as 
previously described in a Nuak1 knockout mouse model (Inazuka et al., 2012). 
Therefore, it is possible that Nuak1 deletion triggers a cross-inhibition between 
AKT and Raf to downregulate ERK phosphorylation, a mechanism previously 
reported (Moelling et al., 2002). However, further investigations will be required 
for a more comprehensive understanding of the mechanisms behind the observed 
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effects of Nuak1 deletion. Firstly, additional studies will be needed to confirm 
the pro-angiogenic role of NUAK1 and explore the mechanism. In addition, given 
the established role of NUAK1 in promoting invasion and metastasis, it will be of 
great interest to investigate the effect of Nuak1 deletion from a metastatic 
perspective in the KRasG12D/MYC NSCLC mouse model. 
Although therapeutic targeting of NUAK1 in NSCLC might not be itself sufficient 
for a substantial regression of the disease, as we improve our understanding of 
the signalling network that includes NUAK1 we might discover new aspects of its 
therapeutic potential. On the other hand, a more in-depth knowledge of the 
mechanisms that drive the progression of lung cancer might as well have 
multiple implications from a therapeutic point of view and offer new 
opportunities for NUAK1 targeting. 
 
With the study of the molecular mechanisms of NSCLC progression, we revealed 
that the ERBB network is significantly upregulated in KRas mutant lung 
adenocarcinoma and demonstrated its involvement in the initial phases of the 
tumorigenic process as well as in the progression of the disease to more 
advanced stages. Indeed, we have compellingly shown that inhibition of the 
ERBB network leads to a better therapeutic outcome when combined with MEK 
inhibition, which as single therapy failed to provide encouraging results in 
clinical trials (Blumenschein et al., 2015). Therefore, the dependence of KRas 
mutant lung tumours on the ERBB network might prompt the revisiting of current 
therapeutic regimes and identify new successful combinatorial therapies.  
Interestingly, LKB1 deletion was shown to sensitize NSCLC cell lines to EGFR 
inhibition (Whang et al., 2016). Additionally, a link between PKC and ERBB 
receptors has been suggested by several studies. For example, PKC was 
reported to increase ERBB2 protein levels in breast cancer, establishing a 
feedback loop in which activation of ERBB2 led to increased PKC, which in 
turns contributed to sustain ERBB2 levels (Magnifico et al., 2007). In addition, 
upregulation of PKC was suggested to mediated the resistance to EGFR 
inhibition in NSCLC cells (Abera and Kazanietz, 2015). As NUAK1 resides 
downstream of both PKC and LKB1, targeting of NUAK1 in combination with 
inhibition of ERBB receptors might represent a new and more efficient 
therapeutic strategy to explore in NSCLC.  
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Collectively, data presented in this thesis have revealed novel mechanisms of 
regulation of NUAK1, strengthening the molecular basis for its targeting in 
tumours addicted to MYC oncogene, and uncovered new potential physiological 
roles of NUAK1. Indeed, the identification of PKC as an alternative upstream 
kinase might be the beginning of a more comprehensive understanding of the 
NUAK1 signalling network. In addition, by improving our knowledge of the 
mechanisms involved in lung cancer progression, we have provided new targets 
that could be exploited for therapeutic purposes not only in lung cancer but also 
in other tumours driven by mutant KRas, such as pancreatic ductal 
adenocarcinoma, that still represents a major challenge in clinical oncology. 
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